UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
þ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the Fiscal Year Ended December 31, 2018
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the transition period from ____________ to ____________
Commission File No. 000-16929
SOLIGENIX, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
29 EMMONS DRIVE, SUITE B-10
PRINCETON, NJ
(Address of principal executive offices)
41-1505029
(I.R.S. Employer
Identification Number)
08540
(Zip Code)
(609) 538-8200
(Registrant’s telephone number, including area code)
Securities registered under Section 12 (b) of the Exchange Act:
Title of Each Class
Common Stock, par value $.001 per share
Common Stock Purchase Warrants
Name of Each Exchange on Which Registered
The Nasdaq Capital Market
Securities registered under Section 12(g) of the Exchange Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No þ
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes þ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
and post such files). Yes þ No ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this 10-K or any amendments to this
Form 10-K. þ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
Non-accelerated filer
☐
☐
Accelerated filer
Smaller reporting company
Emerging growth company
☐
þ
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ
The aggregate market value of the common stock held by non-affiliates of the registrant was approximately $8,437,036 (assuming, for this purpose, that
executive officers, directors and holders of 10% or more of the common stock are affiliates), based on the closing price of the registrant’s common stock as
reported on The Nasdaq Capital Market on June 30, 2018, 8,750,801 shares of the registrant’s Common Stock, par value $0.001 per share, were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE: None.
SOLIGENIX, INC.
ANNUAL REPORT ON FORM 10-K
For the Year Ended December 31, 2018
Table of Contents
Description
Part I
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Part II
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions and Director Independence
Principal Accountant Fees and Services
Part III
Item
1.
1A.
1B.
2.
3.
5.
6.
7.
8.
9.
9A.
9B.
10.
11.
12.
13.
14.
Exhibits and Financial Statement Schedules
15.
Signatures
Consolidated Financial Statements
Part IV
i
Page
1
25
42
42
42
43
44
44
53
53
53
54
55
60
65
67
68
69
72
F-1
Item 1. Business
PART I
This Annual Report on Form 10-K contains statements of a forward-looking nature relating to future events or our future financial performance. These
statements are only predictions and actual events or results may differ materially. In evaluating such statements, you should carefully consider the various
factors identified in this report that could cause actual results to differ materially from those indicated in any forward-looking statements, including those set
forth in “Risk Factors” in this Annual Report on Form 10-K. See “Cautionary Note Regarding Forward Looking Statements.”
Our Business Overview
We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical
need. We maintain two active business segments: BioTherapeutics and Vaccines/BioDefense.
Our BioTherapeutics business segment is developing a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible
fluorescent light for the treatment of cutaneous T-cell lymphoma (“CTCL”), our first-in-class innate defense regulator technology, dusquetide (SGX942) for
the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (“BDP”) for the
prevention/treatment of gastrointestinal (“GI”) disorders characterized by severe inflammation, including pediatric Crohn’s disease (SGX203) and acute
radiation enteritis (SGX201).
Our Vaccines/BioDefense business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate and SGX943, our
therapeutic candidate for antibiotic resistant and emerging infectious disease. The development of our vaccine programs currently is supported by our heat
stabilization technology, known as ThermoVax®, under existing and on-going government contract funding. With the government contract from the National
Institute of Allergy and Infectious Diseases (“NIAID”), we will attempt to advance the development of RiVax® to protect against exposure to ricin toxin..
An outline of our business strategy follows:
● Following positive interim analysis, complete enrollment and report final results in our pivotal Phase 3 clinical trial of SGX301 for the treatment of
CTCL;
● Continue enrollment of the pivotal Phase 3 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer;
● Continue development of RiVax® in combination with our ThermoVax® technology to develop a new heat stable vaccine in biodefense with NIAID
funding support;
● Continue to apply for and secure additional government funding for each of our BioTherapeutics and Vaccines/BioDefense programs through grants,
contracts and/or procurements;
● Pursue business development opportunities for our pipeline programs, as well as explore merger/acquisition strategies; and
● Acquire or in-license new clinical-stage compounds for development.
Corporate Information
We were incorporated in Delaware in 1987 under the name Biological Therapeutics, Inc. In 1987, we merged with Biological Therapeutics, Inc., a North
Dakota corporation, pursuant to which we changed our name to “Immunotherapeutics, Inc.” We changed our name to “Endorex Corp.” in 1996, to “Endorex
Corporation” in 1998, to “DOR BioPharma, Inc.” in 2001, and finally to “Soligenix, Inc.” in 2009. Our principal executive offices are located at 29 Emmons
Drive, Suite B-10, Princeton, New Jersey 08540 and our telephone number is (609) 538-8200.
1
Our Product Candidates in Development
The following tables summarize our product candidates under development:
Soligenix Product
Candidate
Therapeutic Indication
Stage of Development
BioTherapeutic Product Candidates
SGX301
Cutaneous T-Cell Lymphoma
SGX942
Oral Mucositis in Head and Neck
Cancer
SGX203**
Pediatric Crohn’s disease
SGX201**
Acute Radiation Enteritis
Phase 2 trial completed; demonstrated significantly higher response rate
compared to placebo; Phase 3 clinical trial enrolled first patient in December
2015, with positive interim analysis received in October 2018, and final results
expected in the first quarter of 2020
Phase 2 trial completed; demonstrated significant response compared to
placebo with positive long-term (12 month) safety also reported; Phase 3
clinical trial enrolled first patient in December 2017, with interim analysis
enrollment completion expected in the first half of 2019 and the interim
analysis anticipated in the third quarter of 2019; final results expected in the
first half of 2020
Phase 1/2 clinical trial completed; efficacy data, pharmacokinetic
(PK)/pharmacodynamic (PD) profile and safety profile demonstrated; Phase 3
clinical trial initiation contingent upon additional funding, such as through
partnership
Phase 1/2 clinical trial completed; safety profile and preliminary efficacy
demonstrated; further clinical development contingent upon additional
funding, such as through partnership
Soligenix Product
Candidate
ThermoVax®
Soligenix Product
Candidate
RiVax®
OrbeShield®
SGX943
Vaccine Thermostability Platform**
Indication
Stage of Development
Thermostability of aluminum
adjuvanted vaccine for ricin
Pre-clinical
BioDefense Products**
Indication
Stage of Development
Vaccine against Ricin Toxin
Poisoning
Phase 1a and 1b trials completed, safety and neutralizing antibodies for
protection demonstrated; Phase 2 trial planned for the second half of 2019
Therapeutic against GI ARS
Therapeutic against Emerging
Infectious Diseases
Pre-clinical
Pre-clinical
** Contingent upon continued government contract/grant funding or other funding source.
2
BioTherapeutics Overview
SGX301 – for Treating Cutaneous T-Cell Lymphoma
SGX301 is a novel, first-in-class, photodynamic therapy that utilizes safe visible light for activation. The active ingredient in SGX301 is synthetic hypericin,
a photosensitizer which is topically applied to skin lesions and then activated by fluorescent light 16 to 24 hours later. Hypericin is also found in several
species of Hypericum plants, although the drug used in SGX301 is chemically synthesized by a proprietary manufacturing process and not extracted from
plants. Importantly, hypericin is optimally activated with visible light thereby avoiding the negative consequences of ultraviolet light. Other light therapies
using UVA light result in serious adverse effects including secondary skin cancers.
Combined with photoactivation, in clinical trials synthetic hypericin has demonstrated significant anti-proliferative effects on activated normal human
lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. In both settings, it appears that the mode of action is an induction of
cell death in a concentration as well as a light dose-dependent fashion. These effects appear to result, in part, from the generation of singlet oxygen during
photoactivation of hypericin.
Hypericin is one of the most efficient known generators of singlet oxygen, the key component for phototherapy. The generation of singlet oxygen induces
necrosis and apoptosis in adjacent cells. The use of topical synthetic hypericin coupled with directed visible light results in generation of singlet oxygen only
at the treated site. We believe that the use of visible light (as opposed to cancer-causing ultraviolet light) is a major advance in photodynamic therapy. In a
published Phase 2 clinical study in CTCL, after six weeks of twice weekly therapy, a majority of patients experienced a statistically significant (p<0.04)
improvement with SGX301 whereas the placebo was ineffective: 58.3% compared to 8.3%, respectively.
SGX301 has received Orphan Drug designation as well as Fast Track designation from the U.S. Food and Drug Administration (“FDA”). The Orphan Drug
Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition to
providing a seven-year term of market exclusivity for SGX301 upon final FDA approval, Orphan Drug designation also positions us to be able to leverage a
wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of FDA user fees for the potential
submission of a New Drug Application (“NDA”) for SGX301, and certain tax credits. In addition, Fast Track is a designation that the FDA reserves for a drug
intended to treat a serious or life-threatening condition and one that demonstrates the potential to address an unmet medical need for the condition. Fast Track
designation is designed to facilitate the development and expedite the review of new drugs. For instance, should events warrant, we will be eligible to submit
a NDA for SGX301 on a rolling basis, permitting the FDA to review sections of the NDA prior to receiving the complete submission. Additionally, NDAs for
Fast Track development programs ordinarily will be eligible for priority review. SGX301 for the treatment of CTCL also was granted Orphan Drug
designation from the European Medicines Agency (“EMA”) Committee for Orphan Medical Products and Promising Innovative Medicine (“PIM”)
designation from the Medicines and Healthcare Products Regulatory Agency (“MHRA”) in the United Kingdom (“UK”).
In August 2018, the United States Patent Office granted us a patent titled “Systems and Methods for Producing Synthetic Hypericin” for the unique
proprietary process manufacturing the highly purified form of synthetic hypericin, the active pharmaceutical ingredient in SGX301.
We initiated our pivotal Phase 3 clinical study of SGX301 for the treatment of CTCL during December 2015. This trial, referred to as the “FLASH” study
(Fluorescent Light Activated Synthetic Hypericin), aims to evaluate the response to SGX301 as a skin directed therapy to treat early stage CTCL. We are
actively enrolling patients with approximately 35 CTCL centers across the United States (“U.S.”) participating in this pivotal trial. The Phase 3 protocol is a
highly powered, double-blind, randomized, placebo-controlled, multicenter trial and seeks to enroll approximately 120 evaluable subjects. The trial consists
of three treatment cycles, each of eight weeks duration. Treatments are administered twice weekly for the first six weeks and treatment response is determined
at the end of the eighth week. In the first treatment cycle, approximately 80 subjects receive SGX301 and 40 receive placebo treatment of their index lesions.
In the second cycle, all subjects receive SGX301 treatment of their index lesions, and in the third cycle all subjects receive SGX301 treatment of all of their
lesions. The majority of subjects enrolled to date have elected to continue into the third optional, open-label cycle of the study. We continue to work closely
with the Cutaneous Lymphoma Foundation, as well as the National Organization for Rare Disorders. Subjects are followed for an additional six months after
their last evaluation visit. The primary efficacy endpoint is assessed on the percentage of patients in each of the two treatment groups (i.e., SGX301 and
placebo) achieving a partial or complete response of the treated lesions, defined as a ≥ 50% reduction in the total Composite Assessment of Index Lesion
Disease Severity (“CAILS”) score for three index lesions at the Cycle 1 evaluation visit (Week 8) compared to the total CAILS score at baseline. Other
secondary measures assess treatment response including duration, degree of improvement, time to relapse and safety.
3
During September 2017, the National Cancer Institute (“NCI”), part of the National Institutes of Health (“NIH”) awarded us a Small Business Innovation
Research (“SBIR”) grant of approximately $1.5 million over two years to support the conduct of our pivotal, Phase 3, randomized, double-blind, placebo-
controlled study evaluating SGX301 (synthetic hypericin) as a treatment for CTCL.
During October 2018, an Independent Data Monitoring Committee (“DMC”) completed an unblinded interim analysis with data from approximately 100
subjects, including an assessment of the Phase 3 FLASH study’s primary efficacy endpoint. The DMC provided a positive recommendation to randomize
approximately 40 additional subjects into the trial to maintain the rigorous assumption of 90% statistical power for the primary efficacy endpoint. No safety
concerns were reported by the DMC based on the interim analysis.
We estimate the potential worldwide market for SGX301 is in excess of $250 million for all applications, including the treatment of CTCL. This potential
market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this
potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be
realized.
Cutaneous T-Cell Lymphoma
CTCL is a class of non-Hodgkin’s lymphoma (“NHL”), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most
NHLs, which generally involve B-cell lymphocytes (involved in producing antibodies), CTCL is caused by an expansion of malignant T-cell lymphocytes
(involved in cell-mediated immunity) normally programmed to migrate to the skin. These skin-trafficking malignant T-cells migrate to the skin, causing
various lesions to appear that may change shape as the disease progresses, typically beginning as a rash and eventually forming plaques and tumors. Mycosis
fungoides (“MF”) is the most common form of CTCL. It generally presents with skin involvement only, manifested as scaly, erythematous patches. Advanced
disease with diffuse lymph node and visceral organ involvement is usually associated with a poorer response rate to standard therapies. A relatively
uncommon sub-group of CTCL patients present with extensive skin involvement and circulating malignant cerebriform T-cells, referred to as Sézary
syndrome. These patients have substantially graver prognoses (expected five-year survival rate of 24%), than those with MF (expected five-year survival rate
of 88%).
CTCL mortality is related to stage of disease, with median survival generally ranging from about 12 years in the early stages to only 2.5 years when the
disease has advanced. There is currently no FDA-approved drug for front-line treatment of early stage CTCL. Treatment of early-stage disease generally
involves skin-directed therapies. One of the most common unapproved therapies used for early-stage disease is oral 5 or 8-methoxypsoralen (“Psoralen”)
given with ultraviolet A (“UVA”) light, referred to as PUVA, which is approved for dermatological conditions such as disabling psoriasis not adequately
responsive to other forms of therapy, idiopathic vitiligo and skin manifestations of CTCL in persons who have not been responsive to other forms of
treatment. Psoralen is a mutagenic chemical that interferes with DNA causing mutations and other malignancies. Moreover, UVA is a carcinogenic light
source that when combined with the Psoralen, results in serious adverse effects including secondary skin cancers; therefore, the FDA requires a Black Box
warning for PUVA.
CTCL constitutes a rare group of NHLs, occurring in about 4% of the approximate 500,000 individuals living with NHL. We estimate, based upon review of
historic published studies and reports and an interpolation of data on the incidence of CTCL, that it affects over 20,000 individuals in the U.S., with
approximately 2,800 new cases seen annually.
4
Dusquetide
Dusquetide (research name: SGX94) is an innate defense regulator (“IDR”) that regulates the innate immune system to simultaneously reduce inflammation,
eliminate infection and enhance tissue healing.
Dusquetide is based on a new class of short, synthetic peptides known as IDRs. It has a novel mechanism of action in that it modulates the body’s reaction to
both injury and infection and is both simultaneously anti-inflammatory and anti-infective. IDRs have no direct antibiotic activity but modulate host responses,
increasing survival after infections with a broad range of bacterial Gram-negative and Gram-positive pathogens including both antibiotic sensitive and
resistant strains, as well as accelerating resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and
chemo- or radiation-therapy. IDRs represent a novel approach to the control of infection and tissue damage via highly selective binding to an intracellular
adaptor protein, sequestosome-1, also known as p62, which has a pivotal function in signal transduction during activation and control of the innate defense
system. Preclinical data indicate that IDRs may be active in models of a wide range of therapeutic indications including life-threatening bacterial infections as
well as the severe side-effects of chemo- and radiation-therapy. Additionally, due to selective binding to p62, dusquetide may have potential anti-tumor
action.
Dusquetide has demonstrated efficacy in numerous animal disease models including mucositis, colitis, skin infection and other bacterial infections and has
been evaluated in a double-blind, placebo-controlled Phase 1 clinical trial in 84 healthy volunteers with both single ascending dose and multiple ascending
dose components. Dusquetide was shown to have a good safety profile and be well-tolerated in all dose groups when administered by IV over 7 days and was
consistent with safety results seen in pre-clinical studies. We believe that market opportunities for dusquetide include, but are not limited to, oral and
gastrointestinal mucositis, acute Gram-positive bacterial infections (e.g., methicillin resistant Staphylococcus aureus (MRSA)), acute Gram-negative
infections (e.g., acinetobacter, melioidosis), and acute radiation syndrome.
SGX942 – for Treating Oral Mucositis in Head and Neck Cancer
SGX942 is our product candidate containing our IDR technology, dusquetide, targeting the treatment of oral mucositis in head and neck cancer patients. Oral
mucositis in this patient population is an area of unmet medical need where there are currently no approved drug therapies. Accordingly, we received Fast
Track designation for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients from the FDA. In
addition, dusquetide has been granted PIM designation in the UK by the MHRA for the treatment of severe oral mucositis in head and neck cancer patients
receiving chemoradiation therapy. The U.S. Patent and Trademark Office and the European Patent Office granted us the patent titled “Novel Peptides and
Analogs for Use in the Treatment of Oral Mucositis” on August 16, 2016 and January 23, 2019, respectively. The newly issued patent claims therapeutic use
of dusquetide and related IDR analogs, and adds to composition of matter claims for dusquetide and related analogs that have been granted in the U.S. and
worldwide.
We initiated a Phase 2 clinical study of SGX942 for the treatment of oral mucositis in head and neck cancer patients in December of 2013. We completed
enrollment in this trial in the second half of 2015, and in December 2015 released positive preliminary results. In this Phase 2 proof-of-concept clinical study
that enrolled 111 patients, SGX942, at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50%, from 18 days to 9 days
(p=0.099) in all patients and by 67%, from 30 days to 10 days (p=0.040) in patients receiving the most aggressive chemoradiation therapy for treatment of
their head and neck cancer. The p-values met the prospectively defined statistical threshold of p<0.1 in the study protocol. A less severe occurrence of oral
mucositis, ulcerative oral mucositis (defined as oral mucositis with a WHO score ≥2 corresponding to the occurrence of overt ulceration in the mouth), was
also monitored during the study. In the patients receiving the most aggressive chemoradiation therapy, the median duration of oral mucositis was found to
decrease from 65 days in the placebo treated patients to 51 days in the patients treated with SGX942 1.5 mg/kg (p=0.099).
In addition to identifying the best dose of 1.5 mg/kg, this study achieved all objectives, including increased incidence of “complete response” of tumor at the
one month follow-up visit (47% in placebo vs. 63% in SGX942 at 1.5 mg/kg). Decreases in mortality and decreases in infection rate were also observed with
SGX942 treatment, consistent with the preclinical results observed in animal models.
5
SGX942 was found to be generally safe and well tolerated, consistent with the safety profile observed in the prior Phase 1 study conducted in 84 healthy
volunteers. The long-term (12 month) follow-up data was consistent with the preliminary positive safety and efficacy findings. While the placebo population
experienced the expected 12-month survival rate of approximately 80%, as defined in the Surveillance, Epidemiology, and End Results statistics 1975-2012
from the National Cancer Institute, the SGX942 1.5 mg/kg treatment group reported a 12-month survival rate of 93% (7% mortality in the SGX942 1.5 mg/kg
group compared to 19% in the placebo group). Similarly, tumor resolution (complete response) at 12 months was better in the SGX942 1.5 mg/kg treatment
group relative to the placebo population (80% in the 1.5 mg/kg group compared to 74% in the placebo group). Moreover, in the patients receiving
chemotherapy every third week, the SGX942 1.5 mg/kg treatment group had a tumor resolution rate (complete response) of 82% throughout the 12 months
following chemoradiation therapy, while the placebo group experienced a 64% complete response rate. The long-term follow-up results from the Phase 2
study are reviewed in “Dusquetide: Reduction in Oral Mucositis associated with Enduring Ancillary Benefits in Tumor Resolution and Decreased Mortality in
Head and Neck Cancer Patients” published online in Biotechnology Reports and available at the following link: https://doi.org/10.1016/j.btre.2017.05.002. In
addition to safety, evaluations of other secondary efficacy endpoints, such as the utilization of opioid pain medication, indicated that the SGX942 1.5mg/kg
treatment group had a 40% decrease in the use of opioids at the later stage of the treatment phase of the trial, when oral mucositis is usually most severe and
expected to increase pain medication use. This was in contrast to the placebo group, which demonstrated a 10% increase in use of opioids over this same
period. Data from this Phase 2 trial was published online in the Journal of Biotechnology. The publication also delineates the supportive nonclinical data in
this indication, demonstrating consistency in the qualitative and quantitative biological response, including dose response, across the nonclinical and clinical
data sets. The results are available at the following link: http://authors.elservier.com/sd/article/S01681656116315668.
On September 9, 2016, we and SciClone Pharmaceuticals, Inc. (“SciClone”) entered into an exclusive license agreement, pursuant to which we granted rights
to SciClone to develop, promote, market, distribute and sell SGX942 in defined territories. Under the terms of the license agreement, SciClone will be
responsible for all aspects of development, product registration and commercialization in the territories, having access to data generated by us. In exchange
for exclusive rights, SciClone will pay us royalties on net sales, and we will supply commercial drug product to SciClone on a cost-plus basis, while
maintaining worldwide manufacturing rights.
We have received clearance from the FDA to advance the pivotal Phase 3 protocol for SGX942 in the treatment of oral mucositis in patients with head and
neck cancer receiving chemoradiation therapy. Additionally, we have received positive Scientific Advice from the EMA for the development of SGX942 as a
treatment for oral mucositis in patients with head and neck cancer. The Scientific Advice from the EMA indicates that a single, double-blind, placebo-
controlled, multinational, Phase 3 pivotal study, if successful, in conjunction with the Phase 2 dose-ranging study, is generally considered sufficient to support
a marketing authorization application (“MAA”) to the EMA for potential licensure in Europe. The advice also provided several suggestions to strengthen the
study design and data collection that were integrated into the final protocol. Scientific Advice is offered by the EMA to stakeholders for clarification of
questions arising during development of medicinal products. The scope of Scientific Advice is limited to scientific issues and focuses on development
strategies rather than pre-evaluation of data to support an MAA. Scientific Advice is legally non-binding and is based on the current scientific knowledge
which may be subject to future changes.
We are working with leading oncology centers, a number of which participated in the Phase 2 study, to advance this Phase 3 clinical trial referred to as the
“DOM–INNATE” study (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity). Based on the positive and previously published Phase
2 results (Study IDR-OM-01), the pivotal Phase 3 clinical trial (Study IDR-OM-02) is a highly powered, double-blind, randomized, placebo-controlled,
multinational trial that will seek to enroll approximately 190 subjects with squamous cell carcinoma of the oral cavity and oropharynx who are scheduled to
receive a minimum total cumulative radiation dose of 55 Gy fractionated as 2.0-2.2 Gy per day with concomitant cisplatin chemotherapy given as a dose of
80-100 mg/m2 every third week. Subjects are randomized to receive either 1.5 mg/kg SGX942 or placebo given twice a week during and for two weeks
following completion of chemoradiation therapy (“CRT”). The primary endpoint for the study is the median duration of severe oral mucositis, which is
assessed by oral examination at each treatment visit and then through six weeks following completion of CRT. Oral mucositis is evaluated using the WHO
Grading system. Severe oral mucositis is defined as a WHO Grade of ≥3. Subjects are followed for an additional 12 months after the completion of treatment.
6
During July 2017, we initiated our pivotal Phase 3 study with a controlled roll-out of U.S. study sites, followed by the addition of European centers in 2018.
We anticipate that approximately fifty U.S. and European oncology centers will be participating in this pivotal Phase 3 study. We anticipate an interim
analysis report from an independent data monitoring committee to be available in the third quarter of 2019.
During September 2017, the National Institute of Dental and Craniofacial Research (“NIDCR”), part of the NIH, awarded us a SBIR grant of approximately
$1.5 million over two years to support the conduct of our Phase 3, multinational, randomized, double-blind, placebo-controlled study evaluating SGX942
(dusquetide) as a treatment for severe oral mucositis in patients with head and neck cancer receiving CRT.
We estimate the potential worldwide market for SGX942 is in excess of $500 million for all applications, including the treatment of oral mucositis. This
potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined
this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or
not be realized.
Oral Mucositis
Mucositis is the clinical term for damage done to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonly associated
with the mouth, followed by the small intestine. We estimate, based upon our review of historic studies and reports, and an interpolation of data on the
incidence of mucositis, that mucositis affects approximately 500,000 people in the U.S. per year and occurs in 40% of patients receiving chemotherapy.
Mucositis can be severely debilitating and can lead to infection, sepsis, the need for parenteral nutrition and narcotic analgesia. The GI damage causes severe
diarrhea. These symptoms can limit the doses and duration of cancer treatment, leading to sub-optimal treatment outcomes.
The mechanisms of mucositis have been extensively studied and have been linked to the interaction of chemotherapy and/or radiation therapy with the innate
defense system. Bacterial infection of the ulcerative lesions is regarded as a secondary consequence of dysregulated local inflammation triggered by therapy-
induced cell death, rather than as the primary cause of the lesions.
We estimate, based upon our review of historic studies and reports, and an interpolation of data on the incidence of oral mucositis, that oral mucositis is a
subpopulation of approximately 90,000 patients in the U.S., with a comparable number in Europe. Oral mucositis almost always occurs in patients with head
and neck cancer treated with radiation therapy (greater than 80% incidence of severe mucositis) and is common in patients undergoing high dose
chemotherapy and hematopoietic cell transplantation, where the incidence and severity of oral mucositis depends greatly on the nature of the conditioning
regimen used for myeloablation.
Oral BDP
Oral BDP (beclomethasone 17,21-dipropionate) represents a first-of-its-kind oral, locally acting therapy tailored to treat GI inflammation. BDP has been
marketed in the U.S. and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the
treatment of patients with allergic rhinitis and asthma. Oral BDP is specifically formulated for oral administration as a single product consisting of two
tablets. One tablet is intended to release BDP in the upper sections of the GI tract and the other tablet is intended to release BDP in the lower sections of the
GI tract.
Based on its pharmacological characteristics, oral BDP may have utility in treating other conditions of the gastrointestinal tract having an inflammatory
component. We are planning to pursue development programs for the treatment of pediatric Crohn’s disease, acute radiation enteritis and GI ARS pending
further grant funding. We are also exploring the possibility of testing oral BDP for local inflammation associated with ulcerative colitis, among other
indications.
7
We estimate the potential worldwide market for oral BDP is in excess of $500 million for all applications, including the treatment of pediatric Crohn’s
disease. This potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we
have determined this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause our
expectations to change or not be realized.
SGX203 – for Treating Pediatric Crohn’s Disease
SGX203 is a two tablet delivery system of BDP specifically designed for oral use that allows for administration of immediate and delayed release BDP
throughout the small bowel and the colon. The FDA has given SGX203 Orphan Drug designation as well as Fast Track designation for the treatment of
pediatric Crohn’s disease. We will pursue a pivotal Phase 3 clinical trial of SGX203 for the treatment of pediatric Crohn’s disease contingent upon additional
funding, such as through partnership funding support.
Pediatric Crohn’s Disease
Crohn’s disease causes inflammation of the GI tract. Crohn’s disease can affect any area of the GI tract, from the mouth to the anus, but it most commonly
affects the lower part of the small intestine, called the ileum. The swelling caused by the disease extends deep into the lining of the affected organ. The
swelling can induce pain and can make the intestines empty frequently, resulting in diarrhea. Because the symptoms of Crohn’s disease are similar to other
intestinal disorders, such as irritable bowel syndrome and ulcerative colitis, it can be difficult to diagnose. People of Ashkenazi Jewish heritage have an
increased risk of developing Crohn’s disease.
Crohn’s disease can appear at any age, but it is most often diagnosed in adults in their 20s and 30s. However, approximately 30% of people with Crohn’s
disease develop symptoms before 20 years of age. We estimate, based upon our review of historic published studies and reports, and an interpolation of data
on the incidence of pediatric Crohn’s disease, that pediatric Crohn’s disease is a subpopulation of approximately 80,000 patients in the U.S. with a comparable
number in Europe. Crohn’s disease tends to be both severe and extensive in the pediatric population and a relatively high proportion (approximately 40%) of
pediatric Crohn’s patients have involvement of their upper gastrointestinal tract.
Crohn’s disease presents special challenges for children and teens. In addition to bothersome and often painful symptoms, the disease can stunt growth, delay
puberty, and weaken bones. Crohn’s disease symptoms may sometimes prevent a child from participating in enjoyable activities. The emotional and
psychological issues of living with a chronic disease can be especially difficult for young people.
SGX201 – for Preventing Acute Radiation Enteritis
SGX201 is a delayed-release formulation of BDP specifically designed for oral use. In 2012, we completed a Phase 1/2 clinical trial testing SGX201 in
prevention of acute radiation enteritis. Patients with rectal cancer scheduled to undergo concurrent radiation and chemotherapy prior to surgery were
randomized to one of four dose groups. The objectives of the study were to evaluate the safety and maximal tolerated dose of escalating doses of SGX201, as
well as the preliminary efficacy of SGX201 for prevention of signs and symptoms of acute radiation enteritis. The study demonstrated that oral administration
of SGX201 was safe and well tolerated across all four dose groups. There was also evidence of a potential dose response with respect to diarrhea, nausea and
vomiting and the assessment of enteritis according to National Cancer Institute Common Terminology Criteria for Adverse Events for selected
gastrointestinal events. In addition, the incidence of diarrhea was lower than that seen in published historical control data in this patient population. This
program was supported in part by a $500,000 two-year SBIR grant awarded by the NIH. We continue to work with our Radiation Enteritis medical advisors to
identify additional funding opportunities to support the clinical development program.
We have received Fast Track designation from the FDA for SGX201 for acute radiation enteritis.
8
Acute Radiation Enteritis
External radiation therapy is used to treat most types of cancer, including cancer of the bladder, uterine, cervix, rectum, prostate, and vagina. During delivery
of treatment, some level of radiation will also be delivered to healthy tissue, including the bowel, leading to acute and chronic toxicities. The large and small
bowels are very sensitive to radiation and the larger the dose of radiation the greater the damage to normal bowel tissue. Radiation enteritis is a condition in
which the lining of the bowel becomes swollen and inflamed during or after radiation therapy to the abdomen, pelvis, or rectum. Most tumors in the abdomen
and pelvis need large doses, and almost all patients receiving radiation to the abdomen, pelvis, or rectum will show signs of acute enteritis.
Patients with acute enteritis may have nausea, vomiting, abdominal pain and bleeding, among other symptoms. Some patients may develop dehydration and
require hospitalization. With diarrhea, the gastrointestinal tract does not function normally, and nutrients such as fat, lactose, bile salts, and vitamin B12 are
not well absorbed.
Symptoms will usually resolve within two to six weeks after therapy has ceased. Radiation enteritis is often not a self-limited illness, as over 80% of patients
who receive abdominal radiation therapy complain of a persistent change in bowel habits. Moreover, acute radiation injury increases the risk of development
of chronic radiation enteropathy, and overall 5% to 15% of the patients who receive abdominal or pelvic irradiation will develop chronic radiation enteritis.
We estimate, based upon our review of historic published studies and reports, and an interpolation of data on the treatment courses and incidence of cancers
occurring in the abdominal and pelvic regions, there to be over 100,000 patients annually in the U.S., with a comparable number in Europe, who receive
abdominal or pelvic external beam radiation treatment for cancer, and these patients are at risk of developing acute and chronic radiation enteritis.
Vaccines/BioDefense Overview
ThermoVax® – Thermostability Technology
ThermoVax® is a novel method of rendering aluminum salt, (known colloquially as Alum), adjuvanted vaccines stable at elevated temperatures. Alum is the
most widely employed adjuvant technology in the vaccine industry. The value of ThermoVax® lies in its potential ability to eliminate the need for cold chain
production, transportation, and storage for Alum adjuvanted vaccines. This would relieve the high costs of producing and maintaining vaccines under
refrigerated conditions. Based on historical reports from the World Health Organization and other scientific reports, we believe that a meaningful proportion
of vaccine doses globally are wasted due to excursions from required cold chain temperature ranges. This is due to the fact that most Alum adjuvanted
vaccines need to be maintained at between 2 and 8 degrees Celsius (“C”) and even brief excursions from this temperature range (especially below freezing)
usually necessitates the destruction of the product or the initiation of costly stability programs specific for the vaccine lots in question. ThermoVax® has the
potential to facilitate easier storage and distribution of strategic national stockpile vaccines for ricin exposure in emergency settings.
ThermoVax® development was supported pursuant to our $9.4 million NIAID grant enabling development of thermo-stable ricin (RiVax®) and anthrax
(VeloThrax®) vaccines. Proof-of-concept preclinical studies with ThermoVax® indicate that it is able to produce stable vaccine formulations using adjuvants,
protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage
conditions. These studies were conducted with our aluminum-adjuvanted ricin toxin vaccine, RiVax® and our aluminum-adjuvanted anthrax vaccine,
VeloThrax®. Each vaccine was manufactured under precise lyophilization conditions using excipients that aid in maintaining native protein structure of the
key antigen. When RiVax® was kept at 40 degrees C (104 degrees Fahrenheit) for up to one year, all of the animals vaccinated with the lyophilized RiVax®
vaccine developed potent and high titer neutralizing antibodies. In contrast, animals that were vaccinated with the liquid RiVax® vaccine kept at 40 degrees C
did not develop neutralizing antibodies and were not protected against ricin exposure. The ricin A chain is extremely sensitive to temperature and rapidly
loses the ability to induce neutralizing antibodies when exposed to temperatures higher than 8 degrees C. When VeloThrax® was kept for up to 16 weeks at 70
degrees C, it was able to develop a potent antibody response, unlike the liquid formulation kept at the same temperature. Moreover, we also have
demonstrated the compatibility of our thermostabilization technology with other secondary adjuvants such as TLR-4 agonists.
9
We also entered into a collaboration agreement with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology,
John A. Burns School of Medicine, University of Hawaiʻi at Manoa (“UH Manoa”) and Hawaii Biotech, Inc. (“HBI”) to develop a heat stable subunit Ebola
vaccine. Dr. Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept efficacy with subunit Ebola vaccines in non-human primates.
The most advanced Ebola vaccines involve the use of vesicular stomatitis virus and adenovirus vectors – live, viral vectors which complicate the
manufacturing, stability and storage requirements. Dr. Lehrer’s vaccine candidate is based on highly purified recombinant protein antigens, circumventing
many of these manufacturing difficulties. Dr. Lehrer and HBI have developed a robust manufacturing process for the required proteins. Application of
ThermoVax® may allow for a product that can avoid the need for cold chain distribution and storage, yielding a vaccine ideal for use in both the developed
and developing world. This agreement has expired in accordance with its terms.
On February 7, 2019, European Journal of Pharmaceutics and Biopharmaceutics published a scientific article demonstrating the successful
thermostabilization of an Ebola subunit vaccine candidate.
During September 2017, we announced we will be participating in a NIAID Research Project (R01) grant awarded to UH Manoa for the development of a
trivalent thermostabilized Ebola vaccine, with our awarded funding of approximately $700,000 over five years. Previous collaborations demonstrated the
feasibility of developing a heat stable subunit Ebola vaccine. Under the terms of the subaward, we will continue to support vaccine formulation development
with our proprietary vaccine thermostabilization technology, ThermoVax®. Ultimately, the objective is to produce a thermostable trivalent filovirus vaccine
for protection against Ebola and related diseases, allowing worldwide distribution without the need for cold storage.
On December 21, 2010, we executed a worldwide exclusive license agreement with the University of Colorado (“UC”) for certain patents relating to
ThermoVax® in all fields of use. In April 2018, the UC delivered a notice of termination of our license agreement based upon our failure to achieve one of the
development milestones: initiation of the Phase 1 clinical trial of the heat stabilization technology by March 31, 2018. After negotiating with the UC, we and
the UC agreed to extend the termination date to October 31, 2018 in order to allow us time to agree upon a potential agreement that would allow us to keep
the rights to, and to continue to develop, the heat stabilization technology or a product candidate containing the heat stabilization technology in our field of
use.
On October 31, 2018, in a series of related transactions, (a) we and the UC agreed to terminate the original license agreement, (b) the UC and VitriVax, Inc.
(“VitriVax”) executed a worldwide exclusive license agreement for the heat stabilization technology for all fields of use, and (c) we and VitriVax executed a
worldwide exclusive sublicense agreement for the heat stabilization technology for use in the fields of ricin and Ebola vaccines. We paid a $100,000
sublicense fee on the effective date of the sublicense agreement. To maintain the sublicense we are obliged to pay a minimum annual royalty of $20,000 until
first commercial sale of a sublicensed product, upon which point, we shall pay an earned royalty of 2% of net sales subject to a minimum royalty of $50,000
each year. We are also required to pay royalty on any sub-sublicense income based on a declining percentage of all sub-sublicense income calculated within
the contractual period until reaching a minimum of 15% after two years. In addition, we are required to pay VitriVax milestone fees of: (a) $50,000 upon
initiation of a Phase II clinical trial of the sublicensed product, (b) $200,000 upon regulatory approval of a sublicensed product, and (c) $1 million upon
achieving $10 million in aggregate net sales of a sublicensed product in the U.S. or equivalent. To date none of these milestones have been met.
10
RiVax® – Ricin Toxin Vaccine
RiVax® is our proprietary vaccine candidate being developed to protect against exposure to ricin toxin and if approved, would be the first ricin vaccine. The
immunogen in RiVax® induces a protective immune response in animal models of ricin exposure and functionally active antibodies in humans. The
immunogen consists of a genetically inactivated ricin A chain subunit that is enzymatically inactive and lacks residual toxicity of the holotoxin. RiVax® has
demonstrated statistically significant (p < 0.0001) preclinical survival results, providing 100% protection against acute lethality in an aerosol exposure non-
human primate model (Roy et al, 2015, Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing
antibodies correlate with protection, PNAS USA 112:3782-3787), and has also been shown to be well tolerated and immunogenic in two Phase 1 clinical
trials in healthy volunteers. Results of the first Phase 1 human trial of RiVax® established that the immunogen was safe and induced antibodies that we
believe may protect humans from ricin exposure. The antibodies generated from vaccination, concentrated and purified, were capable of conferring immunity
passively to recipient animals, indicating that the vaccine was capable of inducing functionally active antibodies in humans. The outcome of this study was
published in the Proceedings of the National Academy of Sciences (Vitetta et al., 2006, A Pilot Clinical Trial of a Recombinant Ricin Vaccine in Normal
Humans, PNAS, 103:2268-2273). The second trial which was completed in September 2012 and was sponsored by University of Texas Southwestern Medical
Center (“UTSW”), evaluated a more potent formulation of RiVax® that contained an aluminum adjuvant (Alum). The results of the Phase 1b study indicated
that Alum-adjuvanted RiVax® was safe and well tolerated, and induced greater ricin neutralizing antibody levels in humans than adjuvant-free RiVax®. The
outcomes of this second study were published in the Clinical and Vaccine Immunology (Vitetta et al., 2012, Recombinant Ricin Vaccine Phase 1b Clinical
Trial, Clin. Vaccine Immunol. 10:1697-1699). We have adapted the original manufacturing process for the immunogen contained in RiVax® for
thermostability and large scale manufacturing and recent studies have confirmed that the thermostabilized RiVax® formulation enhances the stability of the
RiVax® antigen, enabling storage for at least 1 year at temperatures up to 40°C (104 °F). The program will pursue approval via the FDA “Animal Rule” since
it is not possible to test the efficacy of the vaccine in a clinical study which would expose humans to ricin. Uniform, easily measured and species-neutral
immune correlates of protection that can be measured in humans and animals, and are indicative of animal survival to subsequent ricin challenge, are central
to the application of the “Animal Rule”. Recent work has identified such potential correlates of immune protection in animals and work to qualify and
validate these approaches is continuing, with the goal of utilizing these assays in a planned Phase 1/2 clinical trial with the thermostable RiVax® formulation.
During September 2018, we published an extended stability study of RiVax®, showing up to 100% protection in mice after 12 months storage at 40°C (104
°F) as well as identification of a potential in vitro stability indicating assay, critical to adequately confirming the long-term shelf life of the vaccine. We have
entered into a collaboration with IDT Biologika GmbH to scale-up the formulation/filling process and continue development and validation of analytical
methods established at IDT to advance the program. We also have initiated a development agreement with Emergent BioSolutions, Inc. to implement a
commercially viable, scalable production technology for the RiVax® drug substance protein antigen.
The development of RiVax® has been sponsored through a series of overlapping challenge grants, UC1, and cooperative grants, U01, from the NIH, granted
to us and to UTSW where the vaccine originated. The second clinical trial was supported by a grant from the FDA’s Office of Orphan Products to UTSW. To
date, we and UTSW have collectively received approximately $25 million in grant funding from the NIH for the development of RiVax®. In September 2014,
we entered into a contract with the NIH for the development of RiVax® that would provide up to an additional $24.7 million of funding in the aggregate if
options to extend the contract are exercised by the NIH. The development agreements with Emergent BioSolutions and IDT are specifically funded under this
NIH contract.
During June 2017 NIAID exercised an option for the evaluation of RiVax® to fund additional animal efficacy studies. The exercised option will provide us
with approximately $2.0 million in additional funding. Additionally, during August 2017 NIAID exercised an option to fund good manufacturing practices
compliant RiVax® bulk drug substance and finished drug product manufacturing, which is required for the conduct of future preclinical and clinical safety and
efficacy studies. The exercised option will provide us with approximately $2.5 million in additional non-dilutive funding, bringing the total amount awarded
to date under this contract to $21.2 million, of which $13.5 million is still available. If all contract options are exercised, the total award of up to $24.7 million
will support the preclinical, manufacturing and clinical development activities necessary to advance heat stable RiVax® with the FDA. In addition to the
ongoing funding of up to $24.7 million for the development of RiVax®, biomarkers for RiVax® testing have been successfully identified, facilitating potential
approval under the FDA Animal Rule.
RiVax® has been granted Orphan Drug designation by the FDA for the prevention of ricin intoxication. In addition, RiVax® has also been granted Orphan
Drug designation in the EU from the EMA Committee for Orphan Medical Products.
11
Assuming development efforts are successful for RiVax®, we believe potential government procurement contract(s) could reach as much as $200 million.
This potential procurement contract information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While
we have determined this potential procurement contract value based on assumptions that we believe are reasonable, there are a number of factors that could
cause our expectations to change or not be realized.
As a new chemical entity, an FDA approved RiVax® vaccine has the potential to qualify for a biodefense Priority Review Voucher (“PRV”). Approved under
the 21st Century Cures Act in late 2016, the biodefense PRV is awarded upon approval as a medical countermeasure when the active ingredient(s) have not
been otherwise approved for use in any context. PRVs are transferable and can be sold, with sales in recent years of up to $350 million. When redeemed,
PRVs entitle the user to an accelerated review period of nine months, saving a median of seven months review time as calculated in 2009. However, FDA
must be advised 90 days in advance of the use of the PRV and the use of a PRV is associated with an additional user fee ($2.7 million in 2017).
Ricin Toxin
Ricin toxin can be cheaply and easily produced, is stable over long periods of time, is toxic by several routes of exposure and thus has the potential to be used
as a biological weapon against military and/or civilian targets. As a bioterrorism agent, ricin could be disseminated as an aerosol, by injection, or as a food
supply contaminant. The potential use of ricin toxin as a biological weapon of mass destruction has been highlighted in a Federal Bureau of Investigation
Bioterror report released in November 2007 titled Terrorism 2002-2005, which states that “Ricin and the bacterial agent anthrax are emerging as the most
prevalent agents involved in WMD investigations” (http://www.fbi.gov/stats-services/publications/terrorism-2002-2005/terror02_05.pdf). In recent years, Al
Qaeda in the Arabian Peninsula has threatened the use of ricin toxin to poison food and water supplies and in connection with explosive devices.
Domestically, the threat from ricin remains a concern for security agencies. In April 2013, letters addressed to the President of the United States, a U.S.
Senator and a judge tested positive for ricin. As recently as October 2018, an envelope addressed to President Trump was suspected to contain this potent and
potentially lethal toxin, which was subsequently confirmed to contain pieces of castor beans used to make ricin.
The Centers for Disease Control and Prevention has classified ricin toxin as a Category B biological agent. Ricin works by first binding to glycoproteins
found on the exterior of a cell, and then entering the cell and inhibiting protein synthesis leading to cell death. Once exposed to ricin toxin, there is no
effective therapy available to reverse the course of the toxin. The recent ricin threat to government officials has heightened the awareness of this toxic threat.
Currently, there is no FDA approved vaccine to protect against the possibility of ricin toxin being used in a terrorist attack, or its use as a weapon on the
battlefield nor is there a known antidote for ricin toxin exposure.
OrbeShield® – for Treating GI Acute Radiation Syndrome
OrbeShield® is an oral immediate and delayed release formulation of the topically active corticosteroid BDP and is being developed for the treatment of GI
ARS. Corticosteroids are a widely used class of anti-inflammatory drugs. BDP is a corticosteroid with predominantly topical activity that is approved for use
in asthma, psoriasis and allergic rhinitis.
OrbeShield® has demonstrated positive preclinical results in a canine GI ARS model which indicate that dogs treated with OrbeShield® demonstrated
statistically significant (p=0.04) improvement in survival with dosing at either two hours or 24 hours after exposure to lethal doses of total body irradiation
(“TBI”) when compared to control dogs. OrbeShield® appears to significantly mitigate the damage to the GI epithelium caused by exposure to high doses of
radiation using a well-established canine model of GI ARS.
The GI tract is highly sensitive to ionizing radiation and the destruction of epithelial tissue is one of the first effects of radiation exposure. The rapid loss of
epithelial cells leads to inflammation and infection that are often the primary cause of death in acute radiation injury. This concept of GI damage also applies
to the clinical setting of oncology, where high doses of radiation cannot be administered effectively to the abdomen because radiation is very toxic to the
intestines. We are seeking to treat the same type of toxicity in our acute radiation enteritis clinical program with SGX201. As a result, we believe that
OrbeShield® has the potential to be a “dual use” compound, a desirable characteristic which is a specific priority for ARS and other medical countermeasure
indications.
12
In September 2013, we received two government contracts from the Biomedical Advanced Research and Development Authority (“BARDA”) and NIAID for
the advanced preclinical and manufacturing development of OrbeShield® leading to FDA approval to treat GI ARS. The BARDA contract contained a two
year base period with two contract options, exercisable by BARDA, for a total of five years and up to $26.3 million. The NIAID contract consisted of a one
year base period and two contract options, exercisable by NIAID, for a total of three years and up to $6.4 million. We received a combined approximate $18
million in contract funding from both BARDA and NIAID which includes combined supplemental funding of $634,000, extending the programs through the
first quarter of 2017. The NIAID contract was completed during the first quarter of 2017 along with the expiration of the base period of the BARDA contract
for the development of OrbeShield®, with BARDA electing not to extend the current contract beyond the base period. We will continue to apply for
additional government funding. Previously, development of OrbeShield® had been largely supported by a $1 million NIH grant to our academic partner, the
Fred Hutchinson Cancer Research Center. In July 2012, we received an SBIR grant from NIAID of approximately $600,000 to support further preclinical
development of OrbeShield® for the treatment of acute GI ARS. The FDA has given OrbeShield® Orphan Drug designation and Fast Track designation for
the prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.
Assuming development efforts are successful for OrbeShield®, we believe potential government procurement contracts could reach as much as $450 million.
This potential procurement contract information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While
we have determined this potential procurement contract value based on assumptions that we believe are reasonable, there are a number of factors that could
cause our expectations to change or not be realized.
GI Acute Radiation Syndrome
ARS occurs after toxic radiation exposure and involves several organ systems, notably the bone marrow, the GI tract and later the lungs. In the event of a
nuclear disaster or terrorist detonation of a nuclear bomb, casualties exposed to greater than 2 grays (“Gy”) of absorbed radiation are at high risk for
development of clinically significant ARS. Exposure to high doses of radiation exceeding 10-12 Gy causes acute GI injury which can result in death. The GI
tract is highly sensitive due to the continuous need for crypt stem cells and production of mucosal epithelium. The extent of injury to the bone marrow and the
GI tract are the principal determinants of survival after exposure to TBI. Although the hematopoietic syndrome can be rescued by bone marrow
transplantation or growth factor administration, there is no established treatment or preventive measure for the GI damage that occurs after high-dose
radiation. As a result, we believe there is an urgent medical need for specific medical counter measures against the lethal pathophysiological manifestations of
radiation-induced GI injury.
SGX943 – for Treating Emerging and/or Antibiotic-Resistant Infectious Diseases
SGX943 is an IDR, containing the same active ingredient as SGX942. Dusquetide is a fully synthetic, 5-amino acid peptide with high aqueous solubility and
stability. Extensive in vivo preclinical studies have demonstrated enhanced clearance of bacterial infection with SGX943 administration. SGX943 has shown
efficacy against both Gram-negative and Gram-positive bacterial infections in preclinical models, independent of whether the bacteria is antibiotic-resistant or
antibiotic-sensitive.
The innate immune system is responsible for rapid and non-specific responses to combat bacterial infection. Augmenting these responses represents an
alternative approach to treating bacterial infections. In animal models, IDRs are efficacious against both antibiotic-sensitive and antibiotic-resistant infections,
both Gram-positive and Gram-negative bacteria, and are active irrespective of whether the bacteria occupies a primarily extracellular or intracellular niche.
IDRs are also effective as stand-alone agents or in conjunction with antibiotics. An IDR for the treatment of serious bacterial infections encompasses a
number of clinical advantages including:
● Treatment when antibiotics are contraindicated, such as:
o
o
before the infectious organism and/or its antibiotic susceptibility is known; or
in at-risk populations prior to infection.
13
● An ability to be used as an additive, complementary treatment with antibiotics, thereby:
o
o
o
enhancing efficacy of sub-optimal antibiotic regimens (e.g., partially antibiotic-resistant infections);
enhancing clearance of infection, thereby minimizing the generation of antibiotic resistance (e.g., in treating melioidosis); and
reducing the required antibiotic dose, again potentially minimizing the generation of antibiotic resistance.
● An ability to modulate the deleterious consequences of inflammation in response to the infection, including the inflammation caused by antibiotic-
driven bacterial lysis; and
● Being unlikely to generate bacterial resistance since the IDR acts on the host, and not the pathogen.
Importantly, systemic inflammation and multi-organ failure is the ultimate common outcome of not only emerging and/or antibiotic-resistant infectious
diseases, but also of most biothreat agents (e.g., Burkholderia pseudomallei), indicating that dusquetide would be applicable not only to antibiotic-resistant
infection, but also to biothreat agents, especially where the pathogen is not known and/or has been engineered for enhanced antibiotic resistance.
The Drug Approval Process
The FDA and comparable regulatory agencies in state, local and foreign jurisdictions impose substantial requirements on the clinical development,
manufacture and marketing of new drug and biologic products. The FDA, through regulations that implement the Federal Food, Drug, and Cosmetic Act, as
amended (“FDCA”), and other laws and comparable regulations for other agencies, regulate research and development activities and the testing, manufacture,
labeling, storage, shipping, approval, recordkeeping, advertising, promotion, sale, export, import and distribution of such products. The regulatory approval
process is generally lengthy, expensive and uncertain. Failure to comply with applicable FDA and other regulatory requirements can result in sanctions being
imposed on us or the manufacturers of our products, including holds on clinical research, civil or criminal fines or other penalties, product recalls, or seizures,
or total or partial suspension of production or injunctions, refusals to permit products to be imported into or exported out of the United States, refusals of the
FDA to grant approval of drugs or to allow us to enter into government supply contracts, withdrawals of previously approved marketing applications and
criminal prosecutions.
Before human clinical testing in the U.S. of a new drug compound or biological product can commence, an Investigational New Drug (“IND”), application is
required to be submitted to the FDA. The IND application includes results of pre-clinical animal studies evaluating the safety and efficacy of the drug and a
detailed description of the clinical investigations to be undertaken.
Clinical trials are normally done in three phases, although the phases may overlap. Phase 1 trials are smaller trials concerned primarily with metabolism and
pharmacologic actions of the drug and with the safety of the product. Phase 2 trials are designed primarily to demonstrate effectiveness and safety in treating
the disease or condition for which the product is indicated. These trials typically explore various doses and regimens. Phase 3 trials are expanded clinical
trials intended to gather additional information on safety and effectiveness needed to clarify the product’s benefit-risk relationship and generate information
for proper labeling of the drug, among other things. The FDA receives reports on the progress of each phase of clinical testing and may require the
modification, suspension or termination of clinical trials if an unwarranted risk is presented to patients. When data is required from long-term use of a drug
following its approval and initial marketing, the FDA can require Phase 4, or post-marketing, studies to be conducted.
14
With certain exceptions, once successful clinical testing is completed, the sponsor can submit a New Drug Application (“NDA”), for approval of a drug, or a
Biologic License Application (“BLA”), for biologics such as vaccines, which will be reviewed, and if successful, approved by the FDA, allowing the product
to be marketed. The process of completing clinical trials for a new drug is likely to take a number of years and require the expenditure of substantial
resources. Furthermore, the FDA or any foreign health authority may not grant an approval on a timely basis, if at all. The FDA may deny the approval of an
NDA or BLA, in its sole discretion, if it determines that its regulatory criteria have not been satisfied or may require additional testing or information. Among
the conditions for marketing approval is the requirement that the prospective manufacturer’s quality control and manufacturing procedures conform to good
manufacturing practice regulations. In complying with standards contained in these regulations, manufacturers must continue to expend time, money and
effort in the area of production, quality control and quality assurance to ensure full technical compliance. Manufacturing facilities, both foreign and domestic,
also are subject to inspections by, or under the authority of, the FDA and by other federal, state, local or foreign agencies.
Even after initial FDA or foreign health authority approval has been obtained, further studies, including Phase 4 post-marketing studies, may be required to
provide additional data on safety and will be required to gain approval for the marketing of a product as a treatment for clinical indications other than those
for which the product was initially tested. For certain drugs intended to treat serious, life-threatening conditions that show great promise in earlier testing, the
FDA can also grant conditional approval. However, drug developers are required to study the drug further and verify clinical benefit as part of the conditional
approval provision, and the FDA can revoke approval if later testing does not reproduce previous findings. The FDA may also condition approval of a
product on the sponsor agreeing to certain mitigation strategies that can limit the unfettered marketing of a drug. Also, the FDA or foreign regulatory
authority will require post-marketing reporting to monitor the side effects of the drug. Results of post-marketing programs may limit or expand the further
marketing of the product. Further, if there are any modifications to the drug, including any change in indication, manufacturing process, labeling or
manufacturing facility, an application seeking approval of such changes will likely be required to be submitted to the FDA or foreign regulatory authority.
In the U.S., the FDCA, the Public Health Service Act, the Federal Trade Commission Act, and other federal and state statutes and regulations govern, or
influence the research, testing, manufacture, safety, labeling, storage, record keeping, approval, advertising and promotion of drug, biological, medical device
and food products. Noncompliance with applicable requirements can result in, among other things, fines, recall or seizure of products, refusal to permit
products to be imported into the U.S., refusal of the government to approve product approval applications or to allow us to enter into government supply
contracts, withdrawal of previously approved applications and criminal prosecution. The FDA may also assess civil penalties for violations of the FDCA
involving medical devices.
For biodefense development, such as with RiVax® and OrbeShield®, the FDA has instituted policies that are expected to result in shorter pathways to market.
This potentially includes approval for commercial use utilizing the results of animal efficacy trials, rather than efficacy trials in humans. However, we will
still have to establish that the vaccine and countermeasures it is developing are safe in humans at doses that are correlated with the beneficial effect in
animals. Such clinical trials will also have to be completed in distinct populations that are subject to the countermeasures; for instance, the very young and the
very old, and in pregnant women, if the countermeasure is to be licensed for civilian use. Other agencies will have an influence over the benefit-risk scenarios
for deploying the countermeasures and in establishing the number of doses utilized in the Strategic National Stockpile. We may not be able to sufficiently
demonstrate the animal correlation to the satisfaction of the FDA, as these correlates are difficult to establish and are often unclear. Invocation of the animal
rule may raise issues of confidence in the model systems even if the models have been validated. For many of the biological threats, the animal models are not
available and we may have to develop the animal models, a time-consuming research effort. There are few historical precedents, or recent precedents, for the
development of new countermeasure for bioterrorism agents. Despite the animal rule, the FDA may require large clinical trials to establish safety and
immunogenicity before licensure and it may require safety and immunogenicity trials in additional populations. Approval of biodefense products may be
subject to post-marketing studies, and could be restricted in use in only certain populations.
Vaccines are approved under the BLA process that exists under the Public Health Service Act. In addition to the greater technical challenges associated with
developing biologics, the potential for generic competition is lower for a BLA product than a small molecule product subject to an NDA under the Federal
Food, Drug and Cosmetic Act. Under the Patient Protection and Affordable Care Act enacted in 2010, a “generic” version of a biologic is known as a
biosimilar and the barriers to entry – whether legal, scientific, or logistical – for a biosimilar version of a biologic approved under a BLA are higher.
15
Orphan Drug Designation
Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a rare disease or condition – generally a
disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting an NDA or
BLA. After the FDA grants orphan drug designation, the generic identity of the drug or biologic and its potential orphan use are disclosed publicly by the
FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA or
BLA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-
year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve
any other applications to market the same drug or biologic for the same disease, except in limited circumstances, such as a showing of clinical superiority to
the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease
or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain
research and a waiver of the NDA or BLA application user fee.
Fast Track Designation and Accelerated Approval
The FDA is required to facilitate the development, and expedite the review, of drugs or biologics that are intended for the treatment of a serious or life-
threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the
condition. Under the fast track program, the sponsor of a new drug or biologic candidate may request that the FDA designate the candidate for a specific
indication as a fast track drug or biologic concurrent with, or after, the filing of the IND for the candidate. The FDA must determine if the drug or biologic
candidate qualifies for fast track designation within 60 days of receipt of the sponsor’s request. Unique to a fast track product, the FDA may initiate review of
sections of a fast track product’s NDA or BLA before the application is complete. This rolling review is available if the applicant provides, and the FDA
approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA’s time period goal for
reviewing an application does not begin until the last section of the NDA or BLA is submitted. Additionally, the fast track designation may be withdrawn by
the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.
Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite
development and review, such as accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-
threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means the FDA may
approve the product based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier
than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into
account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.
In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of
how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug or biologic
candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical
trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing
studies, will allow the FDA to withdraw the drug or biologic from the market on an expedited basis. All promotional materials for drug candidates approved
under accelerated regulations are subject to prior review by the FDA.
16
Pediatric Information
Under the Pediatric Research Equity Act (“PREA”), NDAs or BLAs or supplements to NDAs or BLAs must contain data to assess the safety and
effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric
subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise
required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.
Early Access to Medicines Scheme
Launched in April 2014 in the United Kingdom by the MHRA, the Early Access to Medicines Scheme (“EAMS”) offers severely ill patients with life-
threatening and seriously debilitating conditions the lifeline of trying ground-breaking new medicines earlier than they would normally be accessible. PIM
designation is the first phase of EAMS and is awarded following an assessment of early nonclinical and clinical data by the MHRA. The criteria product
candidates must meet to obtain PIM designation are:
● Criterion 1 – The condition should be life-threatening or seriously debilitating with a high unmet medical need (i.e., there is no method of treatment,
diagnosis or prevention available or existing methods have serious limitations).
● Criterion 2 – The medicinal product is likely to offer major advantage over methods currently used in the UK.
● Criterion 3 – The potential adverse effects of the medicinal product are likely to be outweighed by the benefits, allowing for the reasonable
expectation of a positive benefit risk balance. A positive benefit risk balance should be based on preliminary scientific evidence that the safety
profile of the medicinal product is likely to be manageable and acceptable in relation to the estimated benefits.
False Claims Laws
The federal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for
payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false
or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes “any
request or demand” for money or property presented to the U.S. government.
Anti-Kickback Laws
The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving
any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the
purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been
interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical
manufacturers on one hand and prescribers, purchasers, and formulary managers on the other.
United States Healthcare Reform
Federal Physician Payments Sunshine Act and its implementing regulations require that certain manufacturers of drugs, devices, biological and medical
supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report information
related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or
designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their
immediate family members.
17
In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. The
Health Insurance Portability and Accountability Act (“HIPAA”), as amended by the Health Information Technology for Economic and Clinical Health Act
(“HITECH”), and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable
health information. Among other things, HITECH makes HIPAA’s privacy and security standards directly applicable to “business associates” – independent
contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered
entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business
associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to
enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy
and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus
complicating compliance efforts.
Third-Party Suppliers and Manufacturers
Drug substance and drug product manufacturing is outsourced to qualified suppliers. We do not have manufacturing capabilities/infrastructure and do not
intend to develop the capacity to manufacture drug products substances. We have agreements with third-party manufacturers to supply bulk drug substances
for our product candidates and with third parties to formulate, package and distribute our product candidates. Our employees include professionals with
expertise in pharmaceutical manufacturing development, quality assurance and third party supplier management who oversee work conducted by third-party
companies. We believe that we have on hand or can easily obtain sufficient amounts of product candidates to complete our currently contemplated clinical
trials. All of the drug substances used in our product candidates currently are manufactured by single suppliers. While we have not experienced any supply
disruptions, the number of manufacturers of the drug substances is limited. In the event it is necessary or advisable to acquire supplies from alternative
suppliers, assuming commercially reasonable terms could be reached, the challenge would be the efficient transfer of technology and know-how from current
manufactures to the new supplier. Formulation and distribution of our finished product candidates also currently are conducted by single suppliers but we
believe that alternative sources for these services are readily available on commercially reasonable terms, subject to the efficient transfer of technology and
know-how from current suppliers to the new supplier.
All of the current agreements for the supply of bulk drug substances for our product candidates and for the formulation or distribution of our product
candidates relate solely to the development (including preclinical and clinical) of our product candidates. Under these contracts, our product candidates are
manufactured upon our order of a specific quantity. In the event that we obtain marketing approval for a product candidate, we will qualify secondary
suppliers for all key manufacturing activities supporting the marketing application.
Marketing and Collaboration
We do not currently have any sales and marketing capability, other than to potentially market our biodefense vaccine products directly to government
agencies. With respect to other commercialization efforts, we currently intend to seek distribution and other collaboration arrangements for the sales and
marketing of any product candidate that is approved, while also evaluating the potential to commercialize on our own in orphan disease indications. From
time to time, we have had and are having strategic discussions with potential collaboration partners for our biodefense vaccine product candidates, although
no assurance can be given that we will be able to enter into one or more collaboration agreements for our product candidate on acceptable terms, if at all. We
believe that both military and civilian health authorities of the U.S. and other countries will increase their stockpiling of therapeutics and vaccines to treat and
prevent diseases and conditions that could ensue following a bioterrorism attack.
On December 20, 2012, we re-acquired the North American and European commercial rights to oral BDP through an amendment of our collaboration and
supply agreement with Sigma-Tau Pharmaceuticals, Inc., which is now known as Leadiant Biosciences, Inc. (“Leadiant”). The amendment requires us to
make certain approval and commercialization milestone payments to Leadiant which could reach up to $6 million. In addition, we have agreed to pay
Leadiant: (a) a royalty amount equal to 3% of all net sales of oral BDP made directly by us, and any third-party partner and/or their respective affiliates in the
U.S., Canada, Mexico and in each country in the European Territory for the later to occur of: (i) a period of ten years from the first commercial sale of oral
BDP in each country, or (ii) the expiration of our patents and patent applications relating to oral BDP in such country (the “Payment Period”); and (b) 15% of
all up-front payments, milestone payments and any other consideration (exclusive of equity payments) received by us and/or a potential partner from us
and/or potential partner’s licensees, distributors and agents for oral BDP in each relevant country in the territory, which amount will be paid on a product-by-
product and a country-by-country basis for the Payment Period.
18
On August 25, 2013, we entered into an agreement with SciClone Pharmaceuticals, Inc. (“SciClone”), pursuant to which SciClone provided us with access to
its oral mucositis clinical and regulatory data library in exchange for exclusive commercialization rights for SGX942 in the People’s Republic of China,
including Hong Kong and Macau, subject to the negotiation of economic terms. SciClone’s data library was generated from two sequential Phase 2 clinical
studies conducted in 2010 and 2012 evaluating SciClone’s compound, SCV-07, for the treatment of oral mucositis caused by chemoradiation therapy in head
and neck cancer patients, before SciClone terminated its program. By analyzing data available from the placebo subjects in the SciClone trials, we acquired
valuable insight into disease progression, along with quantitative understanding of its incidence and severity in the head and neck cancer patient population.
This information assisted us with the design of the SGX942 Phase 2 clinical trial, in which positive preliminary results were announced in December 2015.
On September 9, 2016, we and SciClone entered into an exclusive license agreement, pursuant to which we granted rights to SciClone to develop, promote,
market, distribute and sell SGX942 in the People’s Republic of China, including Hong Kong and Macau, as well as Taiwan, South Korea and Vietnam. Under
the terms of the license agreement, SciClone will be responsible for all aspects of development, product registration and commercialization in the territory,
having access to data generated by us. In exchange for exclusive rights, SciClone will pay us royalties on net sales, and we will supply commercial drug
product to SciClone on a cost-plus basis, while maintaining worldwide manufacturing rights. We also entered into a common stock purchase agreement with
SciClone pursuant to which we sold 352,942 shares of our common stock to SciClone for approximately $8.50 per share, for an aggregate price of
$3,000,000.
Competition
Our competitors are pharmaceutical and biotechnology companies, most of whom have considerably greater financial, technical, and marketing resources
than we do. Universities and other research institutions, including the U.S. Army Medical Research Institute of Infectious Diseases, also compete in the
development of treatment technologies, and we face competition from other companies to acquire rights to those technologies.
SGX301 Competition
The FDA has approved several treatments for later stages (IIB-IV) of CTCL and/or in conditions that are unresponsive to prior treatment. Three are targeted
therapies (Targretin®-caps, Ontak® and Adcetris®), two are histone deacetylases inhibitors (Zolina® and Istodax®) and the remaining two are topical
therapies (Valchor® and Targretin®-gel). There are currently no FDA approved therapies for the treatment of front-line, early stage (I-IIA) CTCL; however
certain topical chemotherapies and topical, radiation, photodynamic and other therapies which are approved for indications other than CTCL are prescribed
off-label for the treatment of early stage CTCL. These include psoralen combined with ultraviolet A (UVA) light therapy (“PUVA”); however, PUVA
treatments are usually limited to three times per week and 200 times in total due to the potentially carcinogenic side effect. There are other drugs currently in
development that may have the potential to be used in early stage (I-IIA) CTCL – two in phase 2 (vorinostat (Zolina®), cobomarsen), one initiating a Phase 2
study in Poland (TTI-621) and others in phase 1.
SGX94/942 Competition
Because SGX94 (dusquetide) uses a novel mechanism of action in combating bacterial infections, there are no direct competitors at this time. Bacterial
infections are routinely treated with antibiotics and SGX94 treatment is anticipated to be utilized primarily where antibiotics are insufficient (e.g., due to
antibiotic resistance) or contra-indicated (e.g., in situations where the development of antibiotic resistance is a significant concern). Many groups are working
on the antibiotic resistance problem and research into the innate immune system is intensifying, making emerging competition likely (from companies such as
Celtaxsys Inc., Innaxon Therapeutics and Innate Pharma SA).
19
There is currently one drug approved for the treatment of oral mucositis in hematological cancer (palifermin). There are currently no approved drugs for
treatment of oral mucositis in cancers with solid tumors (e.g., head and neck cancer). There are several drugs in clinical development for oral mucositis –
three in Phase 3 (an epidermal growth factor under development by Daewoong Pharmaceutical Co. Ltd. a protease inhibitor under investigation at a Chinese
hospital, and daily infused GC4419 by Galera Therapeutics Inc.), four in Phase 2 (under development by Innovation Pharmaceuticals, Intrexon Corporation,
Monopar Therapeutics LLC, Moberg Pharma) and various natural products in small and/or open label studies (including sage, turmeric, honey and olive oil).
In addition, there are medical devices approved for the treatment of oral mucositis including MuGard, GelClair, Episil and Caphosol. These devices attempt to
create a protective barrier around the oral ulceration with no biologic activity in treating the underlying disease.
Oral BDP Competition
There are a number of approved treatments for Crohn’s disease and additional compounds are in late-stage development.
Remicade (infliximab) and Humira (adalimumab) are currently approved for the treatment of pediatric Crohn’s disease; however, both carry significant Black
Box warnings in their labeling for increased risk of serious infection and malignancy, and therefore are approved for treatment of moderate to severe patients.
Entocort (enteric-coated budesonide) is currently approved for the treatment of mild to moderate active Crohn’s disease involving the lower GI tract (ileum
and/or the ascending colon) in patients 8 years of age and older who weigh more than 25 kilograms. There is one other marketed biologic, Tysabri
(natalizumab), in a Phase 2 study for pediatric Crohn’s.
ThermoVax® Competition
Multiple groups and companies are working to address the unmet need of vaccine thermostability using a variety of technologies. In addition, other
organizations, such as the Bill and Melinda Gates Foundation and PATH, have programs designed to advance technologies to address this need.
Several stabilization technologies currently being developed involve mixing vaccine antigen +/- adjuvant with various proprietary excipients or co-factors that
either serve to stabilize the vaccine or biological product in a liquid or dried (lyophilized) form. Examples of these approaches include the use of various
plant-derived sugars and macromolecules being developed by companies such as Stabilitech Ltd. Variation Biotechnologies, Inc. (“VBI”) is developing a
lipid system (resembling liposomes) to stabilize viral antigens, including virus-like particles (“VLPs”), and for potential application to a conventional
influenza vaccine among others.
Other approaches involve process variations to freeze-dry live virus vaccines. For example, PaxVax, Inc. is seeking to employ a spray drying technology in
concert with enteric coating to achieve formulations for room temperature stability of live virus vaccines using adenovirus vectors. VBI is seeking to utilize
their proprietary stabilization technology for a number of vaccines (as a co-development service, similar to the business model being developed by Stabilitech
Ltd.), whereas PaxVax is applying the technology to their own proprietary vaccine development programs. Stabilitech uses combinations of excipients, which
include glassifying sugars similar to the ThermoVax® technology, and variations in drying cycles during lyophilization, as does the ThermoVax® technology.
Additionally, companies like Pharmathene, Inc., Panacea Biotec Ltd., and Compass Biotech Inc. are developing proprietary vaccines with the application of
some form of stabilization technology.
Vaccines/BioDefense Competition
We face competition in the area of biodefense product development from various public and private companies, universities and governmental agencies, such
as the U.S. Army, some of whom may have their own proprietary technologies which may directly compete with our technologies.
20
The U.S. Army Medical Research Institute of Infectious Diseases, the DoD’s lead laboratory for medical research to counter biological threats is also
developing a ricin vaccine candidate, RVEc™. RVEc™ has been shown to be fully protective in mice exposed to lethal doses of ricin toxin by the aerosol
route. Further studies, in both rabbits and nonhuman primates, were conducted to evaluate RVEc™’s safety as well as its immunogenicity, with positive
results observed. A monoclonal antibody is also being developed by Mapp Biopharmaceutical Inc. as a ricin therapeutic, with administration 4 hours after
exposure demonstrating efficacy while administration 12 hours after ricin exposure was not protective in animal models.
In the area of radiation-protective antidotes such as OrbeShield®, various companies, such as Cleveland Biolabs, Inc., Pluristem Therapeutics, Inc., Aeolus
Pharmaceuticals, Inc. Boulder Biotechnology, Inc., RxBio, Inc., Avaxia Biologics, Inc., Exponential Biotherapies, Inc., Osiris Therapeutics, Inc.,
ImmuneRegen BioSciences, Inc., Neumedicines, Inc., Cellerant Therapeutics, Inc., Onconova Therapeutics, Inc., Araim Pharmaceuticals, Inc., EVA
Pharmaceuticals, LLC, Terapio Corporation, Cangene Corporation, Humanetics Corporation and the University of Arkansas Medical Sciences Center are
developing biopharmaceutical products that may directly compete with OrbeShield®, even though their approaches to such treatment are different.
RxBio, Avaxia Biologics and the University of Arkansas have programs specifically for GI ARS. RxBio’s Rx100 is a stem cell protectant designed as a single
dose (oral or injection) which has shown promise in nonhuman primate studies. Avaxia is developing an orally delivered anti-TNF antibody as a treatment
agent for exposure to radiation following a nuclear accident, attack or explosion. Pasireotide, a drug in development by Novartis for Cushing’s disease, is
being developed at the University of Arkansas to protect the intestine by reducing pancreatic secretions that exacerbate intestinal inflammation.
Patents and Other Proprietary Rights
Our goal is to obtain, maintain and enforce patent protection for our products, formulations, processes, methods and other proprietary technologies, preserve
our trade secrets, and operate without infringing on the proprietary rights of other parties, both in the U.S. and in other countries. Our policy is to actively
seek to obtain, where appropriate, the broadest intellectual property protection possible for our product candidates, proprietary information and proprietary
technology through a combination of contractual arrangements and patents, both in the U.S. and elsewhere in the world.
We also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other
contractors, none of which is patentable. To help protect our proprietary knowledge and experience that is not patentable, and for inventions for which patents
may be difficult to enforce, we rely on trade secret protection and confidentiality agreements to protect our interests. To this end, we require all employees,
consultants, advisors and other contractors to enter into confidentiality agreements, which prohibit the disclosure of confidential information and, where
applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.
In 2014, we acquired a novel photodynamic therapy that utilizes safe visible light for activation, which we refer to as SGX301. The active ingredient in
SGX301 is synthetic hypericin, a photosensitizer which is topically applied to skin lesions and then activated by fluorescent light 16 to 24 hours later. As part
of the acquisition, we acquired a license agreement relating to the use of photo-activated hypericin, composition of matter patent for SGX301 (U.S. patent
8,629,302) and additional issued and pending applications, both in the US and abroad. U.S. patent 8,629,302 is expected to expire in September 2030. In
August 2018, we were granted a U.S. patent (No. 10,053,513) titled “Systems and Methods for Producing Synthetic Hypericin”. This newly issued patent,
expected to expire in 2036, broadens the production around synthetic hypericin. Our proprietary formulation of synthetic hypericin also has been granted a
European patent for the treatment of psoriasis, EP 2571507, and complements the method of treatment claims covered by the previously issued US patent
6001882, Photoactivated hypericin and the use thereof.
In addition to issued and pending patents, we also have “Orphan Drug” designations for SGX301 in the U.S. and the EU for CTCL, SGX203 in the U.S. for
pediatric Crohn’s disease, and OrbeShield® in the U.S. for GI ARS, as well as for RiVax® in the U.S and EU. Our Orphan Drug designations provide for
seven years of post-approval marketing exclusivity in the U.S. and ten years exclusivity in Europe. We have pending patent applications for this indication
that, if granted, may extend our anticipated marketing exclusivity beyond the U.S. seven year or E.U. ten year post-approval exclusivity provided by Orphan
Drug legislation.
21
In 2013, we expanded our patent portfolio to include innate defense regulation through the acquisition of the novel drug technology, known as SGX94. By
binding to the pivotal regulatory protein p62, also known as sequestosome-1, SGX94 regulates the innate immune system to reduce inflammation, eliminate
infection and enhance healing. As part of the acquisition, we acquired all rights, including composition of matter patents for SGX94 as well as other analogs
and crystal structures of SGX94 with its protein target p62, including U.S. patent 8,124,721 and additional pending applications, both in the U.S. and abroad.
SGX94 was developed pursuant to discoveries made by Professors B. Brett Finlay and Robert Hancock of University of British Columbia (“UBC”). U.S.
patent 8,124,721 is expected to expire in April 2028. The U.S. Patent Office has granted the patent entitled “Novel Peptides and Analogs for Use in the
Treatment of Oral Mucositis”. The newly issued patent claims therapeutic use of dusquetide and related IDR analogs, and adds to composition of matter
claims for dusquetide and related analogs that have been granted in the U.S. and worldwide. In January 2019, the European Patent Office granted the patent
entitled “Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate
Immunity”. This newly issued patient claims composition of matter of IDR analogs, expanding patent protection around our lead IDR, dusquetide.
We have issued U.S. patents 8,263,582 that cover the use of oral BDP for treating inflammatory disorders of the gastrointestinal tract, which patent is
expected to expire in March 2022. We also have European patent EP 1392321 claiming the use of topically active corticosteroids in orally administered
dosage forms that act concurrently to treat inflammation in the upper and lower gastrointestinal tract, as well as European patent EP 2242477 claiming the use
of orally ingested BDP for treatment of interstitial lung disease. European patents EP 1392321 and EP 2242477 are expected to expire in March 2022 and
January 2029.
The subject of U.S. patent application number 12/633,631 filed December 8, 2009 and continued into patent application 15/495,798 filed April 24, 2017 and
corresponding European patent application number 09836727.9, which was granted as patent 2373160 in October 2017 and pursued in multiple European
countries, is the use of topically active BDP in radiation and chemotherapeutics injury. Additionally, we have numerous patent filings currently issued or
pending in foreign jurisdictions covering this subject matter, including Australia, Canada, China, Hong Kong, Israel, Japan, South Korea and New Zealand.
ThermoVax® is the subject of U.S. patent 8,444,991 issued on May 21, 2013 titled “Method of Preparing an Immunologically-Active Adjuvant-Bound Dried
Vaccine Composition” and also U.S. patent application number 13/474,661 filed May 17, 2012 titled “Thermostable Vaccine Compositions and Methods of
Preparing Same.” The patent application and the corresponding foreign filings for both patents are pending and licensed to us by the UC and they address the
use of adjuvants in conjunction with vaccines that are formulated to resist thermal inactivation. The license agreement covers thermostable vaccines for
biodefense as well as other potential vaccine indications. U.S. patent 8,444,991 is expected to expire in February 2030.
RiVax® is the subject of three issued U.S. patent numbers 6,566,500, 6,960,652, and 7,829,668, all titled “Compositions and methods for modifying toxic
effects of proteinaceous compounds.” This patent family includes composition of matter claims for the modified ricin toxin A chain which is the immunogen
contained in RiVax®, and issued in 2003, 2005 and 2010 respectively. The initial filing date of these patents is March 2000 and they are expected to expire in
March 2020. The issued patents contain claims that describe alteration of sequences within the ricin A chain that affect vascular leak, one of the deadly
toxicities caused by ricin toxin. Another U.S. patent number 7,175,848 titled “Ricin A chain mutants lacking enzymatic activity as vaccines to protect against
aerosolized ricin,” was filed in October of 2000 and is expected to expire in September 2020.
22
SGX301 License Agreement
In September 2014, we acquired a worldwide exclusive license agreement with New York University and Yeda Research and Development Company Ltd. for
the rights to a novel photodynamic therapy that utilizes safe visible light for activation, which we refer to as SGX301. To maintain this license we are
obligated to pay $25,000 in annual license fees. In addition, we will pay the licensors: (a) a royalty amount equal to 3% of all net sales of SGX301 made
directly by us and/or any affiliates; (b) a royalty amount equal to 2.5% of all net sales of SGX301 made by our sublicensees, subject to stated maximums and
(c) 20% of all payments, not based on net sales, received by us from our sublicensees. This license may be terminated by either party upon notice of a
material breach by the other party that is not cured within the applicable cure period. The exclusive license includes rights to several issued U.S. patents,
including U.S. patent numbers 6,867,235 and 7,122,518, among other domestic and foreign patent applications. U.S. Patent numbers 6,867,235 and 7,122,518
are expected to expire in January 2020 and November 2023, respectively.
We acquired the license agreement for SGX301 and related intangible assets, including U.S. patent 8,629,302, properties and rights pursuant to an asset
purchase agreement with Hy Biopharma Inc. (“Hy Biopharma”). As consideration for the assets acquired, we paid $275,000 in cash and issued 184,912
shares of common stock with a market value of $3,750,000. Provided all future success-orientated milestones are attained, we will be required to make
payments of up to $10.0 million, if and when achieved, payable in our common stock.
SGX94 License Agreements
On December 18, 2012, we announced the acquisition of a first in class drug technology, known as SGX94 (dusquetide), representing a novel approach to
modulation of the innate immune system. SGX94 is an IDR that regulates the innate immune system to reduce inflammation, eliminate infection and enhance
tissue healing by binding to the pivotal regulatory protein p62, also known as sequestosome-1. As part of the acquisition, we acquired all rights, including
composition of matter patents, preclinical and Phase 1 clinical study datasets for SGX94. We also assumed a license agreement with UBC to advance the
research and development of the SGX94 technology. The license agreement with UBC provides us with exclusive worldwide rights to manufacture,
distribute, market sell and/or license or sublicense products derived or developed from this technology. Under the license agreement we are obligated to pay
UBC (i) an annual license maintenance fee of CAN $1,000, and (ii) milestone payments which could reach up to CAN $1.2 million. This license agreement
(a) will automatically terminate if we file, or become subject to an involuntary filing, for bankruptcy, and (b) may be terminated by UBC in the event of,
among other things, our insolvency, dissolution, grant of a security interest in the technology licensed to us pursuant to the license agreement, or material
breach of or failure to perform material obligations under the license agreement or other research agreements between us and UBC.
Oral BDP License Agreement
On November 24, 1998, the Company, known at the time as Enteron Pharmaceuticals, Inc. (“Enteron”) and George B. McDonald (“Dr. McDonald”) entered
into an exclusive license agreement for the rights to intellectual property, including know-how, relating to oral BDP. We have an exclusive license to
commercially exploit the covered products worldwide, subject to Dr. McDonald’s right to make and use the technology for research purposes and the U.S.
Government’s right to use the technology for government purposes. Pursuant to the license agreement, as amended, we are is required to (i) reimburse Dr.
McDonald for certain out-of-pocket expenses incurred by Dr. McDonald in connection with the patent applications and issued patents, (ii) pay Dr. McDonald
$300,000 upon approval by the FDA of our first NDA incorporating oral BDP; (iii) pay Dr. McDonald royalty payments equal to 3% of net sales of the
covered products and (iv) pay Dr. McDonald $400,000 in cash upon an approval of oral BDP by the European Medicines Agency.
Additionally, in the event that sublicenses our rights under the license agreement, we will be required to pay Dr. McDonald 10% of any sublicense fees and
royalty payments paid by the sublicense to us.
The term of the license agreement expires upon the expiration of the licensed patent applications or patents. Dr. McDonald has the right to terminate the
license agreement in its entirety or to terminate exclusivity under the agreement if we or its sublicenses have not commercialized or are not actively
attempting to commercialize a covered product.
Additionally, the agreement terminates: (i) automatically upon us becoming insolvent; (ii) upon 30 days’ notice, if we breach any obligation under the
agreement without curing such breach during the notice period; and (iii) upon 90 days’ notice by us. After any termination, we will have the right to sell our
inventory for a period not to exceed three months following the date of termination, subject to the payment of the amounts owed under the agreement.
23
ThermoVax® License Agreement
On December 21, 2010, we executed a worldwide exclusive license agreement with the UC for ThermoVax®, which is the subject of U.S. patent number
8,444,991 issued on May 21, 2013 titled “Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition.” This patent and its
corresponding foreign filings are licensed to us by the UC and they address the use of adjuvants in conjunction with vaccines that are formulated to resist
thermal inactivation. U.S. Patent 8,444,991 is expected to expire in December 2031. The license agreement also covers thermostable vaccines for biodefense
as well as other potential vaccine indications. In addition, we, in conjunction with UC, filed domestic and foreign patent applications claiming priority back to
a provisional application filed on May 17, 2011 titled: “Thermostable Vaccine Compositions and Methods of Preparing Same.” In April 2018, the UC
delivered a notice of termination of our license agreement based upon our failure to achieve one of the development milestones: initiation of the Phase 1
clinical trial of the heat stabilization technology by March 31, 2018. After negotiating with the UC, we and the UC agreed to extend the termination date to
October 31, 2018 in order to allow us time to agree upon a potential agreement that would allow us to keep the rights to, and to continue to develop, the heat
stabilization technology or a product candidate containing the heat stabilization technology in our field of use.
On October 31, 2018, in a series of related transactions, (a) we and the UC agreed to terminate the original license agreement, (b) the UC and VitriVax
executed a worldwide exclusive license agreement for the heat stabilization technology for all fields of use, and (c) we and VitriVax executed a worldwide
exclusive sublicense agreement for the heat stabilization technology for use in the fields of ricin and Ebola vaccines. We paid a $100,000 sublicense fee on
the effective date of the sublicense agreement. To maintain the sublicense we are obliged to pay a minimum annual royalty of $20,000 until first commercial
sale of a sublicensed product, upon which point, we will be required to pay an earned royalty of 2% of net sales subject to a minimum royalty of $50,000 each
year. We are also required to pay royalties on any sub-sublicense income based on a declining percentage of all sub-sublicense income calculated within the
contractual period until reaching a minimum of 15% after two years. In addition, we are required to pay VitriVax milestone fees of: (a) $50,000 upon
initiation of a Phase II clinical trial of the sublicensed product, (b) $200,000 upon regulatory approval of a sublicensed product, and (c) $1 million upon
achieving $10 million in aggregate net sales of a sublicensed product in the U.S. or equivalent. To date none of these milestones have been met.
RiVax® License Agreement
In June 2003, we executed a worldwide exclusive option to license patent applications with UTSW for the nasal, pulmonary and oral uses of a non-toxic ricin
vaccine. In June 2004, we entered into a license agreement with UTSW for the injectable rights to the ricin vaccine and, in October 2004, we negotiated the
remaining oral rights to the ricin vaccine. To maintain this license we are obligated to pay $50,000 in annual license fees. Through this license, we have rights
to the issued patent number 7,175,848 titled “Ricin A chain mutants lacking enzymatic activity as vaccines to protect against aerosolized ricin.” This patent
includes methods of use and composition claims for RiVax®.
Research and Development Expenditures
We spent approximately $6.8 million and $5.5 million in the years ended December 31, 2018 and 2017, respectively, on research and development. The
amounts we spent on research and development per product during the years ended December 31, 2018, and 2017 are set forth in “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” in this Annual Report on Form 10-K.
Employees
As of December 31, 2018, we had 14 full-time employees, 6 of whom are MDs/PhDs.
Available Investor Information
We file electronically with the Securities and Exchange Commission (“SEC”) our annual reports on Form 10-K, quarterly reports on Form 10-Q, current
reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) of 15(d) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”). We make available through our website, free of charge, copies of these reports as soon as reasonably practicable after we
electronically file or furnish them to the SEC. Our website is located at www.soligenix.com. You can also request copies of such documents by contacting the
company at (609) 538-8200 or sending an email to info@soligenix.com.
24
Item 1A. Risk factors
An investment in our securities involves a high degree of risk. You should carefully consider the following information about these risks, together with the
other information about these risks contained in this Annual Report, as well as the other information contained in this Annual Report generally, before
deciding to buy our securities. Any of the risks we describe below could adversely affect our business, financial condition, operating results or prospects. The
market prices for our securities could decline if one or more of these risks and uncertainties develop into actual events and you could lose all or part of your
investment. Additional risks and uncertainties that we do not yet know of, or that we currently think are immaterial, may also impair our business operations.
You should also refer to the other information contained in this Annual Report, including our financial statements and the related notes.
Risks Related to our Business
We have had significant losses and anticipate future losses; if additional funding cannot be obtained, we may reduce or discontinue our product
development and commercialization efforts.
We have experienced significant losses since inception and, at December 31, 2018, had an accumulated deficit of approximately $166 million. We expect to
incur additional operating losses in the future and expect our cumulative losses to increase. As of December 31, 2018, we had approximately $9.0 million in
cash and cash equivalents available. Based on our projected budgetary needs, funding from existing contracts and grants over the next two years and sales
pursuant to our At the Market Issuance Sales Agreement (“FBR Sales Agreement”) with B. Riley FBR, Inc. (“FBR”), we expect to be able to maintain the
current level of our operations through at least March 31, 2020.
In September 2014, we entered into a contract with the NIH for the development of RiVax® to protect against exposure to ricin toxin that would provide up to
$24.7 million of funding in the aggregate over six years if options to extend the contract are exercised by the NIH. In September 2013, we entered into
contracts with NIAID and BARDA for the development of OrbeShield® that would provide up to $32.7 million of funding in the aggregate if options to
extend the contracts are exercised by BARDA and the NIH. We have received approximately $18 million in combined BARDA and NIH contract funding for
the development of OrbeShield®. We have completed the contract with NIAID and the BARDA contract base period, with BARDA electing not to extend the
contract. In addition, in 2017, we were awarded two separate grants from the NIH of approximately $1.5 million each to support our pivotal Phase 3 trials of
SGX301 for the treatment of CTCL and SGX942 for the treatment of oral mucositis in head and neck cancer. Our biodefense grants have an overhead
component that allows us an agency-approved percentage over our incurred costs. We estimate that the overhead component associated with our existing
contracts and grants will fund some fixed costs for direct employees working on these contracts and grants as well as other administrative costs. As of
December 31, 2018, we have approximately $14.6 million in awarded contract and grant funding, assuming the NIAID option is exercised for the
development of RiVax®.
Our product candidates are positioned for or are currently in clinical trials, and we have not yet generated any significant revenues from sales or licensing of
these product candidates. From inception through December 31, 2018, we have expended approximately $83.0 million developing our current product
candidates for pre-clinical research and development and clinical trials, and we currently expect to spend approximately $9.3 million for the year ending
December 31, 2019 in connection with the development of our therapeutic and vaccine products, licenses, employment agreements, and consulting
agreements, of which approximately $3.3 million is expected to be reimbursed through our existing government contracts and grants.
25
We have no control over the resources and funding NIH, BARDA and NIAID may devote to our programs, which may be subject to periodic renewal and
which generally may be terminated by the government at any time for convenience. Any significant reductions in the funding of U.S. government agencies or
in the funding areas targeted by our business could materially and adversely affect our biodefense program and our results of operations and financial
condition. If we fail to satisfy our obligations under the government contracts, the applicable Federal Acquisition Regulations allow the government to
terminate the agreement in whole or in part, and we may be required to perform corrective actions, including but not limited to delivering to the government
any incomplete work. If NIH, BARDA or NIAID do not exercise future funding options under the contracts or grants, terminate the funding or fail to perform
their responsibilities under the agreements or grants, it could materially impact our biodefense program and our financial results.
Unless and until we are able to generate sales or licensing revenue from one of our product candidates, we will require additional funding to meet these
commitments, sustain our research and development efforts, provide for future clinical trials, and continue our operations. There can be no assurance we can
raise such funds. If additional funds are raised through the issuance of equity securities, stockholders may experience dilution of their ownership interests, and
the newly issued securities may have rights superior to those of the common stock. If additional funds are raised by the issuance of debt, we may be subject to
limitations on our operations. If we cannot raise such additional funds, we may have to delay or stop some or all of our drug development programs.
If we are unable to develop our product candidates, our ability to generate revenues and viability as a company will be significantly impaired.
In order to generate revenues and profits, our organization must, along with corporate partners and collaborators, positively research, develop and
commercialize our technologies or product candidates. Our current product candidates are in various stages of clinical and pre-clinical development and will
require significant further funding, research, development, pre-clinical and/or clinical testing, regulatory approval and commercialization, and are subject to
the risks of failure inherent in the development of products based on innovative or novel technologies. Specifically, each of the following is possible with
respect to any of our product candidates:
● we may not be able to maintain our current research and development schedules;
● we may be unable to secure procurement contracts on beneficial economic terms or at all from the U.S. government or others for our biodefense
products;
● we may encounter problems in clinical trials; or
● the technology or product may be found to be ineffective or unsafe, or may fail to obtain marketing approval.
If any of the risks set forth above occur, or if we are unable to obtain the necessary regulatory approvals as discussed below, we may be unable to develop our
technologies and product candidates and our business will be seriously harmed. Furthermore, for reasons including those set forth below, we may be unable to
commercialize or receive royalties from the sale of any other technology we develop, even if it is shown to be effective, if:
● it is not economical or the market for the product does not develop or diminishes;
● we are not able to enter into arrangements or collaborations to manufacture and/or market the product;
● the product is not eligible for third-party reimbursement from government or private insurers;
● others hold proprietary rights that preclude us from commercializing the product;
● we are not able to manufacture the product reliably;
● others have brought to market similar or superior products; or
● the product has undesirable or unintended side effects that prevent or limit its commercial use.
26
We expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our
future performance.
We are a late-stage biopharmaceutical company. Our operations to date have been primarily limited to developing our technology and undertaking pre-clinical
studies and clinical trials of our product candidates in our two active business segments, BioTherapeutics and Vaccines/BioDefense. We have not yet obtained
regulatory approvals for any of our product candidates. Consequently, any predictions made about our future success or viability may not be as accurate as
they could be if we had commercialized products. Our financial condition has varied significantly in the past and will continue to fluctuate from quarter-to-
quarter or year-to-year due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these
fluctuations include other factors described elsewhere in this Annual Report and also include:
● our ability to obtain additional funding to develop our product candidates;
● delays in the commencement, enrollment and timing of clinical trials;
● the success of our product candidates through all phases of clinical development;
● any delays in regulatory review and approval of product candidates in clinical development;
● our ability to obtain and maintain regulatory approval for our product candidates in the United States and foreign jurisdictions;
● potential side effects of our product candidates that could delay or prevent commercialization, limit the indications for any approved drug, require
the establishment of risk evaluation and mitigation strategies, or cause an approved drug to be taken off the market;
● our dependence on third-party contract manufacturing organizations to supply or manufacture our products;
● our dependence on contract research organizations to conduct our clinical trials;
● our ability to establish or maintain collaborations, licensing or other arrangements;
● market acceptance of our product candidates;
● our ability to establish and maintain an effective sales and marketing infrastructure, either through the creation of a commercial infrastructure or
through strategic collaborations;
● competition from existing products or new products that may emerge;
● the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for our products;
● our ability to discover and develop additional product candidates;
● our ability and our licensors’ abilities to successfully obtain, maintain, defend and enforce intellectual property rights important to our business;
● our ability to attract and retain key personnel to manage our business effectively;
● our ability to build our finance infrastructure and improve our accounting systems and controls;
● potential product liability claims;
27
● potential liabilities associated with hazardous materials; and
● our ability to obtain and maintain adequate insurance policies.
Accordingly, the results of any quarterly or annual periods should not be relied upon as indications of future operating performance.
We have no approved products on the market and therefore do not expect to generate any revenues from product sales in the foreseeable future, if at all.
To date, we have no approved product on the market and have not generated any significant product revenues. We have funded our operations primarily from
sales of our securities and from government contracts and grants. We have not received, and do not expect to receive for at least the next several years, if at
all, any revenues from the commercialization of our product candidates. To obtain revenues from sales of our product candidates, we must succeed, either
alone or with third parties, in developing, obtaining regulatory approval for, manufacturing and marketing drugs with commercial potential or successfully
obtain government procurement or stockpiling agreements. We may never succeed in these activities, and we may not generate sufficient revenues to continue
our business operations or achieve profitability.
Our business is subject to extensive governmental regulation, which can be costly, time consuming and subjects us to unanticipated delays.
Our business is subject to very stringent federal, foreign, state and local government laws and regulations, including the Federal Food, Drug and Cosmetic
Act, the Environmental Protection Act, the Occupational Safety and Health Act, and state and local counterparts to these acts. These laws and regulations may
be amended, additional laws and regulations may be enacted, and the policies of the FDA and other regulatory agencies may change.
The regulatory process applicable to our products requires pre-clinical and clinical testing of any product to establish its safety and efficacy. This testing can
take many years, is uncertain as to outcome, and requires the expenditure of substantial capital and other resources. We estimate that the clinical trials of our
product candidates that we have planned will take at least several years to complete. Furthermore, failure can occur at any stage of the trials, and we could
encounter problems that cause us to abandon or repeat clinical trials. Favorable results in early studies or trials, if any, may not be repeated in later studies or
trials. Even if our clinical trials are initiated and completed as planned, we cannot be certain that the results will support our product candidate claims.
Success in preclinical testing, Phase 1 and Phase 2 clinical trials does not ensure that later Phase 2 or Phase 3 clinical trials will be successful. In addition, we,
the FDA or other regulatory authorities may suspend clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or
the FDA or other regulatory authorities find deficiencies in our submissions or conduct of our trials.
We may not be able to obtain, or we may experience difficulties and delays in obtaining, necessary domestic and foreign governmental clearances and
approvals to market a product. Also, even if regulatory approval of a product is granted, that approval may entail limitations on the indicated uses for which
the product may be marketed.
Following any regulatory approval, a marketed product and its manufacturer are subject to continual regulatory review. Later discovery of problems with a
product or manufacturer may result in restrictions on such product or manufacturer. These restrictions may include product recalls and suspension or
withdrawal of the marketing approval for the product. Furthermore, the advertising, promotion and export, among other things, of a product are subject to
extensive regulation by governmental authorities in the U.S. and other countries. If we fail to comply with applicable regulatory requirements, we may be
subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and/or criminal prosecution.
28
There may be unforeseen challenges in developing our biodefense products.
For development of biodefense vaccines and therapeutics, the FDA has instituted policies that are expected to result in accelerated approval. This includes
approval for commercial use using the results of animal efficacy trials, rather than efficacy trials in humans, referred to as the Animal Rule. However, we will
still have to establish that the vaccines we are developing are safe in humans at doses that are correlated with the beneficial effect in animals. Such clinical
trials will also have to be completed in distinct populations that are subject to the countermeasures; for instance, the very young and the very old, and in
pregnant women, if the countermeasure is to be licensed for civilian use. Other agencies will have an influence over the risk benefit scenarios for deploying
the countermeasures and in establishing the number of doses utilized in the Strategic National Stockpile. We may not be able to sufficiently demonstrate the
animal correlation to the satisfaction of the FDA, as these correlates are difficult to establish and are often unclear. Invocation of the Animal Rule may raise
issues of confidence in the model systems even if the models have been validated. For many of the biological threats, the animal models are not available and
we may have to develop the animal models, a time-consuming research effort. There are few historical precedents, or recent precedents, for the development
of new countermeasures for bioterrorism agents. Despite the Animal Rule, the FDA may require large clinical trials to establish safety and immunogenicity
before licensure and it may require safety and immunogenicity trials in additional populations. Approval of biodefense products may be subject to post-
marketing studies, and could be restricted in use in only certain populations. The government’s biodefense priorities can change, which could adversely affect
the commercial opportunity for the products we are developing. Further, other countries have not, at this time, established criteria for review and approval of
these types of products outside their normal review process, i.e., there is no Animal Rule equivalent, and consequently there can be no assurance that we will
be able to make a submission for marketing approval in foreign countries based on such animal data.
Additionally, few facilities in the United States and internationally have the capability to test animals with ricin, or otherwise assist us in qualifying the
requisite animal models. We have to compete with other biodefense companies for access to this limited pool of highly specialized resources. We therefore
may not be able to secure contracts to conduct the testing in a predictable timeframe or at all.
We are dependent on government funding, which is inherently uncertain, for the success of our biodefense operations.
We are subject to risks specifically associated with operating in the biodefense industry, which is a new and unproven business area. We do not anticipate that
a significant commercial market will develop for our biodefense products. Because we anticipate that the principal potential purchasers of these products, as
well as potential sources of research and development funds, will be the U.S. government and governmental agencies, the success of our biodefense division
will be dependent in large part upon government spending decisions. The funding of government programs is dependent on budgetary limitations,
congressional appropriations and administrative allotment of funds, all of which are inherently uncertain and may be affected by changes in U.S. government
policies resulting from various political and military developments. Our receipt of government funding is also dependent on our ability to adhere to the terms
and provisions of the original grant and contract documents and other regulations. We can provide no assurance that we will receive or continue to receive
funding for grants and contracts we have been awarded. The loss of government funds could have a material adverse effect on our ability to progress our
biodefense business.
If the parties we depend on for supplying our drug substance raw materials and certain manufacturing-related services do not timely supply these
products and services, it may delay or impair our ability to develop, manufacture and market our products. We do not have or anticipate having internal
manufacturing capabilities.
We rely on suppliers for our drug substance raw materials and third parties for certain manufacturing-related services to produce material that meets
appropriate content, quality and stability standards, which material will be used in clinical trials of our products and, after approval, for commercial
distribution. To succeed, clinical trials require adequate supplies of drug substance and drug product, which may be difficult or uneconomical to procure or
manufacture. We and our suppliers and vendors may not be able to (i) produce our drug substance or drug product to appropriate standards for use in clinical
studies, (ii) perform under any definitive manufacturing, supply or service agreements with us or (iii) remain in business for a sufficient time to be able to
develop, produce, secure regulatory approval of and market our product candidates. If we do not maintain important manufacturing and service relationships,
we may fail to find a replacement supplier or required vendor or develop our own manufacturing capabilities which could delay or impair our ability to obtain
regulatory approval for our products and substantially increase our costs or deplete profit margins, if any. If we do find replacement manufacturers and
vendors, we may not be able to enter into agreements with them on terms and conditions favorable to us and, there could be a substantial delay before a new
facility could be qualified and registered with the FDA and foreign regulatory authorities.
29
We rely on third parties for pre-clinical and clinical trials of our product candidates and, in some cases, to maintain regulatory files for our product
candidates. If we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their
services as required, or if these third parties fail to timely transfer any regulatory information held by them to us, we may not be able to obtain regulatory
approval for, or commercialize, our product candidates.
We rely on academic institutions, hospitals, clinics and other third-party collaborators for preclinical and clinical trials of our product candidates. Although we
monitor, support, and/or oversee our pre-clinical and clinical trials, because we do not conduct these trials ourselves, we have less control over the timing and
cost of these studies and the ability to recruit trial subjects than if we conducted these trials wholly by ourselves. If we are unable to maintain or enter into
agreements with these third parties on acceptable terms, or if any such engagement is terminated, we may be unable to enroll patients on a timely basis or
otherwise conduct our trials in the manner we anticipate. In addition, there is no guarantee that these third parties will devote adequate time and resources to
our studies or perform as required by a contract or in accordance with regulatory requirements, including maintenance of clinical trial information regarding
our product candidates. If these third parties fail to meet expected deadlines, fail to timely transfer to us any regulatory information, fail to adhere to protocols
or fail to act in accordance with regulatory requirements or our agreements with them, or if they otherwise perform in a substandard manner or in a way that
compromises the quality or accuracy of their activities or the data they obtain, then preclinical and/or clinical trials of our product candidates may be
extended, delayed or terminated, or our data may be rejected by the FDA or regulatory agencies.
The manufacturing of our products is a highly exacting process, and if we or one of our materials suppliers encounter problems manufacturing our
products, our business could suffer.
The FDA and foreign regulators require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to
confirm compliance with current Good Manufacturing Practice (“cGMP”) or similar requirements that the FDA or foreign regulators establish. We, or our
materials suppliers, may face manufacturing or quality control problems causing product production and shipment delays or a situation where we or the
supplier may not be able to maintain compliance with the FDA’s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing our
drug substance. Any failure to comply with cGMP requirements or other FDA or foreign regulatory requirements could adversely affect our clinical research
activities and our ability to market and develop our products.
We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or
product candidates that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and human resources, we are currently focusing on the regulatory approval of certain product candidates. As a result, we
may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our
resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on existing
and future product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial
potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic alliance, licensing
or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such
product candidate, or we may allocate internal resources to a product candidate in an area in which it would have been more advantageous to enter into a
partnering arrangement.
30
Even if approved, our products will be subject to extensive post-approval regulation.
Once a product is approved, numerous post-approval requirements apply. Among other things, the holder of an approved New Drug Application (“NDA”) is
subject to periodic and other FDA monitoring and reporting obligations, including obligations to monitor and report adverse events and instances of the
failure of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for
certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional
material to the FDA and report on ongoing clinical trials.
Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines, injunctions, recall or seizure of
products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supply
contracts, including government contracts. In addition, even if we comply with FDA and other requirements, new information regarding the safety or
effectiveness of a product could lead the FDA to modify or withdraw product approval.
Even if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market.
Even if the FDA approves one or more of our product candidates, physicians and patients may not accept it or use it. Even if physicians and patients would
like to use our products, our products may not gain market acceptance among healthcare payors such as managed care formularies, insurance companies or
government programs such as Medicare or Medicaid. Acceptance and use of our products will depend upon a number of factors including: perceptions by
members of the health care community, including physicians, about the safety and effectiveness of our drug product; cost-effectiveness of our product relative
to competing products; availability of reimbursement for our product from government or other healthcare payers; and effectiveness of marketing and
distribution efforts by us and our licensees and distributors, if any.
The degree of market acceptance of any product that we develop will depend on a number of factors, including:
● cost-effectiveness;
● the safety and effectiveness of our products, including any significant potential side effects, as compared to alternative products or treatment
methods;
● the timing of market entry as compared to competitive products;
● the rate of adoption of our products by doctors and nurses;
● product labeling or product insert required by the FDA for each of our products;
● reimbursement policies of government and third-party payors;
● effectiveness of our sales, marketing and distribution capabilities and the effectiveness of such capabilities of our collaborative partners, if any; and
● unfavorable publicity concerning our products or any similar products.
Our product candidates, if successfully developed, will compete with a number of products manufactured and marketed by major pharmaceutical companies,
biotechnology companies and manufacturers of generic drugs. Our products may also compete with new products currently under development by others.
Physicians, patients, third-party payors and the medical community may not accept and utilize any of our product candidates. If our products do not achieve
market acceptance, we will not be able to generate significant revenues or become profitable.
Because we expect sales of our current product candidates, if approved, to generate substantially all of our product revenues for the foreseeable future, the
failure of these products to find market acceptance would harm our business and could require us to seek additional financing.
31
We do not have extensive sales and marketing experience and our lack of experience may restrict our success in commercializing some of our product
candidates.
We do not have extensive experience in marketing or selling pharmaceutical products whether in the U.S. or internationally. To obtain the expertise necessary
to successfully market and sell any of our products, the development of our own commercial infrastructure and/or collaborative commercial arrangements and
partnerships will be required. Our ability to make that investment and also execute our current operating plan is dependent on numerous factors, including, the
performance of third party collaborators with whom we may contract.
Our products, if approved, may not be commercially viable due to change in health care practice and third party reimbursement limitations.
Initiatives to reduce the federal deficit and to change health care delivery are increasing cost-containment efforts. We anticipate that Congress, state
legislatures and the private sector will continue to review and assess alternative benefits, controls on health care spending through limitations on the growth of
private health insurance premiums and Medicare and Medicaid spending, price controls on pharmaceuticals, and other fundamental changes to the health care
delivery system. Any changes of this type could negatively impact the commercial viability of our products, if approved. Our ability to successfully
commercialize our product candidates, if they are approved, will depend in part on the extent to which appropriate reimbursement codes and authorized cost
reimbursement levels of these products and related treatment are obtained from governmental authorities, private health insurers and other organizations, such
as health maintenance organizations. In the absence of national Medicare coverage determination, local contractors that administer the Medicare program may
make their own coverage decisions. Any of our product candidates, if approved and when commercially available, may not be included within the then
current Medicare coverage determination or the coverage determination of state Medicaid programs, private insurance companies or other health care
providers. In addition, third-party payers are increasingly challenging the necessity and prices charged for medical products, treatments and services.
Our product candidates may cause serious adverse events or undesirable side effects which may delay or prevent marketing approval, or, if approval is
received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
Serious adverse events or undesirable side effects from any of our product candidates could arise either during clinical development or, if approved, after the
approved product has been marketed. The results of future clinical trials may show that our product candidates cause serious adverse events or undesirable
side effects, which could interrupt, delay or halt clinical trials, resulting in delay of, or failure to obtain, marketing approval from the FDA and other
regulatory authorities.
If any of our product candidates cause serious adverse events or undesirable side effects:
● regulatory authorities may impose a clinical hold which could result in substantial delays and adversely impact our ability to continue development
of the product;
● regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and
pharmacies;
● we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;
● we may be required to implement a risk minimization action plan, which could result in substantial cost increases and have a negative impact on our
ability to commercialize the product;
● we may be required to limit the patients who can receive the product;
● we may be subject to limitations on how we promote the product;
32
● sales of the product may decrease significantly;
● regulatory authorities may require us to take our approved product off the market;
● we may be subject to litigation or product liability claims; and
● our reputation may suffer.
Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase
commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from the sale of our products.
If we fail to obtain or maintain orphan drug exclusivity for our product candidates, our competitors may sell products to treat the same conditions and
our revenue will be reduced.
Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient
population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable
expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the European Medicines Agency’s
Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis,
prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union.
Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and
chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment
in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the
medicine must be of significant benefit to those affected by the condition.
In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax
advantages, and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product
is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a
period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the
manufacturer is unable to assure sufficient product quantity. In the European Union, orphan drug designation entitles a party to financial incentives such as
reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if
the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of
market exclusivity.
Even though we have orphan drug designation for SGX301 in the United States and Europe, and SGX203, RiVax® and OrbeShield® in the United States, we
may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing drugs or biologic
products. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because
different drugs with different active moieties can be approved for the same condition. Absent patent or other intellectual property protection, even after an
orphan drug is approved, the FDA or European Medicines Agency may subsequently approve the same drug with the same active moiety for the same
condition if the FDA or European Medicines Agency concludes that the later drug is safer, more effective, or makes a major contribution to patient care.
Federal and/or state health care reform initiatives could negatively affect our business.
The availability of reimbursement by governmental and other third-party payers affects the market for any pharmaceutical product. These third-party payers
continually attempt to contain or reduce the costs of healthcare. There have been a number of legislative and regulatory proposals to change the healthcare
system and further proposals are likely. Medicare’s policies may decrease the market for our products. Significant uncertainty exists with respect to the
reimbursement status of newly approved healthcare products.
33
Third-party payers are increasingly challenging the price and cost-effectiveness of medical products and services. Once approved, we might not be able to sell
our products profitably or recoup the value of our investment in product development if reimbursement is unavailable or limited in scope, particularly for
product candidates addressing small patient populations. On July 15, 2008, the Medicare Improvements for Patients and Providers Act of 2008 became law
with a number of Medicare and Medicaid reforms to establish a bundled Medicare payment rate that includes services and drug/labs that were separately
billed at that time. Bundling initiatives that have been implemented in other healthcare settings have occasionally resulted in lower utilization of services that
had not previously been a part of the bundled payment.
In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing
drug pricing vary widely from country to country. We expect that there will continue to be a number of U.S. federal and state proposals to implement
governmental pricing controls. While we cannot predict whether such legislative or regulatory proposals will be adopted, the adoption of such proposals could
have a material adverse effect on our business, financial condition and profitability.
We may not be able to retain rights licensed to us by third parties to commercialize key products or to develop the third party relationships we need to
develop, manufacture and market our products.
We currently rely on license agreements from New York University, Yeda Research and Development Company Ltd., the University of Texas Southwestern
Medical Center, the University of British Columbia, Harvard University and George B. McDonald, MD as well as sublicense agreement from VitriVax for the
rights to commercialize key product candidates. We may not be able to retain the rights granted under these agreements or negotiate additional agreements on
reasonable terms, if at all. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone
payment, royalty, and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, we may be
required to make certain payments to the licensor, we may lose the exclusivity of our license, or the licensor may have the right to terminate the license, in
which event we would not be able to develop or market products covered by the license.
Additionally, the milestone and other payments associated with these licenses will make it less profitable for us to develop our drug candidates. See “Business
- Patents and Other Proprietary Rights” for a description of our license agreements.
Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise
regarding intellectual property subject to a licensing agreement, including but not limited to:
● the scope of rights granted under the license agreement and other interpretation-related issues;
● the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
● the sublicensing of patent and other rights;
● our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
● the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our
collaborators; and
● the priority of invention of patented technology.
If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on
acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.
34
Additionally, the research resulting in certain of our licensed patent rights and technology was funded by the U.S. government. As a result, the government
may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the
government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for
non-commercial purposes. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical
application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations
or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying
such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results
of operations and prospects.
Furthermore, we currently have very limited product development capabilities and no manufacturing, marketing or sales capabilities. For us to research,
develop and test our product candidates, we need to contract or partner with outside researchers, in most cases with or through those parties that did the
original research and from whom we have licensed the technologies. If products are successfully developed and approved for commercialization, then we will
need to enter into additional collaboration and other agreements with third parties to manufacture and market our products. We may not be able to induce the
third parties to enter into these agreements, and, even if we are able to do so, the terms of these agreements may not be favorable to us. Our inability to enter
into these agreements could delay or preclude the development, manufacture and/or marketing of some of our product candidates or could significantly
increase the costs of doing so. In the future, we may grant to our development partners rights to license and commercialize pharmaceutical and related
products developed under the agreements with them, and these rights may limit our flexibility in considering alternatives for the commercialization of these
products. Furthermore, third-party manufacturers or suppliers may not be able to meet our needs with respect to timing, quantity and quality for the products.
Additionally, if we do not enter into relationships with additional third parties for the marketing of our products, if and when they are approved and ready for
commercialization, we would have to build our own sales force or enter into commercialization agreements with other companies. Development of an
effective sales force in any part of the world would require significant financial resources, time and expertise. We may not be able to obtain the financing
necessary to establish a sales force in a timely or cost effective manner, if at all, and any sales force we are able to establish may not be capable of generating
demand for our product candidates, if they are approved.
We may suffer product and other liability claims; we maintain only limited product liability insurance, which may not be sufficient.
The clinical testing, manufacture and sale of our products involves an inherent risk that human subjects in clinical testing or consumers of our products may
suffer serious bodily injury or death due to side effects, allergic reactions or other unintended negative reactions to our products. As a result, product and other
liability claims may be brought against us. We currently have clinical trial and product liability insurance with limits of liability of $10 million, which may
not be sufficient to cover our potential liabilities. Because liability insurance is expensive and difficult to obtain, we may not be able to maintain existing
insurance or obtain additional liability insurance on acceptable terms or with adequate coverage against potential liabilities. Furthermore, if any claims are
brought against us, even if we are fully covered by insurance, we may suffer harm such as adverse publicity.
We may use hazardous chemicals in our business. Potential claims relating to improper handling, storage or disposal of these chemicals could affect us
and be time consuming and costly.
Our research and development processes and/or those of our third party contractors involve the controlled use of hazardous materials and chemicals. These
hazardous chemicals are reagents and solvents typically found in a chemistry laboratory. Our operations also may produce hazardous waste products. Federal,
state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. While we attempt to comply with all
environmental laws and regulations, including those relating to the outsourcing of the disposal of all hazardous chemicals and waste products, we cannot
eliminate the risk of contamination from or discharge of hazardous materials and any resultant injury. In the event of such an accident, we could be held liable
for any resulting damages and any liability could materially adversely affect our business, financial condition and results of operations.
35
Compliance with environmental laws and regulations may be expensive. Current or future environmental regulations may impair our research, development
or production efforts. We might have to pay civil damages in the event of an improper or unauthorized release of, or exposure of individuals to, hazardous
materials. We are not insured against these environmental risks. We may agree to indemnify our collaborators in some circumstances against damages and
other liabilities arising out of development activities or products produced in connection with these collaborations.
In addition, the federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous or radioactive
materials and waste products may require us to incur substantial compliance costs that could materially adversely affect our business, financial condition and
results of operations.
We may not be able to compete with our larger and better financed competitors in the biotechnology industry.
The biotechnology industry is intensely competitive, subject to rapid change and sensitive to new product introductions or enhancements. Most of our
existing competitors have greater financial resources, larger technical staffs, and larger research budgets than we have, as well as greater experience in
developing products and conducting clinical trials. Our competition is particularly intense in the gastroenterology and transplant areas and is also intense in
the therapeutic area of inflammatory bowel diseases. We face intense competition in the biodefense area from various public and private companies and
universities as well as governmental agencies, such as the U.S. Army, which may have their own proprietary technologies that may directly compete with our
technologies. In addition, there may be other companies that are currently developing competitive technologies and products or that may in the future develop
technologies and products that are comparable or superior to our technologies and products. We may not be able to compete with our existing and future
competitors, which could lead to the failure of our business.
Additionally, if a competitor receives FDA approval before we do for a drug that is similar to one of our product candidates, FDA approval for our product
candidate may be precluded or delayed due to periods of non-patent exclusivity and/or the listing with the FDA by the competitor of patents covering its
newly-approved drug product. Periods of non-patent exclusivity for new versions of existing drugs such as our current product candidates can extend up to
three and one-half years. See “Business - The Drug Approval Process.”
These competitive factors could require us to conduct substantial new research and development activities to establish new product targets, which would be
costly and time consuming. These activities would adversely affect our ability to commercialize products and achieve revenue and profits.
Competition and technological change may make our product candidates and technologies less attractive or obsolete.
We compete with established pharmaceutical and biotechnology companies that are pursuing other forms of treatment for the same indications we are
pursuing and that have greater financial and other resources. Other companies may succeed in developing products earlier than us, obtaining FDA approval
for products more rapidly, or developing products that are more effective than our product candidates. Research and development by others may render our
technology or product candidates obsolete or noncompetitive, or result in treatments or cures superior to any therapy we develop. We face competition from
companies that internally develop competing technology or acquire competing technology from universities and other research institutions. As these
companies develop their technologies, they may develop competitive positions that may prevent, make futile, or limit our product commercialization efforts,
which would result in a decrease in the revenue we would be able to derive from the sale of any products.
There can be no assurance that any of our product candidates will be accepted by the marketplace as readily as these or other competing treatments.
Furthermore, if our competitors’ products are approved before ours, it could be more difficult for us to obtain approval from the FDA. Even if our products
are successfully developed and approved for use by all governing regulatory bodies, there can be no assurance that physicians and patients will accept our
product(s) as a treatment of choice.
36
Furthermore, the pharmaceutical research industry is diverse, complex, and rapidly changing. By its nature, the business risks associated therewith are
numerous and significant. The effects of competition, intellectual property disputes, market acceptance, and FDA regulations preclude us from forecasting
revenues or income with certainty or even confidence.
Our business could be harmed if we fail to retain our current personnel or if they are unable to effectively run our business.
We currently have 16 employees and we depend upon these employees, in particular Dr. Christopher Schaber, our President and Chief Executive Officer, to
manage the day-to-day activities of our business. Because we have such limited personnel, the loss of any of them or our inability to attract and retain other
qualified employees in a timely manner would likely have a negative impact on our operations. We may be unable to effectively manage and operate our
business, and our business may suffer, if we lose the services of our employees.
Instability and volatility in the financial markets could have a negative impact on our business, financial condition, results of operations, and cash flows.
During recent years, there has been substantial volatility in financial markets due at least in part to the uncertainty with regard to the global economic
environment. In addition, there has been substantial uncertainty in the capital markets and access to additional financing is uncertain. Moreover, customer
spending habits may be adversely affected by current and future economic conditions. These conditions could have an adverse effect on our industry and
business, including our financial condition, results of operations, and cash flows.
To the extent that we do not generate sufficient cash from operations, we may need to issue stock or incur indebtedness to finance our plans for growth.
Recent turmoil in the credit markets and the potential impact on the liquidity of major financial institutions may have an adverse effect on our ability to fund
our business strategy through borrowings, under either existing or newly created instruments in the public or private markets on terms we believe to be
reasonable, if at all.
We may not be able to utilize all of our net operating loss carryforwards.
The State of New Jersey’s Technology Business Tax Certificate Program allows certain high technology and biotechnology companies to sell unused net
operating loss (“NOL”) carryforwards to other New Jersey-based corporate taxpayers. In accordance with this program, for the year ended December 31,
2016, we sold New Jersey NOL carryforwards, resulting in the recognition of $416,810 of income tax benefit. The Company has not yet sold its 2017 New
Jersey NOLs but may do so in the future. If there is an unfavorable change in the State of New Jersey’s Technology Business Tax Certificate Program
(whether as a result of a change in law, policy or otherwise) that terminates the program or eliminates or reduces our ability to use or sell our NOL
carryforwards, or if we are unable to find a suitable buyer to utilize our New Jersey NOL carryforwards to the extent the NOLs expire before we are able to
utilize them against our taxable income, our cash taxes may increase which may have an adverse effect on our financial condition.
Risks Related to our Intellectual Property
We may be unable to commercialize our products if we are unable to protect our proprietary rights, and we may be liable for significant costs and
damages if we face a claim of intellectual property infringement by a third party.
Our near and long-term prospects depend in part on our ability to obtain and maintain patents, protect trade secrets and operate without infringing upon the
proprietary rights of others. In the absence of patent and trade secret protection, competitors may adversely affect our business by independently developing
and marketing substantially equivalent or superior products and technology, possibly at lower prices. We could also incur substantial costs in litigation and
suffer diversion of attention of technical and management personnel if we are required to defend ourselves in intellectual property infringement suits brought
by third parties, with or without merit, or if we are required to initiate litigation against others to protect or assert our intellectual property rights. Moreover,
any such litigation may not be resolved in our favor.
37
Although we and our licensors have filed various patent applications covering the uses of our product candidates, patents may not be issued from the patent
applications already filed or from applications that we might file in the future. Moreover, the patent position of companies in the pharmaceutical industry
generally involves complex legal and factual questions, and has been the subject of much litigation. Any patents we own or license, now or in the future, may
be challenged, invalidated or circumvented. To date, no consistent policy has been developed in the U.S. Patent and Trademark Office (the “PTO”) regarding
the breadth of claims allowed in biotechnology patents.
In addition, because patent applications in the U.S. are maintained in secrecy until patent applications publish or patents issue, and because publication of
discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain that we and our licensors are the first creators of
inventions covered by any licensed patent applications or patents or that we or they are the first to file. The PTO may commence interference proceedings
involving patents or patent applications, in which the question of first inventorship is contested. Accordingly, the patents owned or licensed to us may not be
valid or may not afford us protection against competitors with similar technology, and the patent applications licensed to us may not result in the issuance of
patents.
It is also possible that our owned and licensed technologies may infringe on patents or other rights owned by others, and licenses to which may not be
available to us. We may be unable to obtain a license under such patent on terms favorable to us, if at all. We may have to alter our products or processes, pay
licensing fees or cease activities altogether because of patent rights of third parties.
In addition to the products for which we have patents or have filed patent applications, we rely upon unpatented proprietary technology and may not be able
to meaningfully protect our rights with regard to that unpatented proprietary technology. Furthermore, to the extent that consultants, key employees or other
third parties apply technological information developed by them or by others to any of our proposed projects, disputes may arise as to the proprietary rights to
this information, which may not be resolved in our favor.
We may be involved in lawsuits to protect or enforce our patents, which could be expensive and time consuming.
The pharmaceutical industry has been characterized by extensive litigation regarding patents and other intellectual property rights, and companies have
employed intellectual property litigation to gain a competitive advantage. We may become subject to infringement claims or litigation arising out of patents
and pending applications of our competitors, or additional interference proceedings declared by the PTO to determine the priority of inventions. The defense
and prosecution of intellectual property suits, PTO proceedings, and related legal and administrative proceedings are costly and time-consuming to pursue,
and their outcome is uncertain. Litigation may be necessary to enforce our issued patents, to protect our trade secrets and know-how, or to determine the
enforceability, scope, and validity of the proprietary rights of others. An adverse determination in litigation or interference proceedings to which we may
become a party could subject us to significant liabilities, require us to obtain licenses from third parties, or restrict or prevent us from selling our products in
certain markets. Although patent and intellectual property disputes might be settled through licensing or similar arrangements, the costs associated with such
arrangements may be substantial and could include our paying large fixed payments and ongoing royalties. Furthermore, the necessary licenses may not be
available on satisfactory terms or at all.
Competitors may infringe our patents, and we may file infringement claims to counter infringement or unauthorized use. This can be expensive, particularly
for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is
unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. An adverse
determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly.
38
Also, a third party may assert that our patents are invalid and/or unenforceable. There are no unresolved communications, allegations, complaints or threats of
litigation related to the possibility that our patents are invalid or unenforceable. Any litigation or claims against us, whether or not merited, may result in
substantial costs, place a significant strain on our financial resources, divert the attention of management and harm our reputation. An adverse decision in
litigation could result in inadequate protection for our product candidates and/or reduce the value of any license agreements we have with third parties.
Interference proceedings brought before the PTO may be necessary to determine priority of invention with respect to our patents or patent applications.
During an interference proceeding, it may be determined that we do not have priority of invention for one or more aspects in our patents or patent applications
and could result in the invalidation in part or whole of a patent or could put a patent application at risk of not issuing. Even if successful, an interference
proceeding may result in substantial costs and distraction to our management.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or interference proceedings, there is a
risk that some of our confidential information could be compromised by disclosure. In addition, there could be public announcements of the results of
hearings, motions or other interim proceedings or developments. If investors perceive these results to be negative, the price of our common stock could be
adversely affected.
If we infringe the rights of third parties we could be prevented from selling products, forced to pay damages, and defend against litigation.
If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantial costs and we may have
to: obtain licenses, which may not be available on commercially reasonable terms, if at all; abandon an infringing product candidate; redesign our products or
processes to avoid infringement; stop using the subject matter claimed in the patents held by others; pay damages; and/or defend litigation or administrative
proceedings which may be costly whether we win or lose, and which could result in a substantial diversion of our financial and management resources.
Risks Related to our Securities
The price of our common stock and warrants may be highly volatile.
The market price of our securities, like that of many other research and development public pharmaceutical and biotechnology companies, has been highly
volatile and the price of our common stock and warrants may be volatile in the future due to a wide variety of factors, including:
● announcements by us or others of results of pre-clinical testing and clinical trials;
● announcements of technological innovations, more important bio-threats or new commercial therapeutic products by us, our collaborative partners or
our present or potential competitors;
● failure of our common stock or warrants to continue to be listed or quoted on a national exchange or market system, such as The Nasdaq Stock
Market (“NASDAQ”) or NYSE Amex LLC;
● our quarterly operating results and performance;
● developments or disputes concerning patents or other proprietary rights;
● acquisitions;
● litigation and government proceedings;
● adverse legislation;
● changes in government regulations;
39
● our available working capital;
● economic and other external factors;
● general market conditions.
Since January 1, 2018, the closing stock price of our common stock has fluctuated between a high of $2.40 per share to a low of $0.85 per share. Since
January 1, 2018, the closing price of our common stock warrants has fluctuated between a high of $0.81 per warrant to a low of $0.13 per warrant. On March
20, 2019 the last reported sales prices of our common stock and our common stock warrant on The Nasdaq Capital Market were $1.01 per share and $0.20 per
warrant. The fluctuation in the price of our common stock and warrants has sometimes been unrelated or disproportionate to our operating performance. In
addition, potential dilutive effects of future sales of shares of common stock and warrants by us, as well as potential sale of common stock by the holders of
warrants and options, could have an adverse effect on the market price of our shares.
We are not currently in compliance with the continued listing requirements for The Nasdaq Capital Market. If the price of our common stock continues to
trade below $1.00 per share for a sustained period or we do not meet other continued listing requirements, our common stock may be delisted from The
Nasdaq Capital Market, which could affect the market price and liquidity for our common stock and reduce our ability to raise additional capital.
Our common stock is listed on The Nasdaq Capital Market. In order to maintain that listing, we must satisfy minimum financial and other requirements
including, without limitation, a requirement that our closing bid price be at least $1.00 per share. On March 11, 2018, we received a written notice from The
Nasdaq Stock Market indicating that we are not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
We have until September 9, 2019 to regain compliance. We can regain compliance if at any time prior to September 9, 2019 the bid price of our common
stock closes at or above $1.00 per share for a minimum of ten consecutive business days.
If we fail to regain compliance with the minimum bid price requirement by September 9, 2019, we may be afforded an additional 180-day period to regain
compliance provided that (i) we meet the applicable market value of publicly held shares requirement for continued listing and all other applicable
requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement) based on our most recent public filings and market
information and (ii) we provide notice of our intent to cure the bid price requirement deficiency prior to the completion of the second 180-day compliance
period by effecting a reverse stock split, if necessary.
We anticipate that we will seek stockholder approval at our annual meeting in 2019 to grant discretionary authority to our board of directors to amend our
certificate of incorporation to effect a reverse split of our outstanding shares of common stock within a range of one share of common stock for every ten
shares of common stock to one share of common stock for every twenty shares of common stock, with the exact reverse split ratio to be decided and publicly
announced by the board of directors prior to the effective time of the amendment to our certificate of incorporation.
We intend to monitor the closing bid price of our common stock and consider our available options to resolve our noncompliance with the minimum bid price
requirement. There can be no assurance that we will be able to regain compliance with the minimum bid price requirement or that we will otherwise be in
compliance with other listing criteria. If we fail to regain compliance with the minimum bid requirement or to meet the other applicable continued listing
requirements for The Nasdaq Capital Market in the future and staff of The Nasdaq Stock Market determines to delist our common stock, the delisting could
adversely affect the market price and liquidity of our common stock and reduce our ability to raise additional capital. In addition, if our common stock is
delisted from The Nasdaq Capital Market and the trading price remains below $5.00 per share, trading in our common stock might also become subject to the
requirements of certain rules promulgated under the Exchange Act, which require additional disclosure by broker-dealers in connection with any trade
involving a stock defined as a “penny stock” (generally, any equity security not listed on a national securities exchange that has a market price of less than
$5.00 per share, subject to certain exceptions).
40
If we fail to remain current with our listing requirements, we could be removed from The Nasdaq Capital Market, which would limit the ability of broker-
dealers to sell our securities and the ability of shareholders to sell their securities in the secondary market.
Companies trading on The Nasdaq Stock Market, such as our Company, must be reporting issuers under Section 12 of the Exchange Act, as amended, and
must meet the listing requirements in order to maintain the listing of common stock on The Nasdaq Capital Market. If we do not meet these requirements, the
market liquidity for our securities could be severely adversely affected by limiting the ability of broker-dealers to sell our securities and the ability of
shareholders to sell their securities in the secondary market.
The warrants may not have any value.
The outstanding warrants do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but
rather merely represent the right to acquire shares of common stock at a fixed price for a limited period of time. Specifically, the holders of the outstanding
warrants may exercise their right to acquire the common stock and pay the per share exercise price, prior to the expiration date, after which date any
unexercised warrants will expire and have no further value. In the event our common stock does not exceed the exercise price of the warrants during the
period when the warrants are exercisable, the warrants may not have any value.
Shareholders may suffer substantial dilution related to issued stock warrants and options.
As of December 31, 2018, we had a number of agreements or obligations that may result in dilution to investors. These include:
● warrants to purchase a total of approximately 6,303,643 shares of our common stock at a current weighted average exercise price of approximately
$3.09;
● options to purchase approximately 1,022,095 shares of our common stock at a current weighted average exercise price of approximately $5.32; and
● The FBR Sales Agreement pursuant to which we may, but have no obligation to, sell up to an additional $8.5 million worth of our common stock as
of March 20, 2019.
We also have an incentive compensation plan for our management, employees and consultants. We have granted, and expect to grant in the future, options to
purchase shares of our common stock to our directors, employees and consultants. To the extent that warrants or options are exercised, our stockholders will
experience dilution and our stock price may decrease.
Our shares of common stock and warrants are thinly traded, so stockholders may be unable to sell at or near ask prices or at all if they need to sell shares
or warrants to raise money or otherwise desire to liquidate their shares.
Our common stock and warrants have from time to time been “thinly-traded,” meaning that the number of persons interested in purchasing our common stock
or warrants at or near ask prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the
fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community
that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow
an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we become more seasoned and viable. As a
consequence, there may be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer
which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give
stockholders any assurance that a broader or more active public trading market for our common shares and warrants will develop or be sustained, or that
current trading levels will be sustained.
We do not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, our stockholders’ ability to achieve a
return on their investment will depend on appreciation in the price of our common stock.
We have never declared or paid cash dividends on our common stock and do not anticipate paying any cash dividends to holders of our common stock in the
foreseeable future. Consequently, our stockholders must rely on sales of their common stock and warrants after price appreciation, which may never occur, as
the only way to realize any future gains on their investments. There is no guarantee that shares of our common stock or warrants will appreciate in value or
even maintain the price at which our stockholders have purchased their shares.
41
Upon our dissolution, our stockholders may not recoup all or any portion of their investment.
In the event of our liquidation, dissolution or winding-up, whether voluntary or involuntary, the proceeds and/or our assets remaining after giving effect to
such transaction, and the payment of all of our debts and liabilities will be distributed to the holders of common stock on a pro rata basis. There can be no
assurance that we will have available assets to pay to the holders of common stock, or any amounts, upon such a liquidation, dissolution or winding-up. In
this event, our stockholders could lose some or all of their investment.
The issuance of our common stock pursuant to the terms of the asset purchase agreement with Hy Biopharma Inc. may cause dilution and the issuance
of such shares of common stock, or the perception that such issuances may occur, could cause the price of our common stock to fall.
On April 1, 2014, we entered into an option agreement pursuant to which Hy Biopharma granted us an option to purchase certain assets, properties and rights
(the “Hypericin Assets”) related to the development of Hy Biopharma’s synthetic hypericin product candidate for the treatment of CTCL, which we refer to as
SGX301, from Hy Biopharma. In exchange for the option, we paid $50,000 in cash and issued 4,307 shares of common stock in the aggregate to Hy
Biopharma and its assignees. We subsequently exercised the option, and on September 3, 2014, we entered into an asset purchase agreement with Hy
Biopharma, pursuant to which we purchased the Hypericin Assets. Pursuant to the purchase agreement, we paid $275,000 in cash and issued 184,912 shares
of common stock in the aggregate to Hy Biopharma and its assignees, and the licensors of the license agreement acquired from Hy Biopharma, and may issue
up to an aggregate of $10 million worth of our common stock (subject to a cap equal to 19.99% of our issued and outstanding common stock) in the aggregate
upon attainment of specified milestones. The next milestone payment will be payable if the Phase 3 clinical trial of SGX301 is successful in demonstrating
efficacy and safety in the CTCL patient population. Also on September 3, 2014, we entered into a Registration Rights Agreement with Hy Biopharma,
pursuant to which we have filed a registration statement with the SEC.
The number of shares that we may issue under the purchase agreement will fluctuate based on the market price of our common stock. Depending on market
liquidity at the time, the issuance of such shares may cause the trading price of our common stock to fall.
We may ultimately issue all, some or none of the additional shares of our common stock that may be issued pursuant to the purchase agreement. We are
required to register any shares issued pursuant to the purchase agreement for resale under the Securities Act of 1933, as amended. After any such shares are
registered, the holders will be able to sell all, some or none of those shares. Therefore, issuances by us under the purchase agreement could result in
substantial dilution to the interests of other holders of our common stock. Additionally, the issuance of a substantial number of shares of our common stock
pursuant to the purchase agreement, or the anticipation of such issuances, could make it more difficult for us to sell equity or equity-related securities in the
future at a time and at a price that we might otherwise wish to effect sales.
Item 1B. Unresolved Staff Comments
None.
Item 2. Properties
We currently lease approximately 6,200 square feet of office space at 29 Emmons Drive, Suite B-10 in Princeton, New Jersey pursuant to a lease that was
amended in October 2017 and expires in October 2020. This office space currently serves as our corporate headquarters. The rent for the first 12 months was
approximately $11,367 per month, or approximately $22.00 per square foot. The rent increased to approximately $11,625 per month, or approximately $22.50
per square foot, for the 12 months beginning November 1, 2018 and will increase to approximately $11,883 per month, or approximately $23.00 per square
foot, beginning November 1, 2019 for the remainder of the lease. Our office space is sufficient to satisfy our current needs.
Item 3. Legal Proceedings
From time to time, we are a party to claims and legal proceedings arising in the ordinary course of business. Our management evaluates our exposure to these
claims and proceedings individually and in the aggregate and allocates additional monies for potential losses on such litigation if it is possible to estimate the
amount of loss and if the amount of the loss is probable.
42
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is traded on The Nasdaq Capital Market under the symbol “SNGX.” The following table sets forth the high and low sales prices per share
of our common stock for the periods indicated, as reported by The Nasdaq Capital Market.
PART II
Period
Year Ended December 31, 2017:
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
Year Ended December 31, 2018:
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
Price Range
High
Low
$
$
$
$
$
$
$
$
3.18 $
5.08 $
2.99 $
2.61 $
3.70 $
1.96 $
1.97 $
2.20 $
1.90
2.00
1.98
1.74
1.86
0.91
0.95
0.80
On March 20, 2019, the last reported price of our common stock quoted on The Nasdaq Capital Market was $1.01 per share. The Nasdaq Capital Market
prices set forth above represent inter-dealer quotations, without adjustment for retail mark-up, mark-down or commission, and may not represent the prices of
actual transactions. Our stock is listed on The Nasdaq Capital Market under the under the symbol “SNGX.” On December 13, 2016, our common stock
warrants began trading on The Nasdaq Capital Market under the symbol “SNGXW”. For the period December 13, 2017 through the fourth quarter ended
December 31, 2018, the high and low sales price per warrant as reported by Nasdaq were $1.08 and $0.13 respectively. On March 20, 2019, the last reported
price of our common stock warrants on Nasdaq was $0.20 per warrant.
Transfer Agent
The transfer agent and registrar for our common stock and warrants is American Stock Transfer & Trust Company, LLC. The address is 6201 15th Avenue,
Brooklyn, NY 11219 and the telephone number is (718) 921-8200.
Holders of Common Stock
As of March 20, 2019, there were 233 holders of record of our common stock. As of such date, 18,189,208 shares of our common stock were issued and
outstanding.
43
Dividends
We have never declared nor paid any cash dividends, and currently intend to retain all our cash and any earnings for use in our business and, therefore, do not
anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of the Board of
Directors and will be dependent upon our consolidated financial condition, results of operations, capital requirements and such other factors as the Board of
Directors deems relevant.
Item 6. Selected Financial Data
Not applicable.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Cautionary Note Regarding Forward-Looking Statements
This Annual Report on Form 10-K contains forward-looking statements that reflect our current expectations about our future results, performance, prospects
and opportunities. These forward-looking statements are subject to significant risks, uncertainties, and other factors, including those identified in “Risk
Factors” above, which may cause actual results to differ materially from those expressed in, or implied by, any forward-looking statements. The forward-
looking statements within this Form 10-K may be identified by words such as “believes,” “anticipates,” “expects,” “intends,” “may,” “would,” “will” and
other similar expressions. However, these words are not the exclusive means of identifying these statements. In addition, any statements that refer to
expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Except as expressly required by the
federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances occurring
subsequent to the filing of this Form 10-K with the U.S. Securities and Exchange Commission (“the SEC”) or for any other reason. You should carefully
review and consider the various disclosures we make in this report and our other reports filed with the SEC that attempt to advise interested parties of the
risks, uncertainties and other factors that may affect our business.
Our Business Overview
We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical
need. We maintain two active business segments: BioTherapeutics and Vaccines/BioDefense.
Our BioTherapeutics business segment is developing a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible
fluorescent light for the treatment of cutaneous T-cell lymphoma (“CTCL”), our first-in-class innate defense regulator technology, dusquetide (SGX942) for
the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (“BDP”) for the
prevention/treatment of gastrointestinal (“GI”) disorders characterized by severe inflammation, including pediatric Crohn’s disease (SGX203) and acute
radiation enteritis (SGX201).
Our Vaccines/BioDefense business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate and SGX943, our
therapeutic candidate for antibiotic resistant and emerging infectious disease. The development of our vaccine programs currently is supported by our heat
stabilization technology, known as ThermoVax®, under existing and on-going government contract funding. With the government contract from the National
Institute of Allergy and Infectious Diseases (“NIAID”), we will attempt to advance the development of RiVax® to protect against exposure to ricin toxin.
An outline of our business strategy follows:
● Following positive interim analysis, complete enrollment and report final results in our pivotal Phase 3 clinical trial of SGX301 for the treatment of
CTCL;
44
● Continue enrollment of the pivotal Phase 3 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer;
● Continue development of RiVax® in combination with our ThermoVax® technology to develop a new heat stable vaccine in biodefense with NIAID
funding support;
● Continue to apply for and secure additional government funding for each of our BioTherapeutics and Vaccines/BioDefense programs through grants,
contracts and/or procurements;
● Pursue business development opportunities for our pipeline programs, as well as explore merger/acquisition strategies; and
● Acquire or in-license new clinical-stage compounds for development..
Our Product Candidates in Development
The following tables summarize our product candidates under development:
Soligenix Product
Candidate
Therapeutic Indication
Stage of Development
BioTherapeutic Product Candidates
SGX301
Cutaneous T-Cell Lymphoma
SGX942
Oral Mucositis in Head and Neck
Cancer
SGX203**
Pediatric Crohn’s disease
SGX201**
Acute Radiation Enteritis
Phase 2 trial completed; demonstrated significantly higher response rate
compared to placebo; Phase 3 clinical trial enrolled first patient in December
2015, with positive interim analysis received in October 2018, and final results
expected in the first quarter of 2020
Phase 2 trial completed; demonstrated significant response compared to
placebo with positive long-term (12 month) safety also reported; Phase 3
clinical trial enrolled first patient in December 2017, with interim analysis
enrollment completion expected in the first half of 2019 and the interim
analysis anticipated in the third quarter of 2019; final results expected in the
first half of 2020
Phase 1/2 clinical trial completed; efficacy data, pharmacokinetic
(PK)/pharmacodynamic (PD) profile and safety profile demonstrated; Phase 3
clinical trial initiation contingent upon additional funding, such as through
partnership
Phase 1/2 clinical trial completed; safety profile and preliminary efficacy
demonstrated; further clinical development contingent upon additional
funding, such as through partnership
45
Soligenix Product
Candidate
ThermoVax®
Soligenix Product
Candidate
RiVax®
OrbeShield®
SGX943
Vaccine Thermostability Platform**
Indication
Stage of Development
Thermostability of aluminum
adjuvanted vaccine for ricin
Pre-clinical
BioDefense Products**
Indication
Stage of Development
Vaccine against
Ricin Toxin Poisoning
Phase 1a and 1b trials completed, safety and neutralizing antibodies for
protection demonstrated; Phase 2 trial planned for the second half of 2019
Therapeutic against GI ARS
Therapeutic against Emerging
Infectious Diseases
Pre-clinical
Pre-clinical
** Contingent upon continued government contract/grant funding or other funding source.
Critical Accounting Policies
Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been
prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates
and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosure of contingent assets and liabilities. We evaluate these
estimates and judgments on an on-going basis.
46
Revenue Recognition
The Company’s revenues are primarily generated from government contracts and grants. The revenue from government contracts and grants is based upon
subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides
funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the
Company incurs reimbursable internal expenses that are related to the government contracts and grants.
Research and Development Costs
Research and development costs are charged to expense when incurred in accordance with FASB ASC 730, Research and Development. Research and
development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and
materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs. Purchased in-process
research and development expense represents the value assigned or paid for acquired research and development for which there is no alternative future use as
of the date of acquisition.
Share-Based Compensation
Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly
for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then
25% each subsequent year for a period of three years. These options have a ten year life for as long as the individuals remain employees or directors. In
general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board.
From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed. Typically these
instruments vest upon issuance and therefore the entire share-based compensation expense is recognized upon issuance to the vendors and/or consultants.
Share-based compensation expense for options, warrants and shares of common stock granted to non-employees has been determined in accordance with
FASB ASC 505-50, Equity-Based Payments to Non-Employees, and represents the fair value of the consideration received, or the fair value of the equity
instruments issued, whichever may be more reliably measured. For options that vest over future periods, the fair value of options granted to non-employees is
amortized as the options vest. The fair value is remeasured each reporting period until performance is complete.
The fair value of each option grant made during 2018 and 2017 was estimated on the date of each grant using the Black-Scholes option pricing model and is
amortized ratably over the option vesting periods, which approximates the service period.
47
Income Taxes
On December 22, 2017, the United States (“U.S.”) government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the
“Tax Act”). The Tax Act significantly revises U.S. corporate income taxation by, among other things, lowering the U.S. corporate income tax rate from 35.0%
to 21.0% effective January 1, 2018. Tax Reform did not have any impact to the tax provision due to the full valuation allowance on its deferred tax assets and
the most significant impact on its consolidated financial statements was the reduction of approximately $14 million for the deferred tax assets related to net
operating losses and other assets recorded in the 2017 financial statements. Such reduction was fully offset by changes to the Company’s valuation allowance.
In December 2017, the SEC issued Staff Accounting Bulletin 118, which allows a measurement period, not to exceed one year, to finalize the accounting for
the income tax impacts of the Tax Act. The accounting for the income tax impacts of the Tax Act is now complete, no additional adjustments were required.
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts
of existing assets and liabilities and their respective tax basis. A valuation allowance is established when it is more likely than not that all or a portion of a
deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company’s current and past
performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward
periods. Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. No current or deferred income taxes have been provided in 2018 due to the net operating losses incurred
by the Company since its inception. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income
tax expense. There were no tax related interest and penalties recorded for the years of 2018 and 2017. Additionally, the Company has not recorded an asset for
unrecognized tax benefits or a liability for uncertain tax positions at December 31, 2018 and December 31, 2017.
Earnings Per Share
Basic earnings per share (“EPS”) excludes dilution and is computed by dividing income (loss) available to common stockholders by the weighted-average
number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue
common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since
there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period
presented.
Use of Estimates and Assumptions
The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and
assumptions such as the fair value of warrants and stock options and recovery of the useful life of intangibles that affect the reported amounts in the financial
statements and accompanying notes. Actual results could differ from those estimates.
48
Material Changes in Results of Operations
Year Ended December 31, 2018 Compared to 2017
For the year ended December 31, 2018, we had a net loss of $8,899,975 as compared to a net loss of $7,147,083 for the prior year, representing an increased
loss of $1,752,892 or 25%. The increase in net loss is primarily due to increased expenditures incurred to support both the pivotal Phase 3 trial of SGX301 in
the treatment of cutaneous T-cell lymphoma and the pivotal Phase 3 trial of SGX942 in the treatment of oral mucositis in head and neck cancer. For the years
ended December 31, 2018 and 2017, revenues and associated costs related to government contracts and grants awarded in support of our development of
OrbeShield® for the treatment of GI ARS and RiVax® and other development programs. For the year ended December 31, 2018, we had revenues of
$5,241,448 as compared to $5,432,472 for the prior year, representing a decrease of $191,024 or 4%. The decrease in revenues was primarily a result of the
completion of the NIAID contract for OrbeShield® during the first quarter of 2017, along with the expiration of the base period of the BARDA contract for
the development of OrbeShield®, with BARDA electing not to extend the current contract beyond the base period. This was partially offset by an increase in
grant revenues awarded in September 2017 to support the development of SGX301 for the treatment of CTCL and SGX942 for the treatment of oral
mucositis in head and neck cancer.
We incurred costs related to contract and grant revenues in the year ended December 31, 2018 and 2017 of $4,597,715 and $4,310,083, respectively,
representing an increase of $287,632 or 7%. The increase in costs was primarily the result of the increased expenditures incurred to support the development
of RiVax®, in addition to the reimbursable costs incurred to support the two Phase 3 trials of SGX301 and SGX942.
Our gross profit for the year ended December 31, 2018 was $643,733 or 12%, as compared to $1,122,389 or 21% for the prior year, representing a decrease of
$478,656 or 43%. The decrease in gross profit and gross profit margin for the year ended December 31, 2018 is attributable to a smaller share of reimbursable
costs that were available for contracted fixed overhead reimbursement compared to the year ended December 31, 2017. Additionally, we received milestone
fees during the year ended December 31, 2017 under our RiVax® contract with NIAID. There were no similar milestones received for the year ended
December 31, 2018.
Research and development expenses increased by $1,243,921 or 23%, to $6,750,954 for the year ended December 31, 2018 as compared to $5,507,033 for the
prior year. The increase in research and development spending for the year ended December 31, 2018 was related to expenditures incurred in the expansion of
the Phase 3 clinical trial of SGX942 as well as the ongoing Phase 3 clinical trial of SGX301.
49
General and administrative expenses decreased $257,395 or 8%, to $2,951,760 for the year ended December 31, 2018, as compared to $3,209,155 for the
prior year. This decrease is primarily related to cost savings in professional fees and employee compensation expenses.
Interest income for the year ended December 31, 2018 was $159,006 as compared to $29,906 for the prior year, reflecting an increase of $129,100 or 432%.
The increase reflected primarily higher interest income on our cash position.
The State of New Jersey’s Technology Business Tax Certificate Program allows certain high technology and biotechnology companies to sell unused net
operating loss (“NOL”) carryforwards to other New Jersey-based corporate taxpayers. In accordance with this program, for the year ended December 31,
2016, we sold New Jersey NOL carryforwards, resulting in the recognition of $416,810 of income tax benefit. The Company has not yet sold its 2017 New
Jersey NOLs but may do so in the future. We will continue to explore opportunities to sell unused NOL carryforwards for the year ended December 31, 2017.
However, there can be no assurance as to the continuation or magnitude of this program in future years.
Business Segments
We maintain two active business segments for the years ended December 31, 2018 and 2017: Vaccines/BioDefense and BioTherapeutics.
Revenues for the Vaccines/BioDefense business segment for the year ended December 31, 2018 were $4,156,641 as compared to $4,749,294 for the year
ended December 31, 2017, representing a decrease of $592,653 or 12%. The decrease in revenues was primarily the result of a decrease in revenue from the
RiVax® development program along with the completion of the NIAID contract and the BARDA base period contract during the first quarter of 2017 for the
development of OrbeShield®, with BARDA electing not to extend the current contract beyond the base period.
Revenues for the BioTherapeutics business segment for the year ended December 31, 2018 were $1,084,807 as compared to $683,178 for the year ended
December 31, 2017, representing an increase of $401,629 or 59%. The increase was due to reimbursable development activity under the two grants that were
awarded in the third quarter of 2017 in support of our pivotal Phase 3 trials of SGX301 and SGX942.
Loss from operations for the Vaccines/BioDefense business segment for the year ended December 31, 2018 was $237,640 as compared to income of $232,166
for the year ended December 31, 2017, representing an increased loss of $469,806 or 202%. Loss from operations is primarily attributable to our decrease in
gross margins related to our government contracts and grants. The decrease in gross margin for the year ended December 31, 2018 was a result of the smaller
share of reimbursable costs available for a fixed overhead component during the year ended December 31, 2018, in addition to milestone fees received during
the year ended December 31, 2017 that improved profitability. Loss from operations for the BioTherapeutics business segment for the year ended December
31, 2018 was $5,439,294 as compared to $4,181,811 for the year ended December 31, 2017, representing an increased loss of $1,257,483 or 30%. This
increased loss is due primarily to expenses incurred in the expansion of the pivotal Phase 3 clinical trial of SGX942 as well as expenses incurred in the
ongoing Phase 3 clinical trial of SGX301.
Amortization and depreciation expense for the Vaccines/BioDefense business segment for the year ended December 31, 2018 was $17,951 as compared to
$33,183 for the year ended December 31, 2017. Amortization and depreciation expense for the BioTherapeutics business segment for the year ended
December 31, 2018 was $21,018 as compared to $30,614 for the year ended December 31, 2017. The decrease in amortization and depreciation expense was
the result of office furniture and equipment and patents becoming fully amortized during the year ended December 31, 2018.
50
Financial Condition and Liquidity
Cash and Working Capital
As of December 31, 2018, we had cash and cash equivalents of $8,983,717 as compared to $7,809,487 as of December 31, 2017, representing an increase of
$1,174,230 or 15%. As of December 31, 2018, we had working capital of $6,131,178, representing a decrease of $54,685 as compared to working capital of
$6,185,863 for the prior year. The increase in cash and cash equivalents was primarily related to the net proceeds from our July 2018 public offering of
approximately $8.4 million. The decrease in working capital was a result of the increased expenditures incurred in the expansion of the pivotal Phase 3
clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer, as well as the ongoing Phase 3 clinical trial of SGX301.
Based on our current rate of cash outflows, cash on hand, proceeds from government contract and grant programs, proceeds available from the FBR Sales
Agreement., management believes that its current cash will be sufficient to meet the anticipated cash needs for working capital and capital expenditures for at
least the next twelve months from issuance of the financial statements.
Our plans with respect to our liquidity management include, but are not limited to, the following:
● We have up to $14.6 million in active government contract funding still available as of December 31, 2018 to support our associated research
programs through 2020 and beyond, provided the federal agencies exercise all options and do not elect to terminate the contracts for convenience.
We plan to submit additional contract and grant applications for further support of our programs with various funding agencies;
● We have continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expect to
continue to do so for the foreseeable future;
● We will continue to pursue Net Operating Loss (“NOL”) sales in the state of New Jersey pursuant to its Technology Business Tax Certificate
Transfer Program if the program is available;
● We plan to pursue potential partnerships for pipeline programs. However, there can be no assurances that we can consummate such transactions;
● We have up to $8.5 million remaining from the FBR Sales Agreement as of March 20, 2019 under the prospectus supplement updated October 3,
2018; and
● We may seek additional capital in the private and/or public equity markets, pursue government contracts and grants as well as business development
activities, to continue our operations, respond to competitive pressures, develop new products and services, and to support new strategic
partnerships. We are currently evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when
appropriate. However, there can be no assurances that we can consummate such a transaction, or consummate a transaction at favorable pricing.
Expenditures
Under our budget and based upon our existing product development agreements and license agreements pursuant to letters of intent and option agreements,
we expect our total research and development expenditures for the year ending December 31, 2019, to be approximately $9.3 million before any contract or
grant reimbursements, of which $7.2 million relates to the BioTherapeutics business and $2.1 million relates to the Vaccines/BioDefense business. We
anticipate contract and grant reimbursements for the same period of approximately $3.3 million to offset research and development expenses in the
BioTherapeutics and Vaccines/BioDefense business segments.
51
The table below details our costs for research and development by program and amounts reimbursed for the years ended December 31, 2018 and 2017:
Research & Development Expenses
RiVax® & ThermoVax® Vaccines
Dusquetide (SGX942)
SGX943
SGX301
Other
Total
Reimbursed under Government Contracts and Grants
OrbeShield®
RiVax® & ThermoVax® Vaccines
SGX942
SGX301
Total
Grand Total
Contractual Obligations
2018
2017
448,039 $
3,834,306
-
2,026,442
442,167
6,750,954 $
607,717
2,774,797
138
1,661,330
463,051
5,507,033
- $
3,868,634
342,604
386,477
4,597,715 $
11,348,670 $
129,376
3,735,998
238,358
206,351
4,310,083
9,817,116
$
$
$
$
$
We have licensing fee commitments of approximately $500,000 for the next five years for several licensing agreements with consultants and universities.
Additionally, we have collaboration and license agreements, which upon clinical or commercialization success may require the payment of milestones of up
to $7.9 million and/or royalties up to 6% of net sales of covered products, if and when achieved. However, there can be no assurance that clinical or
commercialization success will occur.
We currently lease approximately 6,200 square feet of office space at 29 Emmons Drive, Suite B-10 in Princeton, New Jersey pursuant to a lease that was
amended in October 2017 and expires in October 2020. This office space currently serves as our corporate headquarters. The rent for the first 12 months was
approximately $11,367 per month, or approximately $22.00 per square foot. The rent increased to approximately $11,625 per month, or approximately $22.50
per square foot, for the 12 months beginning November 1, 2018 and will increase to approximately $11,883 per month on November 1, 2019, or
approximately $23.00 per square foot for the remainder of the lease. Our office space is sufficient to satisfy our current needs.
On September 3, 2014, we entered into an asset purchase agreement with Hy Biopharma, Inc. (“Hy Biopharma”) pursuant to which we acquired certain
intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharma’s synthetic hypericin product. As consideration for the
assets acquired, we paid $275,000 in cash and issued 184,912 shares of common stock with a fair value based upon our stock price on the date of grant of
$3,750,000. These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in our research and
development activities and do not have alternative future use pursuant to generally accepted accounting principles in the United States. Provided all future
success-oriented milestones are attained, we will be required to make payments of up to $10.0 million, if and when achieved. Payments will be payable in
restricted securities of the Company not to exceed 19.9% ownership of our outstanding stock. As of December 31, 2018, no milestone payments have been
made or accrued.
In February 2007, our Board of Directors authorized the issuance of 5,000 shares of our common stock to Dr. Schaber immediately prior to the completion of
a transaction, or series or a combination of related transactions negotiated by our Board of Directors whereby, directly or indirectly, a majority of our capital
stock or a majority of our assets are transferred from us and/or our stockholders to a third party. Dr. Schaber’s amended employment agreement includes our
obligation to issue such shares if such event occurs.
As a result of the above agreements, we have future contractual obligations over the next five years as follows:
Year
2019
2020
2021
2022
2023
Total
Licensing Fee
Property and
Other Leases
Total
100,000
100,000
100,000
100,000
100,000
500,000 $
148,561
127,377
4,984
-
-
280,922 $
248,561
227,377
104,984
100,000
100,000
780,922
$
52
Item 8. Financial Statements and Supplementary Data
The information required by this Item 8 is contained on pages F-1 through F-24 of this Annual Report on Form 10-K and is incorporated herein by reference.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are the Company’s controls and other procedures that are designed to ensure that information required to be disclosed by
us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized and
reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and
procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Exchange Act is accumulated and
communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding
required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can only provide reasonable
assurance of achieving their objectives and management necessarily applies its judgment in evaluating the possible controls and procedures.
Our management has evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure
controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report.
Based upon that evaluation, our management, including our principal executive officer and principal financial officer, has concluded that, as of the end of the
period covered by this report, the Company’s disclosure controls and procedures were effective at the reasonable assurance level.
Management’s Annual Report on Internal Control over Financial Reporting
Company management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial
reporting is a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by the Company’s Board
of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
·
·
·
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the
Company;
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of
management and directors of the Company; and
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that
could have a material effect on the financial statements.
53
Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of
effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2018. In making this assessment,
management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated
Framework, 2013.
Based on our assessment, management has concluded that, as of December 31, 2018, the Company’s internal control over financial reporting is effective.
Changes in Internal Control over Financial Reporting
There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation of such internal control that
occurred during the Company’s last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control
over financial reporting.
Item 9B. Other Information
On March 26, 2019, we entered into an amendment to our employment agreement with Richard C. Straube, MD, our Chief Medical Officer and Senior Vice
President. Pursuant to the amended agreement, which becomes effective April 1, 2019, Dr. Straube will be required to devote at least 20 hours per week to the
performance of his duties and we will pay him $170,000 per year. The amended employment agreement automatically renews each year, unless otherwise
terminated. Upon termination without “Just Cause”, as defined in the amended employment agreement, we would pay Dr. Straube one month of severance.
For a complete discussion of the terms of the amended employment agreement with Dr. Straube, see Exhibit 10.30.
54
Item 10. Directors, Executive Officers and Corporate Governance
PART III
The table below contains information regarding the current members of the Board of Directors and executive officers. The ages of individuals are provided as
of March 20, 2019:
Name
Christopher J. Schaber, PhD
Keith L. Brownlie, CPA
Mark Pearson
Gregg A. Lapointe, CPA
Robert J. Rubin, MD
Jerome B. Zeldis, MD, PhD
Oreola Donini, PhD
Karen Krumeich
Richard Straube, MD
Age
52
66
53
60
73
68
47
65
67
Position
Chairman of the Board, Chief Executive Officer and President
Director
Director
Director
Director
Director
Chief Scientific Officer and Senior Vice President
Chief Financial Officer, Senior Vice President and Corporate Secretary
Chief Medical Officer and Senior Vice President
Christopher J. Schaber, PhD has over 29 years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been our President and
Chief Executive Officer and a director since August 2006. He was appointed Chairman of the Board on October 8, 2009. He also has served on the board of
directors of the Biotechnology Council of New Jersey (“BioNJ”) since January 2009 and the Alliance for Biosecurity since October 2014, and has been a
member of the corporate councils of both the National Organization for Rare Diseases (“NORD”) and the American Society for Blood and Marrow
Transplantation (“ASBMT”) since October 2009 and July 2009, respectively. Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive
Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of
commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, pre-clinical and clinical research, and
medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, Dr. Schaber was a co-founder of Acute Therapeutics,
Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD,
Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations
positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his BA degree from
Western Maryland College, his MS degree in Pharmaceutics from Temple University School of Pharmacy and his PhD degree in Pharmaceutical Sciences
from the Union Graduate School. Dr. Schaber was selected to serve as a member of our Board of Directors because of his extensive experience in drug
development and pharmaceutical operations, including his experience as an executive senior officer with our Company and Discovery Laboratories, Inc., and
as a member of the board of directors of BioNJ; because of his proven ability to raise funds and provide access to capital; and because of his advanced
degrees in science and business.
Keith L. Brownlie, CPA has been a director since June 2011. In June 2017, Mr. Brownlie began serving on the Board of Directors of Celldex Therapeutics,
Inc., a publicly traded biotechnology company that is developing targeted therapeutics to address devastating diseases. He also serves on the Board of
Directors of Rxi Pharmaceuticals Corporation, a publicly traded biotechnology company involved in the research and development of RNAi products for the
diagnosis, prevention and treatment of human diseases, a position he has held since June 2012. From July 2013 until December 2014, Mr. Brownlie served on
the Board of Directors of Cancer Genetics, Inc., a publicly traded, early stage diagnostics company. Mr. Brownlie served as a member of the Board of
Directors of Epicept Corporation, a publicly traded, specialty pharmaceutical company focused on the clinical development and commercialization of
pharmaceutical products for the treatment of cancer and pain, from April 2011 to August 2013 when Epicept Corporation merged with Immune
Pharmaceuticals, Inc. From 1974 to 2010, Mr. Brownlie worked with the accounting firm of Ernst & Young LLP where he served as audit partner for
numerous public companies and was the Life Sciences Industry Leader for the New York metro area. Mr. Brownlie received a BS in Accounting from Lehigh
University and is a Certified Public Accountant in the state of New Jersey. Mr. Brownlie co-founded the New Jersey Entrepreneur of the Year Program and
was Vice President and Trustee of the New Jersey Society of CPAs. In addition, he served as accounting advisor to the Board of the Biotechnology Council of
New Jersey. Mr. Brownlie was selected to serve as a member of our Board of Directors because of his vast experience as an audit partner for numerous public
companies and as a director of publicly traded specialty pharmaceutical and biotechnology companies.
55
Mark Pearson joined the Board of Directors in July 2018. In January 2017, Mr. Pearson founded and since inception has served as General Partner and CEO
of Altamont Pharmaceutical Holdings, LLC, a privately-held investment company with over $100 million invested in more than 20 life science companies. In
February 2008, Mr. Pearson co-founded and since inception has served as General Partner of Annex Ventures, LLC, a privately-held investment company
providing financing and value-added services to individual entrepreneurs and start-up companies in the high-tech, biotechnology and medical device
markets. Mr. Pearson is also the co-founder and vice-chairman of Drawbridge Realty Management, LLC a real estate development and investment company
which owns over 4.5 million square feet of commercial real estate leased to technology and life science companies predominantly in the western United
States. Previously, Mr. Pearson was the co-founder and Managing Partner of CRESA Partners LLC, a 57-office national corporate real estate firm. Since
February 2009, he has served on the Board of Trustees of The Scripps Research Institute. Mr. Pearson holds a Bachelor of Science degree in Economics from
the University of San Francisco and a Master’s degree from the Stanford University Graduate School of Business. Mr. Pearson was selected to serve as a
member of our Board of Directors because of his significant experience in the areas of corporate finance, business development and acquisitions and
divestitures and his experience as an investor in the high-tech, biotechnology and medical device markets.
Gregg A. Lapointe, CPA, MBA has been a director since March 2009. Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc. and serves on the
Board of Directors of Rigel Pharmaceuticals, Inc., Cytori Therapeutics, Inc. and Catabasis Pharmaceuticals, Inc. Mr. Lapointe has previously served on the
Board of Directors of ImmunoCellular Therapeutics Ltd., Raptor Pharmaceuticals, Inc., SciClone Pharmaceuticals, Inc., the Pharmaceuticals Research and
Manufacturers of America (PhRMA), Questcor Pharmaceuticals, Inc. and the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. He
previously served in varying roles for Sigma-Tau Pharmaceuticals, Inc. (now known as Leadiant Biosciences, Inc.), a private biopharmaceutical company,
from September 2001 through February 2012, including Chief Operating Officer from November 2003 to April 2008 and Chief Executive Officer from April
2008 to February 2012. From May, 1996 to August 2001, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc.
(formerly JWI Inc.). Prior to that, Mr. Lapointe spent several years in the Canadian medical products industry in both distribution and manufacturing. Mr.
Lapointe began his career at Price Waterhouse. Mr. Lapointe received his B.A. degree in Commerce from Concordia University in Montreal, Canada, a
graduate diploma in Accountancy from McGill University and his M.B.A. degree from Duke University. He is a C.P.A. in the state of Illinois. Mr. Lapointe
was selected to serve as a member of our Board of Directors because of his significant experience in the areas of global strategic planning and
implementation, business development, corporate finance, and acquisitions, and his experience as an executive officer and board member in the
pharmaceutical and medical products industries.
Robert J. Rubin, MD has been a director since October 2009. Dr. Rubin was a clinical professor of medicine at Georgetown University from 1995 until 2012
when he was appointed a Distinguished Professor of Medicine. From 1987 to 2001, he was president of the Lewin Group (purchased by Quintiles
Transnational Corp. in 1996), an international health policy and management consulting firm. From 1994 to 1996, Dr. Rubin served as Medical Director of
ValueRx, a pharmaceutical benefits company. From 1992 to 1996, Dr. Rubin served as President of Lewin-VHI, a health care consulting company. From 1987
to 1992, he served as President of Lewin-ICF, a health care consulting company. From 1984 to 1987, Dr. Rubin served as a principal of ICF, Inc., a health care
consulting company. From 1981 to 1984, Dr. Rubin served as the Assistant Secretary for Planning and Evaluation at the Department of Health and Human
Services and as an Assistant Surgeon General in the United States Public Health Service. Dr. Rubin has served on the Board of BioTelemetry, Inc. (formerly
known as CardioNet, Inc.) since 2007. He is a board certified nephrologist and internist. Dr. Rubin received an undergraduate degree in Political Science from
Williams College and his medical degree from Cornell University Medical College. Dr. Rubin was selected to serve as a member of our Board of Directors
because of his vast experience in the health care industry, including his experience as a nephrologist, internist, clinical professor of medicine and Assistant
Surgeon General, and his business experience in the pharmaceutical industry.
56
Jerome B. Zeldis, MD, PhD has been a director since June 2011. Dr. Zeldis is currently Chief Medical Officer and President of Clinical Research, Drug
Safety and Regulatory of Sorrento Therapeutics, Inc. He is also Chief Medical Officer and Principal at Celularity, Inc. Previously, Dr. Zeldis was Chief
Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical
company. He was employed by Celegene from 1997 to 2016. From September 1994 to February 1997, Dr. Zeldis worked at Sandoz Research Institute and the
Janssen Research Institute in both clinical research and medical development. He has been a board member of several biotechnology companies and is
currently on the boards of Metastat, Inc., PTC Therapeutics Inc., BioSig Technologies, Inc., the Castleman’s Disease Organization and Alliqua, Inc. He has
previously served on the boards of the NJ Chapter of the Arthritis Foundation and PTC Therapeutics, Inc. Additionally, he has served as Assistant Professor
of Medicine at the Harvard Medical School (from July 1987 to September 1988), Associate Professor of Medicine at University of California, Davis from
(September 1988 to September 1994), Clinical Associate Professor of Medicine at Cornell Medical School (January 1995 to December 2003) and Professor
of Clinical Medicine at the Robert Wood Johnson Medical School (July 1998 to June 2010). Dr. Zeldis received a BA and an MS from Brown University, and
an MD, and a PhD in Molecular Biophysics and Biochemistry from Yale University. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the
Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. Dr. Zeldis was selected to serve as a member of
our Board of Directors because of his experience as an executive officer of a publicly traded biopharmaceutical company and in clinical research and medical
development, and his experience in the health care industry, including his experience as an internist, gastroenterologist and professor of medicine.
Oreola Donini, PhD, has been with our company since August 15, 2013 and is currently our Chief Scientific Officer and Senior Vice President, a position
she has held since December 5, 2014. Dr. Donini served as our Vice President of Preclinical Research and Development from August 15, 2013 until
December 4, 2014. She has more than 15 years’ experience in drug discovery and preclinical development with start-up biotechnology companies. From 2012
to 2013, Dr. Donini worked with ESSA Pharma Inc. as Vice President Research and Development. From 2004 to 2013, Dr. Donini worked with Inimex
Pharmaceuticals Inc., (“Inimex”), lastly as Senior Director of Preclinical R&D from 2007-2013. Prior to joining Inimex, she worked with Kinetek
Pharmaceuticals Inc., developing therapies for infectious disease, cancer and cancer supportive care. Dr. Donini is a co-inventor and leader of our SGX94
innate defense regulator technology, developed by Inimex and subsequently acquired by us. She was responsible for overseeing the manufacturing and
preclinical testing of SGX94, which demonstrated efficacy in combating bacterial infections and mitigating the effects of tissue damage due to trauma,
infection, radiation and/or chemotherapy treatment. These preclinical studies resulted in a successful Phase 1 clinical study and clearance of Phase 2 protocols
for oral mucositis in head and neck cancer and acute bacterial skin and skin structure infections. While with ESSA Pharma Inc. as the Vice President of
Research and Development, Dr. Donini led the preclinical testing of a novel N-terminal domain inhibitor of the androgen receptor for the treatment of prostate
cancer. While with Kinetek Pharmaceuticals Inc., her work related to the discovery of novel kinase and phosphatase inhibitors for the treatment of cancer. Dr.
Donini received her PhD from Queen’s University in Kinston, Ontario, Canada and completed her post-doctoral work at the University of California, San
Francisco. Her research has spanned drug discovery, preclinical development, manufacturing and clinical development in infectious disease, cancer and
cancer supportive care.
Karen Krumeich has been with our company since June 2015 and is currently our Senior Vice President and Chief Financial Officer. Ms. Krumeich has
served as Chief Financial Officer and Vice President of Finance for public and private emerging-growth, start-up and national companies in various sectors of
healthcare, including pharmaceuticals, medical devices and healthcare service companies. She has expertise in equity financings, both private and public,
Sarbanes-Oxley compliance, acquisitions and integrations, strategic business development and operations analysis. Most recently Ms. Krumeich was the Vice
President of Finance for Cerecor Inc., a clinical stage neuroscience company. At Cerecor she was involved in the company’s equity financings and was
responsible for all finance and administrative functions. Prior to joining Cerecor she was a CFO Partner with Tatum, LLC, a national consulting firm, and a
member of the firm’s National Healthcare Group. As a Partner with Tatum, she served as Interim Chief Financial Officer for drug development and medical
device companies. Prior to joining Tatum in 2006, she was the Vice President of Finance and Chief Financial Officer of Strata Skin Sciences, Inc. (formerly
Mela Sciences, Inc.), a publicly traded development-stage medical device company. At Mela Sciences, she played a key role in the company’s initial public
offering and was responsible for all functional areas of finance and accounting, administration, and investor relations. As Vice President of Finance of Gran
Care Pharmacy, Inc., she was responsible for the financial leadership of the pharmacy division and directed an aggressive acquisition program. Ms. Krumeich
began her career with a B.S. in Pharmacy from the University of Toledo, subsequently completed an accounting major and transitioned into finance after
completing the CPA exam.
57
Richard Straube, MD has been with our company since January 2014 and is currently our Senior Vice President and Chief Medical Officer. Dr. Straube is a
board-certified pediatrician with 36 years’ experience in both academia and industry, including clinical research experience in host-response
modulation. From 2009 until joining our company, he was Chief Medical Officer of Stealth Peptides Incorporated, a privately-held, clinical stage,
biopharmaceutical company. Prior to joining us, Dr. Straube served from 1988 to 1993 in various capacities, including most recently as Senior Director,
Infectious Diseases and Immunology, Clinical Research, for Centocor, Inc., a privately-held biopharmaceutical company focused on developing monoclonal
antibody-based diagnostics. While at Centocor, Inc., Dr. Straube was responsible for the initial anti-cytokine and anti-endotoxin programs targeted at
ameliorating inappropriate host responses to infectious and immunologic challenges. Programs that he managed at Centocor, Inc. include assessments of
immunomodulation using monoclonal removal of inciting molecular triggers, removal of internal immune-messengers, augmentation of normal host defenses,
and maintenance of normal sub-cellular function in the face of injury. From 1993 to 1995, Dr. Straube was Director of Medical Affairs at T-cell Sciences, Inc.,
a privately-held biotechnology company. From 1995 to 1997, he was Director of Clinical Investigations of the Pharmaceutical Products Division of Ohmeda
Corp., a privately-held biopharmaceutical company. He served from 1998 to 2007 as Executive Vice President of Research and Development and Chief
Scientific Officer at INO Therapeutics LLC, a privately-held biotherapeutics company, where he was responsible for the clinical trials and subsequent
approval of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn. From 2007 to 2009, Dr. Straube was the Chief
Medical Officer at Critical Biologics Corporation, a privately-held biotechnology company. Dr. Straube received his medical degree and residency training at
the University of Chicago, completed a joint adult and pediatrician infectious diseases fellowship at the University of California, San Diego (“UCSD”), and as
a Milbank Scholar completed training in clinical trial design at the London School of Hygiene and Tropical Medicine. While on the faculty at the UCSD
Medical Center, his research focused on interventional studies for serious viral infections.
Board Leadership Structure
Our Board of Directors believes that Dr. Schaber’s service as both the Chairman of our Board of Directors and our Chief Executive Officer is in the best
interest of our Company and our stockholders. Dr. Schaber possesses detailed and in-depth knowledge of the issues, opportunities and challenges facing our
Company and our business and, therefore, is best positioned to develop agendas that ensure that the Board of Directors’ time and attention are focused on the
most important matters. His combined role enables decisive leadership, ensures clear accountability, and enhances our ability to communicate our message
and strategy clearly and consistently to our stockholders, employees, and collaborative partners.
Messrs. Brownlie, Lapointe, Pearson, Dr. Rubin, and Dr. Zeldis are independent and the Board of Directors believes that the independent directors provide
effective oversight of management. Moreover, in addition to feedback provided during the course of meetings of the Board of Directors, the independent
directors hold executive sessions. Following an executive session of independent directors, the independent directors’ report back to the full Board of
Directors regarding any specific feedback or issues, provide the Chairman with input regarding agenda items for Board of Directors and Committee meetings,
and coordinate with the Chairman regarding information to be provided to the independent directors in performing their duties. The Board of Directors
believes that this approach appropriately and effectively complements the combined Chairman/Chief Executive Officer structure.
Although we believes that the combination of the Chairman and Chief Executive Officer roles is appropriate under the current circumstances, our corporate
governance guidelines do not establish this approach as a policy, and the Board of Directors may determine that it is more appropriate to separate the roles in
the future.
58
Section 16(a) Beneficial Ownership Reporting Compliance
We are required to identify each person who was an officer, director or beneficial owner of more than 10% of our registered equity securities during our most
recent fiscal year and who failed to file on a timely basis reports required by Section 16(a) of the Exchange Act.
To our knowledge, based solely on review of these filings and written representations from the certain reporting persons, we believe that during the year
ended December 31, 2017, our officers, directors and significant stockholders have timely filed the appropriate form under Section 16(a) of the Exchange
Act.
Committees of the Board of Directors
Our Board of Directors has the following three committees: (1) Compensation, (2) Audit and (3) Nominating and Corporate Governance. Our Board of
Directors has adopted a written charter for each of these committees, which are available on our website at www.soligenix.com under the “Investors” section.
Audit
Committee
Compensation
Committee
Nominating and
Corporate Governance
Committee
Director
Keith L. Brownlie, CPA
Mark E. Pearson
Gregg A. Lapointe, CPA
Robert J. Rubin, MD
Jerome B. Zeldis, MD, PhD
– Committee Chair
– Member
Audit Committee
Our Board of Directors has an Audit Committee, which is comprised of Mr. Brownlie (Chair), Mr. Lapointe and Dr. Rubin. The Audit Committee assists our
Board of Directors in monitoring the financial reporting process, the internal control structure and the independent registered public accountants. Its primary
duties are to serve as an independent and objective party to monitor the financial reporting process and internal control system, to review and appraise the
audit effort of the independent registered public accountants and to provide an open avenue of communication among the independent registered public
accountants, financial and senior management, and our Board of Directors. Our Board of Directors has determined that Mr. Brownlie, Mr. Lapointe and Dr.
Rubin are “independent” directors, within the meaning of applicable listing standards of The Nasdaq Stock Market LLC (“Nasdaq”) and the Exchange Act
and the rules and regulations thereunder. Our Board of Directors has also determined that the members of the Audit Committee are qualified to serve on the
committee and have the experience and knowledge to perform the duties required of the committee and that Mr. Brownlie qualifies as an “audit committee
financial expert” as that term is defined in the applicable regulations of the Exchange Act.
Compensation Committee
Our Board of Directors has a Compensation Committee, which is comprised of Dr. Rubin (Chair), Mr. Pearson and Dr. Zeldis. The Compensation Committee
is responsible for reviewing and approving the executive compensation program, assessing executive performance, setting salary, making grants of annual
incentive compensation and approving certain employment agreements. Our Board of Directors has determined that Dr. Rubin, Mr. Pearson and Dr. Zeldis are
“independent” directors within the meaning of applicable listing standards of Nasdaq and the Exchange Act and the rules and regulations thereunder.
59
Nominating and Corporate Governance Committee
Our Board of Directors has a Nominating and Corporate Governance Committee (“Nominating Committee”), which is comprised of Dr. Zeldis (Chair), Mr.
Brownlie and Mr. Lapointe. The Nominating Committee makes recommendations to the Board of Directors regarding the size and composition of our Board
of Directors, establishes procedures for the nomination process, identifies and recommends candidates for election to our Board of Directors. Our Board of
Directors has determined that Dr. Zeldis, Mr. Brownlie and Mr. Lapointe are “independent” directors, as such term is defined by the applicable Nasdaq listing
standards.
Code of Ethics
We have adopted a code of ethics that applies to all of our executive officers and senior financial officers (including our chief executive officer, chief financial
officer, chief accounting officer and any person performing similar functions). A copy of our code of ethics is publicly available on our website at
www.soligenix.com under the “Investors” section. If we make any substantive amendments to our code of ethics or grant any waiver, including any implicit
waiver, from a provision of the code to our chief executive officer, chief financial officer or chief accounting officer, we will disclose the nature of such
amendment or waiver in a Current Report on Form 8-K.
Diversity Considerations in Identifying Director Nominees
We do not have a formal diversity policy or set of guidelines in selecting and appointing directors that comprise our Board of Directors. However, when
making recommendations to our Board of Directors regarding the size and composition of our Board of Directors, our Nominating Committee does consider
each individual director’s qualifications, skills, business experience and capacity to serve as a director and the diversity of these attributes for the Board of
Directors as a whole.
Compensation Committee Interlocks and Insider Participation
No member of our Compensation Committee is or has at any time during the past year been one of our officers or employees. None of our executive officers
currently serves or in the past year has served as a member of the Board of Directors or Compensation Committee of any entity that has one or more
executive officers serving on our Board of Directors or Compensation Committee.
Item 11. Executive Compensation
In 2018, in furtherance of our compensation philosophy and objectives, the Compensation Committee engaged the Setren Smallberg & Associates (“SS&A”),
an outside executive compensation consulting firm determined to be independent by the Compensation Committee, to conduct a review of, and recommend
changes to, our compensation program for our most highly compensated executive officers. A representative of SS&A attended Compensation Committee
meetings at the invitation of the Compensation Committee Chairman and was also in direct contact with the Compensation Committee and company
management from time to time. SS&A provided the Compensation Committee with assistance and advice in the review of the Company’s salary structure,
annual and equity incentive awards and other related executive pay issues. In addition, SS&A provided advice regarding marketplace trends and best practices
relating to competitive pay levels.
SS&A did not provide any services to us other than its services as the Compensation Committee’s independent compensation consultant, and SS&A did not
receive any fees or compensation from us other than the fee it received as the independent compensation consultant. Except as described above, SS&A did
not provide any services to the Company in 2017 or 2018. The Compensation Committee confirmed that SS&A’s work for the Compensation Committee did
not create any conflicts of interest.
60
Summary Compensation
The following table contains information concerning the compensation paid during each of the two years ended December 31, 2018 and 2017, respectively to
our Chief Executive Officer and each of the three other most highly compensated executive officers (collectively, the “Named Executive Officers”).
Summary Compensation
Name
Christopher J. Schaber (1)
Oreola Donini (2)
Karen Krumeich (3)
Richard C. Straube (4)
Position
CEO &
President
CSO &
Senior VP
CFO &
Senior VP
CMO &
Senior VP
Year
2018
2017
2018
2017
2018
2017
2018
2017
$
$
$
$
$
$
$
$
Salary
Bonus
Option
Awards
All Other
Compensation
Total
452,541 $
443,668 $
94,128 $
106,480 $
39,142 $
78,898 $
32,781 $
44,529 $
618,592
673,575
230,000 $
220,000 $
41,124 $
44,933 $
26,095 $
80,588 $
4,619 $
4,627 $
301,838
350,148
230,969 $
226,440 $
40,604 $
44,835 $
26,095 $
80,588 $
11,324 $
15,184 $
308,992
367,047
329,521 $
323,060 $
53,975 $
56,213 $
26,095 $
80,588 $
22,116 $
29,560 $
431,707
489,421
(1) Dr. Schaber deferred the payment of his 2018 bonus of $94,128 until January 15, 2019. Option awards figure includes the value of Common Stock option
awards at grant date as calculated under FASB ASC 718. Other compensation represents health insurance costs paid by us.
(2) Dr. Donini deferred the payment of her 2018 bonus of $41,124 until January 15, 2019. Option awards figure includes the value of Common Stock option
awards at grant date as calculated under FASB ASC 718. Other compensation represents health insurance costs paid by us.
(3) Ms. Krumeich deferred the payment of her 2018 bonus of $40,604 until January 15, 2019. Option awards figures include the value of Common Stock
option awards at grant date as calculated under FASB ASC 718. Other compensation represents health insurance costs paid by us.
(4) Dr. Straube deferred the payment of his 2018 bonus of $53,975 until January 15, 2019. Option awards figure includes the value of Common Stock option
awards at grant date as calculated under FASB ASC 718. Other compensation represents health insurance costs paid by us.
Employment and Severance Agreements
In August 2006, we entered into a three-year employment agreement with Christopher J. Schaber, PhD. Pursuant to this employment agreement we agreed to
pay Dr. Schaber a base salary of $300,000 per year and a minimum annual bonus of $100,000. Dr. Schaber’s employment agreement automatically renews
every three years, unless otherwise terminated, and was automatically renewed in December 2007, December 2010, December 2013 and December 2016 for
an additional term of three years. We agreed to issue him options to purchase 12,500 shares of our common stock, with one third immediately vesting and the
remainder vesting over three years. Upon termination without “Just Cause” as defined by this agreement, we would pay Dr. Schaber nine months of
severance, as well as any accrued bonuses, accrued vacation, and we would provide health insurance and life insurance benefits for Dr. Schaber and his
dependents. No unvested options shall vest beyond the termination date. Dr. Schaber’s monetary compensation (base salary of $300,000 and bonus of
$100,000) remained unchanged from 2006 with the 2007 renewal. Upon a change in control of the Company due to merger or acquisition, all of Dr. Schaber’s
options shall become fully vested, and be exercisable for a period of five years after such change in control (unless they would have expired sooner pursuant
to their terms). In the event of his death during the term of the agreement, all of his unvested options shall immediately vest and remain exercisable for the
remainder of their term and become the property of Dr. Schaber’s immediate family.
In February 2007, our Board of Directors authorized the issuance of 5,000 shares to Dr. Schaber immediately prior to the completion of a transaction, or series
or a combination of related transactions negotiated by our Board of Directors whereby, directly or indirectly, a majority of our capital stock or a majority of
our assets are transferred from us and/or our stockholders to a third party. The amended agreement with Dr. Schaber includes our obligation to issue such
shares to him if such event occurs.
61
On June 22, 2011, the Compensation Committee eliminated his fixed minimum annual bonus payable and revised it to an annual targeted bonus of 40% of his
annual base salary. On December 14, 2016, the Compensation Committee approved an increase in salary for Dr. Schaber to $443,668. On December 7, 2017,
the Compensation Committee approved an increase in salary for Dr. Schaber to $452,541. On December 13, 2018, the Compensation Committee approved an
increase in salary for Dr. Schaber to $466,117.
In July 2013, we entered into a one-year employment agreement with Oreola Donini, PhD, our Vice President Preclinical Research & Development. Pursuant
to the agreement, we have agreed to pay Dr. Donini $170,000 (CAD) per year and a targeted annual bonus of 20% of base salary. We also agreed to issue her
options to purchase 40,000 shares of our common stock with one-quarter immediately vesting and the remainder vesting over three years. Dr. Donini’s
employment agreement automatically renews each year, unless otherwise terminated, and has automatically renewed each year since execution. Upon
termination without “Just Cause”, as defined in Dr. Donini’s employment agreement, we would pay Dr. Donini three months of severance, accrued bonuses
and vacation, and health insurance benefits. No unvested options vest beyond the termination date. In December 2014, Dr. Donini was named Chief Scientific
Officer and Senior Vice President. Upon Dr. Donini’s promotion to Chief Scientific Officer, the Compensation Committee increased her targeted bonus to
30% of her annual base salary. On December 14, 2016, the Compensation Committee approved an increase in salary for Dr. Donini to $220,000. On
December 7, 2017, the Compensation Committee approved an increase in salary for Dr. Donini to $230,000. On December 13, 2018, the Compensation
Committee approved an increase in salary for Dr. Donini to $241,500.
In December 2014, we entered into a one-year employment agreement with Richard C. Straube, MD, our Chief Medical Officer and Senior Vice President.
Pursuant to the agreement, we agreed to pay Dr. Straube $300,000 per year and a targeted annual bonus of 30% of base salary. We also issued him options to
purchase 10,000 shares of our common stock with one-third immediately vesting and the remainder vesting over three years. On March 26, 2019, we entered
into an amendment to our employment agreement with Dr. Straube. Pursuant to the amended agreement, which amendment becomes effective as of April 1,
2019, Dr. Straube will be required to devote at least 20 hours per week to the performance of his duties and we will pay him $170,000 per year. The amended
employment agreement automatically renews each year, unless otherwise terminated. Upon termination without “Just Cause”, as defined in the amended
employment agreement, we would pay Dr. Straube one month of severance. No unvested options vest beyond the termination date. On December 14, 2016,
the Compensation Committee approved an increase in salary for Dr. Straube to $323,060. On December 7, 2017, the Compensation Committee approved an
increase in salary for Dr. Straube to $329,521. On December 13, 2018, the Compensation Committee approved an increase in salary for Dr. Straube to
$339,407.
On June 16, 2016, we entered into a one-year employment agreement with Karen Krumeich, our Senior Vice President and Chief Financial Officer. Pursuant
to the agreement, we have agreed to pay Ms. Krumeich $222,000 per year and a targeted annual bonus of 30% of base salary. We also agreed to issue her
options to purchase 10,000 shares of our common stock with one-quarter immediately vesting and the remainder vesting over three years. Ms. Krumeich’s
employment agreement automatically renews each year, unless otherwise terminated. Upon termination without “Just Cause”, as defined in Ms. Krumeich’s
employment agreement, we would pay Ms. Krumeich three months of severance, accrued bonuses and vacation, and health insurance benefits. No unvested
options vest beyond the termination date. On December 14, 2016, the Compensation Committee approved an increase in salary for Ms. Krumeich to
$226,440. On December 7, 2017, the Compensation Committee approved an increase in salary for Ms. Krumeich to $230,969. On December 13, 2018, the
Compensation Committee approved an increase in salary for Ms. Krumeich to $237,898.
62
Outstanding Equity Awards at Fiscal Year-End
The following table contains information concerning unexercised options, stock that has not vested, and equity incentive plan awards for the Named
Executive Officers outstanding at December 31, 2018, as adjusted for the reverse stock split of one-for-ten effective October 7, 2016. We have never issued
Stock Appreciation Rights.
Name
Christopher J. Schaber
Oreola Donini
Richard C. Straube
Karen Krumeich
Equity
Incentive Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Unexercisable Options (#)
Number of Securities
Underlying Unexercised
Options (#)
Exercisable
-
-
-
-
-
25,714
45,000
-
-
-
6,250
17,498
30,000
-
-
-
6,250
17,498
30,000
1,250
6,250
17,498
30,000
- $
- $
- $
- $
- $
$
25,714 $
45,000 $
$
$
$
$
6,250 $
17,498 $
30,000 $
- $
- $
- $
6,250 $
17,498 $
30,000 $
1,250 $
6,250 $
17,498 $
30,000 $
11,000
11,219
13,000
10,000
10,000
14,000
34,286
15,000
4,000
2,000
3,000
7,000
13,750
17,502
10,000
10,000
5,000
7,000
13,750
17,502
10,000
8,750
13,750
17,502
10,000
63
Option
Exercise
Price
($)
46.40
6.40
6.80
20.10
15.00
11.30
2.01
0.97
15.60
20.10
15.00
11.30
2.67
2.01
0.97
20.10
15.00
11.30
2.67
2.01
0.97
Option
Expiration
Date
6/30/2020
11/30/2021
12/04/2022
12/04/2023
12/04/2024
12/30/2025
12/06/2027
12/12/2028
8/14/2023
12/4/2023
12/4/2024
12/30/2025
3/30/2027
12/06/2027
12/13/2028
1/06/2024
12/04/2024
12/30/2025
3/30/2027
12/06/2027
12/13/2028
7.40
2.67
2.01
0.97
6/15/2026
3/30/2027
12/06/2027
12/12/2028
Compensation of Directors
The following table contains information concerning the compensation of the non-employee directors during the year ended December 31, 2018.
Name
Keith L .Brownlie
Marco M. Brughera
Gregg A. Lapointe
Robert J. Rubin
Jerome B. Zeldis
Mark Pearson
Fees Earned
Paid in Cash(1)
Option
Awards(2)
Total
$
$
$
$
$
$
55,000 $
30,000
47,500 $
52,500 $
50,000 $
20,000 $
30,000 $
- $
30,000 $
30,000 $
30,000 $
31,830 $
85,000
30,000
77,500
82,500
80,000
51,830
(1) Directors who are compensated as full-time employees receive no additional compensation for service on our Board of Directors. Each independent
director who is not a full-time employee is paid $35,000 annually, on a prorated basis, for their service on our Board of Directors, the chairman of
our Audit Committee is paid $15,000 annually, on a prorated basis, and the chairmen of our Compensation and Nominating Committees is paid $10,000
annually, on a prorated basis. Additionally, Audit Committee members are paid $7,500 annually and Compensation and Nominating Committee members
are paid $5,000 annually. This compensation is paid quarterly. During July 2018, Mr. Pearson was selected by the Nominating Committee and elected by
the Board as a Director. Dr. Brughera elected not to stand for re-election to the Board of Directors for the Annual meeting held on September 27, 2018.
(2) We maintain a stock option grant program pursuant to the nonqualified stock option plan, whereby members of our Board of Directors or its committees
who are not full-time employees receive an initial grant of fully vested options to purchase 1,500 shares of common stock. Upon re-election to the Board,
each Board member will receive stock options with a value of $30,000, calculated using the closing price of the common stock on the trading day prior to
the date of the annual meeting of our stockholders, which vest at the rate of 25% per quarter, commencing with the first quarter after each annual meeting
of stockholders.
Stock Ownership Policy
In April 2012, our Board of Directors adopted a stock ownership policy applicable to our non-employee directors to strengthen the link between director and
stockholder interests. Pursuant to the stock ownership policy, each non-employee director is required to hold a minimum ownership position in the common
stock equal to the annual cash compensation paid for service on the Board of Directors, exclusive of cash compensation paid for service as a chair or member
of any committees of the Board of Directors.
Stock counted toward the ownership requirement includes common stock held by the director, unvested and vested restricted stock, and all shares of common
stock beneficially owned by the director held in a trust and by a spouse and/or minor children of the director. The policy provides that the ownership
requirement must be attained within three years after the later of June 21, 2012 and the date a director is first elected or appointed to the Board of Directors.
To monitor progress toward meeting the requirement, the Nominating Committee will review director ownership levels at the end of March of each year.
Non-employee directors are prohibited from selling any shares of common stock unless such director is in compliance with the stock ownership policy. A
copy of our director compensation and stock ownership policy is publicly available on our website at www.soligenix.com under the “Investors” section.
64
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The table below provides information regarding the beneficial ownership of the common stock as of March 20, 2019, of (1) each person or entity who owns
beneficially 5% or more of the shares of our outstanding common stock, (2) each of our directors, (3) each of the Named Executive Officers, and (4) our
directors and officers as a group. Except as otherwise indicated, and subject to applicable community property laws, we believe the persons named in the table
have sole voting and investment power with respect to all shares of common stock held by them.
Name of Beneficial Owner
Altamont Pharmaceutical Holdings, LLC (1)
ACT Capital Management, LLLP (2)
Christopher J. Schaber (3)
Keith L. Brownlie (4)
Gregg A. Lapointe (5)
Mark E. Pearson (1)
Robert J. Rubin (6)
Jerome B. Zeldis (7)
Richard Straube (8)
Oreola Donini (9)
Karen Krumeich (10)
All directors and executive officers as a group (10 persons)
Shares of
Common
Stock
Beneficially
Owned **
Percent
of Class
2,500,000
1,506,500
200,724
38,156
41,786
2,510,482
44,872
39,239
69,190
63,190
57,865
3,065,502
13.79%
8.20%
1.09%
*
*
13.79%
*
*
*
*
*
16.40%
(1) Beneficial ownership for Mark E. Pearson and Altamont Pharmaceutical Holdings, LLC (“Altamont Pharmaceutical”), a company for which Mr. Pearson
serves as general partner and chief executive officer, includes 2,330,000 shares of common stock purchased on July 2, 2018 in our registered direct
offering, but does not include a warrant to purchase up to 932,000 shares of common stock held by Altamont Pharmaceutical. While the warrant currently
is exercisable, it is subject to a blocker provision that prevents the holder from exercising the warrant if such holder would beneficially own in excess of
4.99% of the common stock following such exercise. Beneficial ownership for Mr. Pearson also includes an option to purchase 10,482 shares of
common stock exercisable within 60 days of March 20, 2019. As general partner and chief executive officer of Altamont Pharmaceutical, Mr. Pearson
exercises voting and dispositive control over the securities beneficially owned by Altamont Pharmaceutical, and therefore may be deemed to be the
beneficial owner thereof; however, Mr. Pearson disclaims beneficial ownership of the securities beneficially owned by Altamont Pharmaceutical except
to the extent of his pecuniary interest therein. The address of Altamont Pharmaceutical is 3031 Tisch Way, Suite 505, San Jose, CA 95128 and of Mr.
Pearson is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.
(2) On February 13, 2019, ACT Capital Management, LLLP, on behalf of itself and Amir L. Ecker and Carol G. Frankenfield, filed Amendment No. 2 to
Schedule 13G with the SEC (as amended, the “Schedule 13G”). The Schedule 13G states that Amir L. Ecker and Carol G. Frankenfield are the General
Partners of ACT Capital Management, LLLP and that investment decisions made on behalf of ACT Capital Management, LLLP are made primarily by
its General Partners. The Schedule 13G indicates that (a) ACT Capital Management, LLLP has sole voting and dispositive power with respect to 377,500
shares and shared dispositive power with respect to 1,506,500 shares; (b) Amir L. Ecker has sole voting power with respect to 730,000 shares, shared
voting power with respect to 490,000 shares and shared dispositive power with respect 1,506,500 shares and (c) Carol G. Frankenfield has sole voting
power with respect to 37,500 shares, shared voting power with respect to 377,500 shares and shared dispositive power with respect 1,506,500 shares. The
address of the principal business office of ACT Capital Management, LLLP, Amir L. Ecker and Carol G. Frankenfield is 100 W. Lancaster Ave., Suite
110, Wayne, PA 19087.
(3) Includes 37,325 shares of common stock owned by Dr. Schaber, options to purchase 143,148 shares of common stock exercisable within 60 days of
March 20, 2019 and warrants to purchase up to 20,251 shares of common stock exercisable within 60 days of March 20, 2019. The address of Dr.
Schaber is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.
65
(4) Includes 5,000 shares of Common Stock and options to purchase 33,156 shares of Common Stock exercisable within 60 days of March 20, 2019. The
address of Mr. Brownlie is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.
(5) Includes 7,379 shares of Common Stock and options to purchase 34,407 shares of Common Stock exercisable within 60 days of March 20, 2019. The
address of Mr. Lapointe is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.
(6) Includes 4,385 shares of Common Stock, options to purchase 36,531 shares of Common Stock exercisable within 60 days of March 20, 2019, and
warrants to purchase up to 3,956 shares of Common Stock exercisable within 60 days of March 20, 2019. The address of Dr. Rubin is c/o Soligenix, 29
Emmons Drive, Suite B-10, Princeton, New Jersey 08540.
(7) Includes 6,917 shares of Common Stock and options to purchase 32,322 shares of Common Stock exercisable within 60 days of March 20, 2019. The
address of Dr. Zeldis is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.
(8) Includes 69,190 options to purchase shares of Common Stock owned by Dr. Straube exercisable within 60 days of March 20, 2019. The address of Dr.
Straube is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.
(9) Includes options to purchase 63,190 shares of Common Stock owned by Dr. Donini exercisable within 60 days of March 20, 2019. The address of Dr.
Donini is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.
(10) Includes 1,300 shares of Common Stock and options to purchase 56,565 shares of Common Stock owned by Ms. Krumeich exercisable within 60 days of
March 20, 2019. The address of Ms. Krumeich is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.
*
Indicates less than 1%.
** Beneficial ownership is determined in accordance with the rules of the SEC. Shares of Common Stock subject to options or warrants currently
exercisable or exercisable within 60 days of March 20, 2019 are deemed outstanding for computing the percentage ownership of the stockholder holding
the options or warrants, but are not deemed outstanding for computing the percentage ownership of any other stockholder. Percentage of ownership is
based on 18,189,208 shares of Common Stock outstanding as of March 20, 2019.
Equity Compensation Plan Information
In December 2005, our Board of Directors approved the 2005 Equity Incentive Plan, which was approved by stockholders on December 29, 2005. In
September 2013, our stockholders approved an amendment to the 2005 Equity Incentive Plan to increase the maximum number of shares of our common
stock available for issuance under the plan by 125,000 shares, bringing the total shares reserved for issuance under the plan to 300,000 shares. In April 2015,
our Board of Directors approved the 2015 Equity Incentive Plan, which was approved by stockholders on June 18, 2015. . In June 2017, our stockholders
approved an amendment to the 2015 Plan to increase the maximum number of shares of our Common Stock available for issuance under the plan to 600,000
shares. In September 2018, our stockholders approved a second amendment to the 2015 Equity Incentive Plan to increase the maximum number of shares of
our common stock available for issuance under the plan, bringing the total shares available for issuance under the plan to 1,000,000 shares. The following
table provides information, as of December 31, 2018 with respect to options outstanding under our 2005 Equity Incentive Plan and our 2015 Equity Incentive
Plan. All share numbers in this paragraph and in the following table have been adjusted for the one-for-ten reverse stock split effective October 7, 2016.
66
Number of
Securities
Remaining
Available for
Future
Issuance
Under Equity
Compensation
Plans
(excluding
securities
reflected in
the first
column)
Number of
Securities
to be Issued
upon Exercise
of Outstanding
Options,
Warrants and
Rights
Weighted-
Average
Exercise Price
of
Outstanding
Options,
Warrants and
Rights
1,022,095 $
5.32
153,149
-
1,022,095 $
-
5.32
-
153,149
Plan Category
Equity compensation plans approved by security holders(1)
Equity compensation plans not approved by security holders
Total
(1) Includes our 2005 Equity Incentive Plan and our 2015 Equity Incentive Plan. Our 2005 Equity Incentive Plan expired in 2015 and thus no securities
remain available for future issuance under that plan.
Item 13. Certain Relationships and Related Transactions and Director Independence
Related Party Transactions
Our audit committee is responsible for the review, approval and ratification of related party transactions. The audit committee reviews these transactions
under our Code of Ethics, which governs conflicts of interests, among other matters, and is applicable to our employees, officers and directors.
We are party to a registration rights agreement with certain stockholders, including Altamont Pharmaceutical Holdings, LLC, ACT Capital Management,
LLLP, and Knoll Capital Management, LP, each of which beneficially owns 5% or more of the shares of our outstanding common stock. The agreement
provides that the stockholders have the right to require that we register its shares under the Securities Act of 1933 (the “Securities Act”) for sale to the public,
subject to certain conditions. The stockholders also have piggyback registration rights, which means that, if not already registered, they have the right to
include their shares in any registration that we effect under the Securities Act, subject to specified exceptions. We must pay all expenses incurred in
connection with the exercise of these demand registration rights.
We are unable to estimate the dollar value of the registration rights to the holders of these rights. The amount of reimbursable expenses under the agreements
depends on a number of variables, including whether registration rights are exercised incident to a primary offering by us, the form on which we are eligible
to register such a transaction, and whether we have a shelf registration in place at the time of a future offering.
Other than as described above, the employment agreements and compensation paid to our directors, we did not engage in any transactions with related parties
since January 1, 2017. For a discussion of our employment agreements and compensation paid to our directors, see “Item 11. Executive Compensation”.
Director Independence
The Board of Directors has determined that Messrs. Brownlie and Lapointe, Dr. Rubin, and Dr. Zeldis are “independent” as such term is defined by the
applicable listing standards of Nasdaq. Our Board of Directors based this determination primarily on a review of the responses of the Directors to
questionnaires regarding their employment, affiliations and family and other relationships.
67
Item 14. Principal Accountant Fees and Services
The following table highlights the aggregate fees billed during each of the two years ended December 31, 2018 and December 31, 2017 by EisnerAmper LLP.
Audit fees
Tax fees
Other fees
Total
Other Fees
$
2018
2017
178,800 $
9,890
-
194,975
9,660
-
$
188,690 $
204,635
Our principal accountants did not bill us for any services or products other than as reported above in this Item 14 during each of the two years.
Pre-Approval Policies and Procedures
The audit committee has adopted a policy that requires advance approval of all audit services and permitted non-audit services to be provided by the
independent auditor as required by the Exchange Act. The audit committee must approve the permitted service before the independent auditor is engaged to
perform it. The audit committee approved all of the services described above in accordance with its pre-approval policies and procedures.
68
Item 15. Exhibits and Financial Statements Schedules
a.
(1) Consolidated Financial Statements:
Part IV
The financial statements required to be filed by Item 8 of this Annual Report on Form 10-K and filed in this Item 15, are as follows:
Consolidated Balance Sheets as of December 31, 2018 and 2017
Consolidated Statements of Operations for the Years Ended December 31, 2018 and 2017
Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2018 and 2017
Consolidated Statements of Changes in Shareholders’ Equity for the Years Ended December 31, 2018 and 2017
Consolidated Statements of Cash Flows for the Years Ended December 31, 2018 and 2017
Notes to Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm
(2) Financial Statement Schedules
F-2
F-3
F-4
F-5
F-6
F-7
F-21
Schedules are omitted because they are not applicable, or are not required, or because the information is included in the consolidated financial statements
and notes thereto.
(3) Exhibits:
2.1
3.1
3.2
3.3
3.4
3.5
3.6
4.1
4.2
4.3
4.4
4.5
4.6
Agreement and Plan of Merger, dated May 10, 2006 by and among the Company, Corporate Technology Development, Inc., Enteron
Pharmaceuticals, Inc. and CTD Acquisition, Inc. (incorporated by reference to Exhibit 2.1 included in our Registration Statement on Form SB-2
(File No. 333-133975) filed on May 10, 2006).
Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 included in our current report on Form 8-K
filed on June 22, 2012).
By-laws (incorporated by reference to Exhibit 3.1 included in our Quarterly Report on Form 10-QSB, as amended, for the fiscal quarter ended June
30, 2003).
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 included in our
current report on Form 8-K filed on June 22, 2016).
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 included in our
current report on Form 8-K filed on October 7, 2016).
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 included in our
current report on Form 8-K filed on June 14, 2017).
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of our current
report on Form 8-K filed on September 28, 2018).
Form of Warrant to Purchase Common Stock issued to each investor in the December 2014 registered public offering (incorporated by reference to
Exhibit 4.12 included in our Registration Statement on Form S-1 (File No. 333-199761) filed on December 17, 2014).
Form of Warrant to Purchase Common Stock issued to Roth Capital Partners, LLC (incorporated by reference to Exhibit 4.13 included in our
Registration Statement on Form S-1 (File No. 333-199761) filed on December 17, 2014).
Warrant Agency Agreement by and between the Company and American Stock Transfer & Trust Company, LLC (incorporated by reference to
Exhibit 10.1 included in our current report on Form 8-K filed on December 16, 2016).
Representative’s Warrant (incorporated by reference to Exhibit 4.15 included in our Registration Statement on Form S-1 (File No. 333-214038) filed
on November 14, 2016).
Form of Warrant to be issued to Aegis Capital Corp. (incorporated by reference to Exhibit 4.1 included in our current report on Form 8-K filed on
October 31, 2017).
Form of Warrant to be issued to each investor in the June 2018 registered public offering Form of Warrant to (incorporated by reference to Exhibit
4.8 included in our Amendment No. 2 to Registration Statement on Form S-1 (File No. 333-225226) filed on June 20, 2018).
69
4.7
10.1
10.2
10.3
10.4
10.5
10.6
10.7
10.8
10.9
Form of Representative’s Warrant (incorporated by reference to Exhibit 4.9 included in our Amendment No. 1 to Registration Statement on Form S-
1 (File No. 333-225226) filed on June 18, 2018).
License Agreement between the Company and the University of Texas Southwestern Medical Center (incorporated by reference to Exhibit 10.9
included in our Annual Report on Form 10-KSB filed March 30, 2004, as amended, for the fiscal year ended December 31, 2004).
2005 Equity Incentive Plan, as amended on September 25, 2013 (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-
K filed on September 30, 2013). **
Form S-8 Registration of Stock Options Plan dated December 30, 2005 (incorporated by reference to our registration statement on Form S-8 filed on
December 30, 2005).
Employment Agreement dated December 27, 2007, between Christopher J. Schaber, PhD and the Company (incorporated by reference to Exhibit
10.30 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008). **
Exclusive License Agreement dated November 24, 1998, between Enteron Pharmaceuticals, Inc. and George B. McDonald, MD and amendments
(incorporated by reference to Exhibit 10.42 included in our Registration Statement on Form S-1 (File No. 333-157322) filed on February 13, 2009).
Collaboration and Supply Agreement dated February 11, 2009, between the Company and Sigma-Tau Pharmaceuticals, Inc. (incorporated by
reference to Exhibit 10.43 included in our Registration Statement on Form S-1 (File No. 333-157322) filed on February 13, 2009). †
First Amendment to Employment Agreement dated as of July 12, 2011, between the Company and Christopher J. Schaber, PhD (incorporated by
reference to Exhibit 10.1 of our current report on Form 8-K filed on July 14, 2011).**
Amendment to the Collaboration and Supply Agreement dated July 26, 2011, between Sigma-Tau Pharmaceuticals, Inc. and the Company
(incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on July 28, 2011).
Amendment to the Exclusive License Agreement dated as of July 26, 2011, between George McDonald, MD and the Company (incorporated by
reference to Exhibit 10.2 of our current report on Form 8-K filed on July 28, 2011).
10.10 Amendment No. 2 to the Collaboration and Supply Agreement between the Company, Enteron and Sigma-Tau dated as of December 20, 2012
(incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on December 27, 2012). †
10.11 Amendment to Exclusive License Agreement dated as of December 20, 2012 between Enteron and McDonald (incorporated by reference to Exhibit
10.4 of our current report on Form 8-K filed on December 27, 2012).
10.12 Amendment to Consulting Agreement dated as of December 20, 2012 between Enteron and McDonald (incorporated by reference to Exhibit 10.5 of
our current report on Form 8-K filed on December 27, 2012).
10.13
Contract HHSO100201300023C dated September 18, 2013 between the Company and the U.S. Department of Health and Human Services
Biomedical Advanced Research and Development Authority (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on
September 24, 2013). †
10.14
Contract HHSN272201300030C dated September 24, 2013 by and between the Company and the National Institutes of Health (incorporated by
reference to Exhibit 10.1 of our current report on Form 8-K filed on September 30, 2013). †
10.15
Employment Agreement dated as of January 6, 2014 between the Company and Richard Straube, M.D. (incorporated by reference to Exhibit 10.1 of
our current report on Form 8-K filed on January 8, 2014). **
10.16 Asset Purchase Agreement dated September 3, 2014 between the Company and Hy Biopharma, Inc. (incorporated by reference to Exhibit 10.1 of our
current report on Form 8-K filed on September 5, 2014). †
10.17
Registration Rights Agreement dated September 3, 2014 between the Company and Hy Biopharma, Inc. (incorporated by reference to Exhibit 10.2
of our current report on Form 8-K filed on September 5, 2014).
10.18
Contract HHSN272201400039C dated September 17, 2014 by and between the Company and the National Institutes of Health (incorporated by
reference to Exhibit 10.1 of our current report on Form 8-K filed on September 23, 2014). †
10.19
Lease Agreement dated November 21, 2014, between the Company and CPP II, LLC (incorporated by reference to Exhibit 10.42 included in our
Annual Report on Form 10-K for the fiscal year ended December 31, 2014).
10.20
2015 Equity Incentive Plan, as amended on September 27. 2018 (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed
on September 28, 2018).
70
10.21
Form of Equity Purchase Agreement dated as of July 29, 2015 between the Company and Kodiak Capital Group, LLC, Kingsbrook Opportunities
Master Fund LP and River North Equity, LLC (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on July 31, 2015).
10.22
Purchase Agreement dated as of March 22, 2016 between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit
10.31 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015).
10.23
Registration Rights Agreement dated as of March 22, 2016 between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to
Exhibit 10.32 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015).
10.24
Employment Agreement dated as of June 16, 2016 between the Company and Karen R. Krumeich (incorporated by reference to Exhibit 10.1 of our
current report on Form 8-K filed on June 22, 2016).
10.25
Common Stock Purchase Agreement dated September 9, 2016 between the Company and SciClone Pharmaceuticals, Inc. (incorporated by reference
to Exhibit 10.1 of our current report on Form 8-K filed on September 12, 2016).
10.26 At Market Issuance Sales Agreement dated August 11, 2017 between Soligenix, Inc. and FBR Capital Markets & Co. (incorporated by reference to
Exhibit 1.1 included in our Quarter Report on Form 10-Q for the fiscal quarter ended June 30, 2017).
10.27
Form of Public Offering Securities Purchase Agreement dated October 31, 2017 (incorporated by reference to Exhibit 10.1 included in our current
report on Form 8-K filed on October 31, 2017).
10.28
Form of Private Placement Securities Purchase Agreement dated October 31, 2017 (incorporated by reference to Exhibit 10.2 included in our current
report on Form 8-K filed on October 31, 2017).
10.29
Form of Registration Rights Agreement dated October 31, 2017 (incorporated by reference to Exhibit 10.3 included in our current report on Form 8-
K filed on October 31, 2017).
10.30
First Amendment to Employment Agreement dated as of April 1, 2019 between the Company and Richard Straube, M.D. **
21.1
Subsidiaries of the Company. *
23.1
Consent of EisnerAmper LLP. *
31.1
Certification of the Chief Executive Officer pursuant to Exchange Act rule 13(a)-14(a) (under Section 302 of the Sarbanes-Oxley Act of 2002). *
31.2
Certification of the Chief Financial Officer pursuant to Exchange Act rule 13(a)-14(a) (under Section 302 of the Sarbanes-Oxley Act of 2002). *
32.1
Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
32.2
Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
*
**
†
Filed herewith.
Indicates management contract or compensatory plan.
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.
71
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
SIGNATURES
SOLIGENIX, INC.
By:
/s/ Christopher J. Schaber
Christopher J. Schaber, PhD
Chief Executive Officer and President
Date: March 26, 2019
In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated
and on the dates indicated.
Name
Capacity
/s/ Christopher J. Schaber
Christopher J. Schaber, PhD
/s/ Keith L. Brownlie
Keith L. Brownlie, CPA
/s/ Mark Pearson
Mark Pearson
/s/ Gregg A. Lapointe
Gregg A. Lapointe, CPA
/s/ Robert J. Rubin
Robert J. Rubin, MD
/s/ Jerome B. Zeldis
Jerome B. Zeldis, MD, PhD
/s/ Karen Krumeich
Karen Krumeich
Chairman of the Board, Chief Executive
Officer and President
(principal executive officer)
Director
Director
Director
Director
Director
Chief Financial Officer,
Senior Vice President, and Corporate Secretary
(principal accounting officer)
72
Date
March 26, 2019
March 26, 2019
March 26, 2019
March 26, 2019
March 26, 2019
March 26, 2019
March 26, 2019
SOLIGENIX, INC. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
Table of Contents
Consolidated Balance Sheets as of December 31, 2018 and 2017
Consolidated Statements of Operations for the Years Ended December 31, 2018 and 2017
Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2018 and 2017
Consolidated Statements of Changes in Shareholders’ Equity for the Years Ended December 31, 2018 and 2017
Consolidated Statements of Cash Flows for the Years Ended December 31, 2018 and 2017
Notes to Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm
F-1
Page
F-2
F-3
F-4
F-5
F-6
F-7
F-21
Soligenix, Inc. and Subsidiaries
Consolidated Balance Sheets
As of December 31,
$
$
$
Assets
Current assets:
Cash and cash equivalents
Contracts and grants receivable
Prepaid expenses
Income tax receivable
Total current assets
Security deposit
Office furniture and equipment, net
Deferred issuance costs
Intangible assets, net
Total assets
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable
Accrued expenses
Accrued compensation
Total current liabilities
Commitments and contingencies
Shareholders’ equity:
Preferred stock: 350,000 shares authorized; none issued or outstanding
Common stock, $.001 par value; 50,000,000 and 25,000,000 shares authorized at December 31, 2018 and 2017,
respectively; 17,682,839 and 8,730,640 shares issued and outstanding at December 31, 2018 and 2017, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total shareholders’ equity
Total liabilities and shareholders’ equity
$
The accompanying notes are an integral part of these consolidated financial statements.
F-2
2018
2017
8,983,717 $
1,201,715
157,278
-
10,342,710
22,734
19,634
59,761
46,863
10,491,702 $
7,809,487
926,251
263,254
416,810
9,415,802
22,734
37,163
-
73,952
9,549,651
2,126,215 $
1,790,689
294,628
4,211,532
1,753,614
1,143,306
333,019
3,229,939
-
-
17,683
172,436,176
(3,669)
(166,170,020)
6,280,170
10,491,702 $
8,731
163,581,026
-
(157,270,045)
6,319,712
9,549,651
Soligenix, Inc. and Subsidiaries
Consolidated Statements of Operations
For the Years Ended December 31,
Revenues:
Contract revenue
Grant revenue
Total revenues
Cost of revenues
Gross profit
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income:
Interest income
Net loss before income taxes
Income tax benefit
Net loss
Basic and diluted net loss per share
Basic and diluted weighted average common shares outstanding
2018
2017
$
$
$
3,965,496 $
1,275,952
5,241,448
(4,597,715)
643,733
6,750,954
2,951,760
9,702,714
(9,058,981)
159,006
(8,899,975)
-
(8,899,975) $
(0.68) $
13,178,154
4,749,294
683,178
5,432,472
(4,310,083)
1,122,389
5,507,033
3,209,155
8,716,188
(7,593,799)
29,906
(7,563,893)
416,810
(7,147,083)
(1.16)
6,144,237
The accompanying notes are an integral part of these consolidated financial statements.
F-3
Soligenix, Inc. and Subsidiaries
Consolidated Statements of Comprehensive Loss
For the Years Ended December 31, 2018 and 2017
Net loss
Other comprehensive loss:
Foreign currency translation adjustments
Comprehensive loss
2018
2017
$
(8,899,975) $
(7,147,083)
(3,669)
(8,903,644) $
-
(7,147,083)
$
The accompanying notes are an integral part of these consolidated financial statements.
F-4
Balance, December 31, 2016
5,470,032 $
5,470 $ 157,514,740 $
Soligenix, Inc. and Subsidiaries
Consolidated Statements of Changes in Shareholders’ Equity
For the Years Ended December 31, 2018 and 2017
Common Stock
Shares
Par Value
Additional
Paid–In
Capital
Accumulated
Other
Comprehensive Accumulated
50,483
50
115,880
450,000
450
1,014,815
-
-
(164,825)
200,125
200
(200)
2,557,500
2,558
5,112,443
-
2,500
-
-
8,730,640 $
-
3
-
-
(507,536)
5,922
489,787
-
8,731 $ 163,581,026 $
Loss
Deficit
- $ (150,122,962) $
Total
7,397,248
-
-
-
-
-
-
115,930
-
1,015,265
-
(164,825)
-
-
-
5,115,001
-
-
-
-
-
-
-
(7,147,083)
- $ (157,270,045) $
(507,536)
5,925
489,787
(7,147,083)
6,319,712
20,161
20
38,380
-
-
38,400
8,932,038
-
-
-
-
17,682,839 $
8,932
-
-
-
-
8,628,014
(192,130)
380,886
-
-
17,683 $ 172,436,176 $
-
-
-
(3,669)
-
-
-
-
-
(8,899,975)
(3,669) $ (166,170,020) $
8,636,946
(192,130)
380,886
(3,669)
(8,899,975)
6,280,170
Issuance of common stock pursuant to
Lincoln Park Equity Line
Issuance of common stock pursuant to FBR
At-the-Market Sales Agreement
Costs associated with FBR At-the-Market
Sales Agreement
Issuance of common stock from cashless
exercise of warrants
Issuance of common stock in concurrent
public and private offerings
Costs associated with concurrent public and
private offerings
Issuance of common stock to vendors
Share-based compensation expense
Net loss
Balance, December 31, 2017
Issuance of common stock pursuant to
Lincoln Park Equity Line
Issuance of common stock in public
offering
Costs associated with public offering
Share-based compensation expense
Foreign currency translation adjustment
Net loss
Balance, December 31, 2018
The accompanying notes are an integral part of these consolidated financial statements.
F-5
Soligenix, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
For the Years Ended December 31,
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation
Share-based compensation
Issuance of common stock for services
Loss on disposition of office furniture
Change in operating assets and liabilities:
Contracts and grants receivable
Prepaid expenses
Security deposit
Income tax receivable
Accounts payable and accrued expenses
Accrued compensation
Total adjustments
Net cash used in operating activities
Investing activities:
Purchases of office furniture and equipment
Proceeds from sale of office furniture
Net cash used in investing activities
Financing activities:
Proceeds from issuance of common stock and warrants pursuant to public and private offerings
Stock issuance costs associated with public and private offerings
Proceeds from issuance of common stock pursuant to FBR At-the-Market Sales Agreement
Costs associated with FBR At-the-Market Sales Agreement
Proceeds from issuance of common stock pursuant to the equity line
Net cash provided by financing activities
Effect of exchange rate on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental information:
Cash paid for state income taxes
2018
2017
$
(8,899,975) $
(7,147,083)
44,060
380,886
-
1,483
(275,464)
105,976
-
416,810
1,019,984
(38,391)
1,655,344
(7,244,631)
68,563
489,787
5,925
-
280,526
(128,823)
(22,734)
(416,810)
382,711
(22,629)
636,516
(6,510,567)
(1,925)
1,000
(925)
(26,348)
-
(26,348)
8,636,946
(251,891)
-
-
38,400
8,423,455
(3,669)
1,174,230
7,809,487
8,983,717 $
5,115,001
(507,536)
1,015,265
(164,825)
115,930
5,573,835
-
(963,080)
8,772,567
7,809,487
2,580 $
5,077
$
$
The accompanying notes are an integral part of these consolidated financial statements.
F-6
Soligenix, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
Note 1. Nature of Business
Basis of Presentation
Soligenix, Inc. (the “Company”) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where
there is an unmet medical need. The Company maintains two active business segments: BioTherapeutics and Vaccines/BioDefense.
The Company’s BioTherapeutics business segment is developing a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with
safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma (“CTCL”), its first-in-class innate defense regulator (“IDR”) technology,
dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate
(“BDP”) for the prevention/treatment of gastrointestinal (“GI”) disorders characterized by severe inflammation, including pediatric Crohn’s disease
(SGX203) and acute radiation enteritis (SGX201).
The Company’s Vaccines/BioDefense business segment includes active development programs for RiVax®, its ricin toxin vaccine candidate and SGX943, a
therapeutic candidate for antibiotic resistant and emerging infectious disease. The development of the vaccine program is currently supported by the heat
stabilization technology, known as ThermoVax®, under existing and on-going government contract funding. With the government contract from the National
Institute of Allergy and Infectious Diseases (“NIAID”), the Company will attempt to advance the development of RiVax® to protect against exposure to ricin
toxin.
The Company generates revenues under government grants primarily from the National Institutes of Health (“NIH”) and government contracts from NIAID.
The Company is currently developing RiVax® under a NIAID contract of up to $24.7 million over six years, and SGX301 and SGX942 under two separate
NIH grants of approximately $1.5 million each over two years. The Company will continue to apply for additional government funding.
The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, development of new technological
innovations, dependence on key personnel, protections of proprietary technology, compliance with the United States Food and Drug Administration (the U.S.
“FDA”) regulations, and other regulatory authorities, litigation, and product liability.
Liquidity
In accordance with Accounting Standards Codification 205-40, Going Concern, the Company has evaluated whether there are conditions and events,
considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the
consolidated financial statements are issued. As of December 31, 2018, the Company had an accumulated deficit of $166,170,020. During the year ended
December 31, 2018, the Company incurred a net loss of $8,899,975 and used $7,244,631 of cash in operations. The Company expects to continue to generate
losses in the foreseeable future. The Company’s liquidity needs will be largely determined by the budgeted operational expenditures incurred in regards to the
progression of its product candidates. The Company’s plans to meet its liquidity needs primarily include its ability to control the timing and spending on its
research and development programs and raising additional funds through potential partnerships and/or financings. Based on the Company’s approved
operating budget, current rate of cash outflows, cash on hand, proceeds from government contract and grant programs, and proceeds available from the At
Market Issuance Sales Agreement (“FBR Sales Agreement”) with B. Riley FBR, Inc. (“FBR”) management believes that its current cash will be sufficient to
meet the anticipated cash needs for working capital and capital expenditures for at least the next 12 months from issuance of the financial statements.
F-7
As of December 31, 2018, the Company had cash and cash equivalents of $8,983,717 as compared to $7,809,487 as of December 31, 2017, representing an
increase of $1,174,230 or 15%. As of December 31, 2018, the Company had working capital of $6,131,178, as compared to working capital of $6,185,863 for
the prior year, representing a decrease of $54,685. The increase in cash and cash equivalents was primarily the result of the Company’s financing activities
through its public offering of common stock. The decrease in working capital was primarily related to the expenditures incurred in the expansion of the
pivotal Phase 3 trial of SGX942 in addition to the ongoing expenditures incurred in the pivotal Phase 3 clinical trial of SGX301.
Management’s business strategy can be outlined as follows:
● Following positive interim analysis, complete enrollment and report final results in the Company’s pivotal Phase 3 clinical trial of SGX301 for the
treatment of CTCL;
● Continue enrollment of the pivotal Phase 3 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer;
● Continue development of RiVax® in combination with the Company’s ThermoVax® technology to develop a new heat stable vaccine in biodefense
with NIAID funding support;
● Continue to apply for and secure additional government funding for each of the Company’s BioTherapeutics and Vaccines/BioDefense programs
through grants, contracts and/or procurements;
● Pursue business development opportunities for the Company’s pipeline programs, as well as explore merger/acquisition strategies; and
● Acquire or in-license new clinical-stage compounds for development.
The Company’s plans with respect to its liquidity management include, but are not limited to, the following:
● The Company has up to $14.6 million in active government contract and grant funding still available as of December 31, 2018, to support its
associated research programs through 2019 and beyond, provided the federal agencies exercise all options and do not elect to terminate the contracts
or grants for convenience. The Company plans to submit additional contract and grant applications for further support of its programs with various
funding agencies;
● The Company has continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and
expects to continue to do so for the foreseeable future;
● The Company will continue to pursue Net Operating Loss (“NOL”) sales in the state of New Jersey pursuant to its Technology Business Tax
Certificate Transfer Program if available;
● The Company plans to pursue potential partnerships for pipeline programs. However, there can be no assurances that we can consummate such
transactions;
● The Company has up to $8.5 million remaining from the FBR Sales Agreement as of March 20, 2019 under the prospectus supplement updated
October 3, 2018; and
● The Company may seek additional capital in the private and/or public equity markets, to continue its operations, respond to competitive pressures,
develop new products and services, and to support new strategic partnerships. The Company is evaluating additional equity/debt financing
opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate
such a transaction, or consummate a transaction at favorable pricing.
Note 2. Summary of Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and
transactions have been eliminated as a result of consolidation.
F-8
Operating Segments
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by
the chief operating decision maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing the
performance of the segment. The Company divides its operations into two operating segments: BioTherapeutics and Vaccines/BioDefense.
Cash and Cash Equivalents
The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
Contracts and Grants Receivable
Contracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred
prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period
end and collected shortly thereafter. Accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged
to operations.
Intangible Assets
One of the most significant estimates or judgments that the Company makes is whether to capitalize or expense patent and license costs. The Company makes
this judgment based on whether the technology has alternative future uses, as defined in Financial Accounting Standards Board (“FASB”) Accounting
Standards Codification (“ASC”) 730, Research and Development. Based on this consideration, the Company capitalizes payments made to legal firms that are
engaged in filing and protecting rights to intellectual property and rights for its current products in both the domestic and international markets. The Company
believes that patent rights are one of its most valuable assets. Patents and patent applications are a key component of intellectual property, especially in the
early stage of product development, as their purchase and maintenance gives the Company access to key product development rights from Soligenix’s
academic and industry partners. These rights can also be sold or sub-licensed as part of its strategy to partner its products at each stage of development as the
intangible assets have alternative future use. The legal costs incurred for these patents consist of work associated with filing new patents designed to protect,
preserve and maintain the Company’s rights, and perhaps extend the lives of the patents. The Company capitalizes such costs and amortizes intangibles on a
straight-line basis over their expected useful life – generally a period of 11 to 16 years.
The Company did not capitalize any patent related costs during the years ended December 31, 2018 or 2017.
These intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable
or if the underlying program is no longer being pursued. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset
or group of assets, a loss is recognized for the difference between the fair value and carrying value of the related asset or group of assets. No such write downs
have occurred during the years ended December 31, 2018 and 2017.
Impairment of Long-Lived Assets
Office furniture and equipment and intangible assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such
assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the
carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or
group of assets. Such analyses necessarily involve significant judgment.
F-9
The Company did not record any impairment of long-lived assets for the years ended December 31, 2018 or 2017.
Fair Value of Financial Instruments
FASB ASC 820 — Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a
liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all
financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on
pertinent information available to the Company on December 31, 2018. Accordingly, the estimates presented in these financial statements are not necessarily
indicative of the amounts that could be realized on disposition of the financial instruments.
FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable.
Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the
highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable
inputs (Level 3 measurement).
The three levels of the fair value hierarchy are as follows:
● Level 1 — Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed
equities.
● Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2
includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including
volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are
observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the
marketplace.
● Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.
The carrying amounts reported in the consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, accounts payable, accrued
expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments.
Revenue Recognition
The Company’s revenues are primarily generated from government contracts and grants. The revenue from government contracts and grants is based upon
subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides
funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the
Company incurs reimbursable internal expenses that are related to the government contracts and grants.
Research and Development Costs
Research and development costs are charged to expense when incurred in accordance with FASB ASC 730, Research and Development. Research and
development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and
materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs. Purchased in-process
research and development expense represents the value assigned or paid for acquired research and development for which there is no alternative future use as
of the date of acquisition.
F-10
Share-Based Compensation
Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly
for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then
25% each subsequent year for a period of three years. These options have a ten year life for as long as the individuals remain employees or directors. In
general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board.
From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed. Typically these
instruments vest upon issuance and therefore the entire share-based compensation expense is recognized upon issuance to the vendors and/or consultants.
Share-based compensation expense for options, warrants and shares of common stock granted to non-employees has been determined in accordance with and
FASB ASC 505-50, Equity-Based Payments to Non-Employees, and represents the fair value of the consideration received, or the fair value of the equity
instruments issued, whichever may be more reliably measured. For options that vest over future periods, the fair value of options granted to non-employees is
amortized as the options vest. The fair value is remeasured each reporting period until performance is complete.
During the year ended December 31, 2018, the Company issued 370,420 stock options at a weighted average exercise price of $1.14 per share. The fair value
of options issued during the years ended December 31, 2018 and 2017 was estimated using the Black-Scholes option-pricing model and the following
assumptions:
● a dividend yield of 0%;
● an expected life of 4 years;
● volatility of 91% - 94% for 2018 and 90% - 93% for 2017;
● forfeitures at a rate of 12%; and
● risk-free interest rates ranging from 2.68% to 2.93% in 2018 and 1.60% to 2.02% in 2017.
The fair value of each option grant made during 2018 and 2017 was estimated on the date of each grant using the Black-Scholes option pricing model and
amortized ratably over the option vesting periods, which approximates the service period.
Foreign Currency Transactions and Translation
In 2018, the Company changed the status of a wholly owned subsidiary in the United Kingdom (“UK”) from inactive to active and incurred expenditures in
multiple currencies including the US dollar, the British Pound and the Euro to fund its clinical trial operations in the UK and select countries in Europe. In
accordance with ASC 830 Foreign Currency Matters, the UK subsidiary expresses its US dollar and Euro denominated transactions in its functional currency,
the British Pound, with related transaction gains or losses included in net income. On a quarterly basis, the financial statements of the UK subsidiary are
translated into US dollars and consolidated into the Company’s financials, with related translation adjustments reported as a cumulative translation adjustment
(“CTA”), which is a component of accumulated other comprehensive income. In 2018, the Company recognized foreign currency transaction gains of $437 in
its consolidated statement of operations and a foreign currency translation loss of $3,669 as CTA in its consolidated balance sheet.
Income Taxes
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts
of existing assets and liabilities and their respective tax basis. A valuation allowance is established when it is more likely than not that all or a portion of a
deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company’s current and past
performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward
periods. Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. No current or deferred income taxes have been provided through December 31, 2018 due to the net
operating losses incurred by the Company since its inception. The Company recognizes accrued interest and penalties associated with uncertain tax positions,
if any, as part of income tax expense. There were no tax related interest and penalties recorded for 2018 and 2017. Additionally, the Company has not
recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at December 31, 2018 and 2017.
F-11
Earnings Per Share
Basic earnings per share (“EPS”) excludes dilution and is computed by dividing income (loss) available to common stockholders by the weighted-average
number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue
common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since
there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period
presented.
The following table summarizes potentially dilutive adjustments to the number of common shares which were excluded from the diluted calculation because
their effect would be anti-dilutive due to the losses in each period.
Common stock purchase warrants
Stock options
Total
For the Year
Ended
December 31,
2018
6,303,643
1,022,095
7,325,738
For the Year
Ended
December 31,
2017
2,577,238
785,655
3,362,893
The weighted average exercise price of the Company’s stock options and warrants outstanding at December 31, 2018 were $5.32 and $3.09 per share,
respectively.
Use of Estimates and Assumptions
The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and
assumptions such as the fair value of warrants and stock options and the useful life of intangibles that affect the reported amounts in the financial statements
and accompanying notes. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements
In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842). The FASB issued this update to increase transparency and comparability among
organizations by requiring all leases with terms longer than 12 months be recognized by the lessee on its balance sheet as a right-of-use asset and a
corresponding lease liability, including leases currently accounted for as operating leases, and disclosing key information about leasing arrangements. The
updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption of the
update is permitted. The Company adopted the new standard on January 1, 2019 using a modified retrospective approach. Upon the adoption of this standard,
we recognized right-of-use assets and corresponding operating lease liabilities pertaining to our operating leases on our balance sheets. The adoption of this
standard did not have a material impact on our consolidated financial statements.
F-12
Note 3. Intangible Assets
The following is a summary of intangible assets which consists of licenses and patents:
December 31, 2018
Licenses
Patents
Total
December 31, 2017
Licenses
Patents
Total
Cost
Accumulated
Amortization
Net Book
Value
$
$
$
$
462,234 $
1,893,185
2,355,419 $
415,371 $
1,893,185
2,308,556 $
462,234 $
1,893,185
2,355,419 $
388,282 $
1,893,185
2,281,467 $
46,863
-
46,863
73,952
-
73,952
Amortization expense was $27,089 and $52,676 in 2018 and 2017, respectively.
Based on the balance of licenses and patents at December 31, 2018, future annual amortization expense is expected to be as follows:
Year
2019
2020
Amortization
Expense
$
$
27,164
19,699
License fees and royalty payments are expensed annually as incurred, as the Company does not attribute any future benefits of such payments.
Note 4. Accrued Expenses
The following is a summary of the Company’s accrued expenses:
Clinical trial expenses
Other
Total
Note 5. Income Taxes
The income tax benefit consisted of the following for the years ended December 31, 2018 and December 31, 2017:
Federal
Foreign
State
Income tax benefit
F-13
As of
December 31,
2018
2017
$
$
1,633,713 $
156,976
1,790,689 $
1,011,666
131,640
1,143,306
2018
2017
- $
-
-
- $
-
-
(416,810)
(416,810)
$
$
The significant components of the Company’s deferred tax assets and liabilities at December 31, 2018 and 2017 are as follows:
Net operating loss carry forwards
Orphan drug and research and development credit carry forwards
Equity based compensation
Intangibles
Total
Valuation allowance
Net deferred tax assets
2018
22,996,000 $
8,333,000
1,331,000
1,164,000
33,824,000
(33,824,000)
- $
2017
21,286,000
7,878,000
1,332,000
1,289,000
31,785,000
(31,785,000)
-
$
$
The Company had gross NOLs at December 31, 2018 of approximately $104,131,000 for federal tax purposes, approximately $14,028,000 for state tax
purposes and approximately $688,000 for foreign tax purposes. Portions of these NOLs will begin to expire in 2019. In addition, the Company has
$8,333,000 of various tax credits which expire from 2019 to 2037. The Company may be able to utilize its NOLs to reduce future federal and state income tax
liabilities. However, these NOLs are subject to various limitations under Internal Revenue Code (“IRC”) Section 382. IRC Section 382 limits the use of NOLs
to the extent there has been an ownership change of more than 50 percentage points. In addition, the NOL carry forwards are subject to examination by the
taxing authority and could be adjusted or disallowed due to such exams. Although the Company has not undergone an IRC Section 382 analysis, it is likely
that the utilization of the NOLs may be substantially limited.
The Company and one or more of its subsidiaries files income tax returns in the U.S. Federal jurisdiction, and various state and local jurisdictions. During the
year ended December 31, 2017, in accordance with the State of New Jersey’s Technology Business Tax Certificate Program, which allowed certain high
technology and biotechnology companies to sell unused NOL carry forwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey
NOL carry forwards, resulting in the recognition of $416,810 of income tax benefit, net of transaction costs. The Company has not yet sold its 2017 New
Jersey NOLs but may be able to do so in the future. There can be no assurance as to the continuation or magnitude of this program in the future.
Reconciliations of the difference between income tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for
the years ended December 31, 2018 and 2017 were as follows:
Federal tax at statutory rate
State tax benefits, plus sale of NJ NOL, net of federal benefit
Foreign tax rate difference
Permanent differences
Orphan drug and research and development credits
Change in statutory rate
Expiration of tax attributes
Change in valuation allowance
Income tax benefit
2018
2017
(21.0)%
(12.5)
0.2
0.9
1.1
-
8.4
22.9
-%
(34.0)%
(11.6)
-
5.7
(13.9)
186.9
-
(138.6)
(5.5)%
On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The
Tax Act significantly revises U.S. corporate income taxation by, among other things, lowering the U.S. corporate income tax rate from 35.0 % to 21.0%
effective January 1, 2018. Tax Reform did not have any impact to the tax provision due to the full valuation allowance on its deferred tax assets and the most
significant impact on its consolidated financial statements was the reduction of approximately $14 million for the deferred tax assets related to net operating
losses and other assets recorded in the 2017 financial statements. Such reduction is fully offset by changes to the Company’s valuation allowance.
F-14
Note 6. Shareholders’ Equity
Preferred Stock
The Company has 350,000 shares of preferred stock authorized, none of which are issued or outstanding.
Common Stock
The following items represent transactions in the Company’s common stock for the year ended December 31, 2018:
● On February 21, 2018, the Company issued 10,083 shares of common stock pursuant to the equity line with Lincoln Park Capital Fund, LLC
(“Lincoln Park”);
● On April 6, 2018, the Company issued 10,078 shares of common stock under the equity line with Lincoln Park;
● On July 2, 2018, the Company closed an underwritten public offering of 7,766,990 shares of its common stock and warrants to purchase 3,106,796
shares of common stock at a combined offering price of $1.03;
● On July 9, 2018, the underwriter for the Company’s underwritten public offering exercised the over-allotment option to purchase 1,165,048
additional shares of common stock and warrants to purchase 466,019 shares of common stock at a combined offering price of $1.03.
The following items represent transactions in the Company’s common stock for the year ended December 31, 2017:
● On January 3, 2017, the Company issued 2,500 shares to a vendor for partial consideration for services performed. The fair value of the fully vested
shares was $2.37 per share;
● On May 4, 2017, warrants to purchase a total of 250,000 shares were exercised on a cashless basis and as a result 200,125 shares of common stock
were issued;
● On May 24, 2017, the Company issued 10,096 shares of common stock pursuant to the equity line with Lincoln Park;
● In July 2017, the Company issued 40,387 shares of common stock pursuant to the equity line with Lincoln Park;
● Between August 14 and October 25, 2017, the Company issued FBR 450,000 shares of common stock pursuant to the FBR Sales Agreement.
● On November 3, 2017, the Company issued 1,575,500 shares of common stock at a purchase price of $2.00 per share in a registered direct offering
and 982,000 shares of common stock at a purchase price of $2.00 per share in a concurrent private placement.
Lincoln Park Equity Line
In March 2016, the Company entered into a common stock purchase agreement with Lincoln Park. The Lincoln Park equity facility allows the Company to
require Lincoln Park to purchase up to 10,000 shares (“Regular Purchase”) of the Company’s common stock every two business days, up to an aggregate of
$12.0 million over approximately a 36-month period with such amounts increasing as the quoted stock price increases. The Regular Purchase may be
increased up to 15,000 shares of common stock if the closing price of the common shares is not below $10.00, up to 20,000 shares of common stock if the
closing price of the common shares is not below $15.00 and up to 25,000 shares of common stock if the closing price of the common shares is not below
$20.00. The purchase price for the Regular Purchase shall be equal to the lesser of (i) the lowest sale price of the common shares during the purchase date, or
(ii) the average of the three lowest closing sale prices of the common shares during the twelve business days prior to the purchase date. Each Regular
Purchase shall not exceed $750,000. Furthermore, for each purchase by Lincoln Park, additional commitment shares in commensurate amounts up to a total
of 50,000 shares will be issued based upon the relative proportion of the aggregate amount of $12.0 million. In addition to the Regular Purchase and provided
that the closing price of the common shares is not below $7.50 on the purchase date, the Company in its sole discretion may direct Lincoln Park on each
purchase date to purchase on the next stock trading day (“Accelerated Purchase Date”) additional shares of Company stock up to the lesser of (i) three times
the number of shares purchased following a Regular Purchase or (ii) 30% of the trading volume of shares traded on the Accelerated Purchase Date at a price
equal to the lesser of the closing sale price on the Accelerated Purchase Date or 95% of the Accelerated Purchase Date’s volume weighted average price. As
of December 31, 2018, the Company had $10.1 million available under the equity facility. The common stock purchase agreement with Lincoln Park will
expire on March 31, 2019, and any issuable amounts of common stock remaining at the expiration date will be forfeited.
F-15
During the year ended December 31, 2017, the Company sold 50,000 shares of common stock and issued 483 commitment shares and received proceeds of
$115,930. The value of commitment shares on the date granted was $1,125, which was accounted for as a stock issuance cost.
During the year ended December 31, 2018, the Company sold 20,000 shares of common stock and issued 161 commitment shares and received proceeds of
$38,400. The value of commitment shares on the date granted was $309, which was accounted for as a stock issuance cost.
FBR At Market Issuance Sales Agreement
On August 11, 2017, the Company entered into the FBR Sales Agreement to sell shares of the Company’s common stock from time to time, through an “at-
the-market” equity offering program under which FBR acts as sales agent. Under the FBR Sales Agreement, the Company sets the parameters for the sale of
shares, including the number of shares to be issued, the time period during which sales may be requested to be made, limitation on the number of shares that
may be sold in any one trading day and any minimum price below which sales may not be made. The FBR Sales Agreement provides that FBR is entitled to
compensation for its services in an amount equal to 3% of the gross proceeds from the sale of shares sold under the FBR Sale Agreement. The Company has
no obligation to sell any shares under the FBR Sales Agreement, and may suspend solicitation and offers under the FBR Sales Agreement at any time.
Sales of common stock made pursuant to the FBR Sales Agreement, if any, will be made pursuant to the Company’s effective shelf registration statement on
Form S-3 (File No. 333-217738) filed on May 5, 2017 with the SEC, the base prospectus filed as part of such registration statement, and any prospectus
supplements. The shares sold pursuant to the FBR Sales Agreement have been and will be issued pursuant to General Instruction I.B.6 of Form S-3, which
permits the Company to sell shelf securities in a public primary offering with a value not exceeding one-third of the average market value of the Company’s
voting and non-voting common equity held by non-affiliates in any 12-month period as long as the aggregate market value of the Company’s outstanding
voting and non-voting common equity held by non-affiliates is less than $75 million.
On August 11, 2017, the Company filed a prospectus supplement for the sale of up to $4.8 million of shares of common stock pursuant to the FBR Sales
Agreement, and the Company sold an aggregate of approximately $1 million of shares thereunder. The offering costs incurred to register the shares pursuant
to the prospectus supplement dated August 11, 2017 were $164,825. On October 3, 2018, the Company filed an updated prospectus supplement with the SEC
and may offer and sell shares of the Company’s common stock pursuant to the FBR Sales Agreement having an aggregate offering price of up to $9.0 million,
from time to time. The prospectus supplement filed on October 3, 2018, supersedes the prospectus supplement dated August 11, 2017, and no additional
shares will be offered or sold pursuant to the prospectus supplement dated August 11, 2017. As of March 20, 2019, there was $8.5 million available for the
sale of common stock under the FBR Sales Agreement.
F-16
Note 9. Stock Option Plans and Warrants to Purchase Common Stock
Stock Option Plans
The Amended and Restated 2005 Equity Incentive Plan (“2005 Plan”) was replaced by the 2015 Equity Incentive Plan (“2015 Plan”), which was approved in
June 2015. No securities are available for future issuance under the 2005 Plan. As of December 31, 2018, approximately 153,000 shares are available for
grants under the 2015 Plan, and are divided into four separate equity programs:
1)
2)
3)
4)
the Discretionary Option Grant Program, under which eligible persons may, at the discretion of the Plan Administrator, be granted options to
purchase shares of common stock,
the Salary Investment Option Grant Program, under which eligible employees may elect to have a portion of their base salary invested each year in
options to purchase shares of common stock,
the Automatic Option Grant Program, under which eligible nonemployee Board members will automatically receive options at periodic intervals to
purchase shares of common stock, and
the Director Fee Option Grant Program, under which non-employee Board members may elect to have all, or any portion, of their annual retainer fee
otherwise payable in cash applied to a special option grant.
Shares available for grant under the 2015 Plan were as follows:
Shares available for grant at January 1, 2018
Increase in shares available for grant
Options granted
Options forfeited
Shares available for grant at December 31, 2018
Activity under the 2005 Plan and the 2015 Plan for the years ended December 31, 2018 and 2017 was as follows:
Balance outstanding at December 31, 2016
Granted
Forfeited
Balance outstanding at December 31, 2017
Granted
Forfeited
Balance outstanding at December 31, 2018
13,969
400,000
(370,420)
109,600
153,149
Weighted
Average
Options
Exercise Price
Options
330,605 $
476,100
(21,050)
785,655 $
370,420
(133,980)
1,022,095 $
17.07
2.24
51.62
7.15
1.14
4.66
5.32
As of December 31, 2018, there were 598,953 options exercisable with a weighted average exercise price of $8.02 and a weighted average remaining
contractual term of 7.28 years. As of December 31, 2018, there were 1,022,095 options outstanding with a weighted average exercise price of $5.32 and
remaining term of 8.20 years.
The Company awarded 370,420 and 476,100 shares of stock options during the years ended December 31, 2018 and 2017, respectively, which had a weighted
average grant date fair value per share of $0.77 and $1.54, respectively. The weighted-average exercise price, by price range, for outstanding options to
purchase common stock at December 31, 2018 was:
Price
Range
$0.97-$17.20
$20.10-$39.80
$41.00-$62.00
Total
Weighted Average Remaining
Contractual Life in Years
Outstanding
Options
Exercisable
Options
8.60
4.50
1.61
8.20
F-17
942,314
53,293
26,488
1,022,095
519,172
53,293
26,488
598,953
The Company’s share-based compensation expense for the years ended December 31, 2018 and 2017 was recognized as follows:
Share-based compensation
Research and development
General and administrative
Total
2018
2017
$
$
174,877 $
206,009
380,886 $
213,944
275,843
489,787
At December 31, 2018, the total compensation cost for stock options not yet recognized was approximately $421,000 and will be expensed over the next three
years.
Warrants to Purchase Common Stock
On November 3, 2017, 1,575,500 shares of common stock were issued at a purchase price of $2.00 per share and 982,000 shares of common stock were
issued at a purchase price of $2.00 per share in a concurrent private placement. In connection with the concurrent registered public offering and the private
placement, warrants to purchase 51,151 shares of the Company’s common stock were issued to the representatives of the underwriters of the offering. The
warrants are exercisable at $2.50 per share of common stock underlying the warrants for a four-year period commencing six months from the effective date of
the offering.
On April 1, 2018, warrants to purchase 10,000 shares of the Company’s common stock were issued to a third party consultant in Europe. The warrants are
exercisable upon the achievement of specified performance milestones at a per share price of $1.95 for a five-year period from issuance. As of December 31,
2018, warrants to purchase 5,000 shares of common stock were exercisable and compensation expense was recognized.
On July 2, 2018, the Company closed an underwritten public offering of 7,766,990 shares of its common stock and exercisable warrants to purchase up to an
aggregate of 3,106,796 shares of its common stock at a combined offering price of $1.03. In addition, at the closing the underwriters exercised the over-
allotment option to purchase 1,165,048 additional shares of common stock and warrants to purchase up to 466,019 shares of common stock at a combined
offering price of $1.03. The warrants have a per share exercise price of $2.25 and will expire 42 months from the date of issuance. On July 9, 2018, warrants
to purchase 155,340 shares of the Company’s common stock were issued to representatives of the underwriters of the offering. The warrants are exercisable at
a per share price of $1.13 and are exercisable twelve months from the effective date of the offering and will expire 42 months from the effective date of the
offering.
Warrant activity for the years ended December 31, 2018 and 2017 was as follows:
Balance at December 31, 2016
Granted
Exercised
Expired
Balance at December 31, 2017
Granted
Exercised
Expired
Balance at December 31, 2018
F-18
Warrants
Weighted
Average
Exercise Price
4.13
2.50
0.80
5.58
4.38
2.20
-
1.64
3.09
2,853,575 $
51,151
(250,000)
(77,488)
2,577,238 $
3,738,155
-
(11,750)
6,303,643 $
The remaining life, by grant date, for outstanding warrants at December 31, 2018 was:
Grant
Date
12/24/2014
12/16/2016
11/3/2017
4/1/2018
7/2/2018
7/2/2018
Total
$
$
$
$
$
$
$
Exercise
Price
Remaining
Contractual Life in
Years
Outstanding
Warrants
Exercisable
Warrants
14.80
3.95
2.50
1.95
2.25
1.13
3.09
0.98
2.96
3.83
4.25
3.05
3.05
2.98
110,932
2,403,405
51,151
10,000
3,572,815
155,340
6,303,643
110,932
2,403,405
51,151
5,000
3,572,815
-
6,143,303
Note 10. Concentrations
At December 31, 2018 and 2017, the Company had deposits in major financial institutions that exceeded the amount under protection by the Securities
Investor Protection Corporation (“SIPC”). Currently, the Company is covered up to $1,000,000 by the SIPC and at times maintains cash balances in excess of
the SIPC coverage.
Note 11. Commitments and Contingencies
The Company has commitments of approximately $500,000 at December 31, 2018 for several licensing agreements with consultants and universities.
Additionally, the Company has collaboration and license agreements, which upon clinical or commercialization success, may require the payment of
milestones of up to $7.9 million and/or royalties up to 6% of net sales of covered products, if and when achieved. However, there can be no assurance that
clinical or commercialization success will occur. In June 2018, the Company paid approximately $197,000 in milestone payments.
The Company currently leases approximately 6,200 square feet of office space at 29 Emmons Drive, Suite B-10 in Princeton, New Jersey pursuant to a lease
that was amended in October 2017 and expires in October 2020. This office space currently serves as the Company’s corporate headquarters. The rent for the
first 12 months was approximately $11,367 per month, or approximately $22.00 per square foot. The rent increased to approximately $11,625 per month, or
approximately $22.50 per square foot, for the 12 months beginning November 1, 2018 and will increase beginning November 1, 2019 to approximately
$11,883 per month, or approximately $23.00 per square foot for the remainder of the lease.
On September 3, 2014, the Company entered into an asset purchase agreement with Hy Biopharma, Inc. (“Hy Biopharma”) pursuant to which the Company
acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharma’s synthetic hypericin product. As
consideration for the assets acquired, the Company paid $275,000 in cash and issued 184,912 shares of common stock with a fair value based on the
Company’s stock price on the date of grant of $3,750,000. These amounts were charged to research and development expense during the third quarter of 2014
as the assets will be used in the Company’s research and development activities and do not have alternative future use pursuant to generally accepted
accounting principles in the United States. Provided all future success-oriented milestones are attained, the Company will be required to make additional
payments of up to $10.0 million, if and when achieved. Payments will be payable in restricted securities of the Company provided they do not exceed 19.9%
ownership of the Company’s outstanding stock. As of December 31, 2018, no milestone or royalty payments have been paid or accrued.
In February 2007, the Company’s Board of Directors authorized the issuance of 5,000 shares of the Company’s common stock to Dr. Schaber immediately
prior to the completion of a transaction, or series or a combination of related transactions, negotiated by its Board of Directors whereby, directly or indirectly,
a majority of its capital stock or a majority of its assets are transferred from the Company and/or its stockholders to a third party. Dr. Schaber’s amended
employment agreement includes the Company’s obligation to issue such shares if such event occurs.
As a result of the above agreements, the Company has future contractual obligations over the next five years as follows:
Year
2019
2020
2021
2022
2023
Total
Research and Development
$
$
100,000 $
100,000
100,000
100,000
100,000
500,000 $
F-19
Property and
Other Leases
Total
148,561 $
127,377
4,984
-
-
280,922 $
248,561
227,377
104,984
100,000
100,000
780,922
Note 12. Operating Segments
The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs
specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.
Revenues
Vaccines/BioDefense
BioTherapeutics
Total
Income (Loss) from Operations
Vaccines/BioDefense
BioTherapeutics
Corporate
Total
Amortization and Depreciation Expense
Vaccines/BioDefense
BioTherapeutics
Corporate
Total
Other Income, Net
Corporate
Share-Based Compensation
Vaccines/BioDefense
BioTherapeutics
Corporate
Total
Identifiable Assets
Vaccines/BioDefense
BioTherapeutics
Corporate
Total
F-20
For the Years Ended December
31,
2018
2017
$
$
$
$
$
$
4,156,641 $
1,084,807
5,241,448 $
4,749,294
683,178
5,432,472
(237,640) $
(5,439,294)
(3,382,047)
(9,058,981) $
232,166
(4,181,811)
(3,644,154)
(7,593,799)
17,951 $
21,018
5,091
44,060 $
33,183
30,614
4,766
68,563
$
159,006 $
29,906
$
$
57,307 $
117,570
206,009
380,886 $
76,625
137,319
275,843
489,787
As of December 31,
2018
2017
$
$
1,181,114 $
78,336
9,232,252
10,491,702 $
906,416
116,344
8,526,891
9,549,651
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To The Board of Directors and Stockholders of
Soligenix, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Soligenix, Inc. and Subsidiaries (the “Company”) as of December 31, 2018 and 2017, and
the related consolidated statements of operations, comprehensive loss, shareholders’ equity, and cash flows for each of the years then ended and the related
notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the consolidated
financial position of the Company as of December 31, 2018 and 2017, and the consolidated results of their operations and their cash flows for each of the
years then ended, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of
the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of
internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial
reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ EisnerAmper LLP
We have served as the Company’s auditor since 2010.
EISNERAMPER LLP
Iselin, New Jersey
March 26, 2019
F-21
FIRST AMENDMENT
TO
EMPLOYMENT AGREEMENT
Exhibit 10.30
This First Amendment to Employment Agreement (the “Amendment”) is made and entered into as of March 26, 2019 to be effective as of April 1,
2019 by and between Soligenix, Inc., a Delaware corporation having a place of business at 29 Emmons Drive, Suite B-10, Princeton, NJ 08540 (the
“Corporation”), and Richard Straube, MD, an individual (the “Employee”).
W I T N E S S E T H:
WHEREAS, the Corporation and Employee entered into that certain Employment Agreement dated January 6, 2014 (the “Employment
Agreement”), pursuant to which the Corporation employed Employee as Senior Vice President and Chief Medical Officer; and
WHEREAS, the Corporation and Employee desire to amend the Employment Agreement in accordance with the terms thereof and upon the terms
set forth herein.
NOW, THEREFORE, in consideration of the foregoing and the mutual promises and covenants herein contained, it is agreed as follows:
I. AMENDMENT OF EMPLOYMENT AGREEMENT
A. Section 1 of the Employment Agreement is hereby amended and restated in its entirety as follows:
1. EMPLOYMENT DUTIES
The Corporation engages and employs Employee, and Employee hereby accepts engagement and employment, as Senior Vice President and
Chief Medical Officer reporting to the Chief Executive Officer of the Corporation, and shall perform high quality service to the Corporation
to direct, supervise and have responsibility for the clinical development efforts of the Corporation, including, but not limited to: (i) directing
the clinical research and regulatory strategies of the Corporation; (ii) supporting the clinical development personnel of the Corporation; and
(iii) medical monitoring of the Corporation’s ongoing and planned clinical trials and such other activities as may be reasonably requested by
the Chief Executive Officer or the Board of Directors of the Corporation. Employee acknowledges and understands that his employment
may entail travel on behalf of the Corporation. Employee shall devote at least 20 hours per week to the performance of his duties hereunder.
B. Section 3(a) of the Employment Agreement is hereby amended and restated in its entirety as follows:
(a) (i) The Corporation shall pay Employee an annual base salary (“Base Salary”) of one hundred and seventy thousand
dollars ($170,000) per annum, payable in accordance with the usual payroll period of the Corporation.
(ii) The Corporation may pay Employee a discretionary annual bonus. The determination whether to pay and the amount
of such bonus shall be made upon the recommendation of the Chief Executive Officer and by the approval of the Board of Directors.
C. Section 3(e) of the Employment Agreement is hereby amended and restated in its entirety as follows:
(e) During the Term, Employee shall be entitled up to a maximum of five (5) paid personal days consistent with
corporate policy.
Section 3(f) of the Employment Agreement is hereby deleted its entirety.
1
D. Section 7(b) of the Employment Agreement is hereby amended and restated in its entirety as follows:
(b) Upon termination by the Corporation pursuant to either subparagraph (i) or (iii) of paragraph (a) above or by
Employee other than pursuant to subparagraph (iv) of paragraph (a) above, the Employee (or his estate in the event of termination pursuant
to subparagraph (i)) shall be entitled to receive the Base Salary unpaid as of the date of termination including any personal days not taken.
E. Section 7(c) of the Employment Agreement is hereby amended and restated in its entirety as follows:
(c) Upon termination by the Corporation without Just Cause or pursuant to subparagraphs (i), (ii) or (iv) of paragraph
(a) above, then the term of the Agreement as set forth in Section 2 hereof shall be deemed to have been terminated as of such date and the
Corporation shall pay to the Employee (or his estate in the event of termination pursuant to subparagraph (i)), (A) Base Salary unpaid as of
the date of termination, including any personal days not taken, (B) severance equal to his annual rate of Base Salary in effect as of the date
of termination payable at said rate in accordance with the Corporation’s payroll practices for a one month period (subject to set-off)
(“Severance Pay”). Notwithstanding anything herein to the contrary, the Employee shall not be entitled to the Severance Pay unless he
executes and delivers to the Corporation a general release of claims in such form as determined by the Corporation (the “Release”) and such
Release becomes effective and irrevocable within sixty (60) days following the date of termination or resignation. Any Severance Pay
required under this Section 7(c) shall commence on the first payroll date coincident or immediately following the sixtieth (60th) day
following the Employee’s date of termination. Notwithstanding anything herein to the contrary, each payment of Severance Pay shall be
deemed to be a separate payment within the meaning of Section 409A of the Code and the regulations thereunder. Health benefits will also
be maintained for Employee (or his dependents in the event of termination pursuant to subparagraph (i)) by Company during severance
period. No unvested options shall vest beyond the termination date, except where previously noted in Section 3(b) or at the discretion of the
Stock Option Plan Administrator. For purposes of payments under this Agreement that are subject to (and not exempt from) Section 409A
of the Code that are payable upon the Employee’s “termination of employment,” such term shall instead mean “separation from service”
within the meaning of Section 409A and the Treasury Regulations promulgated thereunder.
II. OTHER PROVISIONS INCORPORATED AND UNCHANGED
All other provisions of the Employment Agreement are incorporated herein and shall remain in full force and effect.
III. EFFECT OF AMENDMENT
The amendments to the Employment Agreement made hereby shall be effective as of the date hereof and on a prospective basis only.
IV. ENTIRE AGREEMENT MODIFICATION
The Employment Agreement, as amended hereby, contains the entire agreement of the parties relating to the subject matter hereof, and the parties
hereto have made no agreements, representations or warranties relating to the subject matter hereof which are not set forth herein. No modification hereof
shall be valid unless made in writing and signed by the parties hereto.
V. GOVERNING LAW
This Amendment shall be governed by, and construed and interpreted in accordance with, the laws of the State of New Jersey without regard to
principles of conflict of laws.
VI. COUNTERPARTS
This Amendment may be executed in any number of counterparts by the parties on separate counterparts, each of which shall, when executed and
delivered, constitute an original of this Amendment, but all of which shall together constitute one and the same instrument. Counterparts may be delivered via
facsimile, electronic mail (including pdf or any other electronic signature, e.g., www.docusign.com) or other transmission method and any counterpart so
delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
2
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the day and year above written to become effective as of April 1,
2019.
SOLIGENIX, INC.
By:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
Chief Executive Officer
EMPLOYEE:
By:
/s/ Richard Straube
Richard Straube, MD
3
The following represents a list of Soligenix, Inc.’s subsidiaries:
SUBSIDIARIES OF SOLIGENIX, INC.
EXHIBIT 21.1
Name
Enteron Pharmaceuticals, Inc.
Orasomal Technologies Inc.
DOR BioDefense Corp.
Soligenix BioPharma Canada Incorporated
Soligenix UK Limited
Ownership
State of
Incorporation
Delaware
Delaware
Delaware
Canada
100.00%
75.30%
100.00%
100.00%
100.00% United Kingdom
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements of Soligenix, Inc. on Form S-3 (No. 333-217738) and Form S-8 (Nos. 333-
130801, 333-196941 and 333-208515) of our report dated March 26, 2019, on our audits of the consolidated financial statements as of December 31, 2018
and 2017 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 26, 2019.
EXHIBIT 23.1
/s/ EisnerAmper LLP
EISNERAMPER LLP
Iselin, New Jersey
March 26, 2019
EXHIBIT 31.1
CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
I, Christopher J. Schaber, Ph.D., certify that:
1.
I have reviewed this Form 10-K of the Soligenix, Inc. for the fiscal year ended December 31, 2018;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
March 26, 2019
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
EXHIBIT 31.2
CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
I, Karen Krumeich, certify that:
1.
I have reviewed this Form 10-K of the Soligenix, Inc. for the fiscal year ended December 31, 2018;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
March 26, 2019
/s/ Karen Krumeich
Karen Krumeich
Senior Vice President and Chief Financial Officer
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
EXHIBIT 32.1
In connection with this Form 10-K of Soligenix, Inc. (the “Company”) for the fiscal year ended December 31, 2018, as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
March 26, 2019
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
EXHIBIT 32.2
In connection with this Form 10-K of Soligenix, Inc. (the “Company”) for the fiscal year ended December 31, 2018, as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
March 26, 2019
/s/ Karen Krumeich
Karen Krumeich
Senior Vice President and Chief Financial Officer